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ABSTRACT 
 Percutaneous coronary intervention (PCI) acutely improves coronary blood 
flow and myocardial perfusion but at the expense of endovascular laceration and 
endothelial denudation. PCI associated vascular injury is associated with intense 
inflammation and a loss of vascular function that may lead to significant in-stent 
restenosis (ISR), and the potentially catastrophic, acute stent thrombosis. Re-
endothelialisation is essential to the restoration of normal homeostasis and facilitating 
vascular healing. Attention has recently focused on a novel mechanism of re-
endothelialisation mediated by bone marrow-derived precursor or stem cells: 
endothelial progenitor cells (EPC). EPC are thought to home to, and re-
endothelialise sites of endothelial denudation, and therefore offer the potential to 
provide exciting new developments in the management of cardiovascular disease. 
Understanding the role of EPC following vascular injury may help us to enhance 
vascular repair following PCI.  
 The following studies were performed to clarify the relationships between 
putative EPC and vascular injury associated with PCI. In studies of patients 
undergoing elective PCI for stable anginal symptoms I found that concentrations of 
traditional circulating phenotypic EPC expressing CD34+VEGFR-2+ were 
unaffected, unlike CD34+CD45- cell concentrations, which were transiently 
increased six hours following PCI, subsequently returning to normal by 24 hours, 
notably without an increase in CD34+ adhesion molecule expression or VEGF-A 
production. However, the purported progeny of CD34+VEGFR-2+ cells, endothelial 
cell-colony forming units (EC-CFU), were mobilised at 24 hours, commensurate with 
a systemic inflammatory response. Interestingly the concentration of circulating 
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CD34+VEGFR-2+ cells and EC-CFU were unrelated to each other, emphasising the 
distinction between these two cell populations. Although EC-CFU contained 
proliferating cells and exhibited some endothelial characteristics, EC-CFU 
predominantly expressed the leukocyte antigen CD45 in addition to the lymphocyte 
markers CD4 and CD8, and most intensely, the surface markers CD68 and CD105, 
epitopes commonly expressed on macrophages. Notably, EC-CFU were a potent 
stimulus for the migration of mononuclear cells. However, despite being mobilised in 
the context of an acute systemic inflammatory response and being composed of 
leukocytes, isolated systemic inflammation in healthy volunteers (induced by 
Salmonella Typhus vaccination) in the absence of vascular injury did not cause selective 
mobilisation of EC-CFU or indeed of putative phenotypic EPC. It is therefore likely 
that EC-CFU mobilisation is a relatively specific inflammatory response to 
cardiovascular injury. 
 
In a cohort of 201 patients undergoing coronary angiography, traditional 
circulating phenotypic EPC (CD34+VEGFR-2+ and CD34+VEGFR-2+CD133+) 
were very rare indeed and were not increased in response to an acute coronary 
syndrome (ACS). Furthermore traditional EPC concentrations bore no relation to 
atheroma burden or clinical outcome. In contrast, concentrations of CD34+CD45- 
cells were increased in patients with coronary artery disease compared to those with 
normal coronary arteries and were increased in association with more severe coronary 
disease. Increased concentrations of circulating CD34+CD45- cells were also 
associated with a shorter cumulative event-free survival. Both EC-CFU and 
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angiogenic monocytes expressing Tie-2 and VEGFR-2 were increased following 
acute myocardial infarction but did not relate to coronary atheroma or clinical 
outcome.  
 
 These studies examine the behavior of putative EPC in response to both 
discrete vascular injury and myocardial infarction, and isolated inflammation in the 
absence of vascular injury. I have identified novel characteristics of the EC-CFU 
assay and determined that specific factors associated with cardiovascular injury likely 
trigger EC-CFU mobilisation. The clinical relevance of the traditional phenotypic 
EPC population is uncertain, but a novel CD34+CD45- population is mobilised 
acutely following discrete vascular injury and is significantly associated with coronary 
atheroma and clinical events. It is probable that the circulating CD34+CD45- 
concentration reflects vascular injury and atheroma burden, and I suggest that 
CD34+CD45- cells are released directly from the vessel wall following PCI, and do 
not reflect a reparatory response. In order to determine the impact of EPC 
populations on vascular healing, prospective studies examining the impact of peri-
procedural EPC concentrations on vascular healing following PCI are required. 
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 1.1  OVERVIEW 
 Although percutaneous coronary intervention (PCI) improves myocardial 
perfusion and clinical outcomes in patients with ischaemic heart disease, the treated 
coronary artery segment inevitably undergoes significant mechanical trauma. 
Endothelial denudation and endovascular laceration by rigid stent struts and high-
pressure balloon inflations disturb vascular function and initiate an intense local 
inflammatory response. As a consequence of this, vascular injury is invariably 
associated with a degree of neo-intimal hyperplasia, which if severe may lead to 
clinically significant in-stent restenosis (ISR). The thrombotic milieu resulting from 
PCI underlies the potentially catastrophic complication of acute stent thrombosis. 
Re-endothelialisation is a critical component of vascular healing necessary for 
restoring vascular homeostasis. Re-endothelialisation was previously thought to occur 
purely through the migration and proliferation of mature endothelial cells adjacent to 
regions of endothelial denudation [Risau, 1995]. However, attention has recently 
focused on a novel mechanism of vascular repair involving a bone marrow-derived 
precursor or stem cell: the endothelial progenitor cell (EPC). It has been proposed 
that EPC are mobilised in response to vascular injury, and can home to sites of 
endothelial denudation [Asahara et al., 1997] in order to facilitate re-
endothelialisation [Shi et al., 1998]. The discovery of the EPC launched a new field of 
cardiovascular research, changed our understanding of the mechanisms involved in 
vascular repair, and has offered exciting and novel developments in the management 
of cardiovascular disease and the complications associated with modern 
revascularisation strategies.  
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1.2  PERCUTANEOUS CORONARY INTERVENTION AND VASCULAR INJURY 
Adverse cardiac events following PCI were initially very common, with major 
complications occurring in up to 20% of patients undergoing stent implantation 
[Serruys et al., 1994]. Technological advances have improved patient outcomes, 
though angiographic restenosis following PCI remains significant, occurring in 
approximately 11% of cases, although the incidence can approach 30% in higher risk 
populations using bare metal stents [Mauri et al., 2008]. Stent thrombosis, although a 
relatively rare complication of PCI, still occurs in up to 2% of cases and has 
potentially devastating and fatal consequences [de la Torre-Hernandez et al., 2008]. 
These complications occur, in part, as a consequence of the vascular injury that 
occurs during PCI [Farb et al., 1999]. High-pressure balloon inflations and the 
forceful apposition of rigid stent struts against the vessel wall which occur during PCI 
invariably cause laceration of the tunica intima and the disruption of endothelial 
continuity. Endovascular laceration may extend through the media to involve the 
external elastic lamina, and even vessel rupture is an uncommon but well recognised 
complication of PCI. Disruption of endogenous fibrinolytic and vasomotor function, 
combined with the exposure of underlying collagen and tissue factor, leads to 
activation of platelets and the coagulation cascade which may lead to acute or sub-
acute stent occlusion [Mak et al., 1996]. An intense local [Farb et al., 1999] and 
systemic inflammatory response [Almagor et al., 2003] is generated, involving a rapid 
influx of neutrophils, and later monocytic cell populations into the vessel wall. The 
endothelium normally provides a protective barrier for smooth muscle cells against 
inflammatory cytokines and growth factors, and also secretes a number of cytostatic 
factors that prevent smooth muscle cell proliferation. In the absence of a functional 
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endothelium fibroblastic activation and smooth muscle hypertrophy are potentiated, 
leading to in-stent restenosis and myocardial ischaemia [Wilcox et al., 2001]. Rapid 
re-endothelialisation is therefore important in the restoration of normal vascular 
function, reduction of vascular inflammation and the prevention of adverse 
remodelling following PCI [Kipshidze et al., 2004].  
 
The process of stent integration into the vessel wall has been elegantly 
characterised using electron microscopy [Grewe et al., 2000]. During the first 6 weeks 
following PCI a thin multi-layered thrombus is present on the endovascular surface 
and progressive smooth muscle hyperplasia and deposition of extracellular matrix 
occurs. From 6 to 12 weeks following PCI the thrombus resolves and endothelial cells 
begin to cover the stented segment. At approximately three months, re-
endothelialisation is complete, commensurate with a diminution in the quantity of 
smooth muscle cells. The use of drug eluting stents (DES) has dramatically reduced 
the incidence of ISR [Mak et al., 1996], however rather than encouraging re-
endothelialisation, this approach is based on the suppression of cellular proliferation. 
Re-endothelialisation is therefore also suppressed [Hofma et al., 2006] and the 
thrombotic risk is increased as a consequence. The use of DES therefore demands a 
prolongation of anti-platelet therapy, which unfortunately is associated with an 
increased risk of bleeding complications. A means of encouraging re-
endothelialisation is therefore highly attractive. EPC may comprise an important 
component of the cellular response to vascular injury and are therefore a potential 
therapeutic target through which re-endothelialisation following PCI can be 
enhanced. 
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1.3  HISTORICAL PERSPECTIVE OF ENDOTHELIAL PROGENITOR CELLS 
The concept that naïve precursor cells with the capacity to differentiate into 
mature cell types exist within the adult circulation is supported primarily by studies of 
bone marrow transplant recipients, within whom exist appropriately differentiated 
cells of donor origin, integrated into host structures such as the heart [Quaini et al., 
2002], lung [Suratt et al., 2003] and vasculature [Jiang et al., 2004]. The formation of 
blood vessels by naïve precursor cells in the adult is contrary to the traditional 
paradigm of re-endothelialisation or neovascularisation, whereby new endothelial 
cells are generated through the proliferation and migration of mature endothelial 
cells [Risau, 1995]. Although the recipient of enormous interest in the last decade, 
the concept of circulating vascular progenitor cells is not so novel. In the 1930s, the 
formation of vascular structures arising from peripheral blood cultures was observed 
in vitro [Hueper WC, 1932; Parker, 1933], and in the 1960s, ‘islands’ of endothelium 
were observed developing on the surface of implanted devices and intravascular 
prostheses [Florey et al., 1961; Mackenzie et al., 1960; Poole et al., 1962; Stump et al., 
1963]. The presence of circulating progenitors capable of re-endothelialisation was 
later suggested by Scott, et al., in 1994 following the successful re-endothelialisation of 
a vascular graft that was suspended within the aorta of a dog [Scott et al., 1994].  
 
In 1997 Asahara et al, popularised the term EPC by isolating cell populations 
from peripheral blood which were capable of homing to regions of ischaemia and 
facilitating vascular regeneration [Asahara et al., 1997]. EPC have been recognised as 
circulating [Asahara et al., 1997], bone marrow [Peichev et al., 2000] or tissue 
resident [Zengin et al., 2006] cells, that are mobilised in response to tissue ischaemia 
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or vascular perturbation, and possess the capacity to home to regions of injury and 
differentiate into a mature endothelial cells, or adopt an ‘endothelial like’ phenotype 
and participate in vascular repair. However, the term EPC is ambiguous, having 
been used to define a variety of different cell populations. Whilst our understanding is 
incomplete it is likely that the various populations so far identified fulfil different 
components of a vascular repair system. Broadly speaking EPC have been identified 
either phenotypically using flow cytometry, or ‘functionally’ using cell culture assays 
whereby the presence of an EPC is inferred through the demonstration of the 
evolution of mature endothelial characteristics in a population of cultured 
heterogeneous cell types. 
 
1.4 IDENTIFYING ENDOTHELIAL PROGENITOR CELLS BY SURFACE PROTEINS 
Through the close spatial relationship observed between endothelial and 
haematopoietic cell lineages in developing embryos, it is evident that a common 
progenitor, the haemangioblast, gives rise to both the vascular and haematopoietic 
systems [Sabin, 1920]. This is supported by gene deletion studies that identified the 
existence of common cell surface proteins necessary for vascular and haematopoietic 
development [Cheng et al., 1996; Shalaby et al., 1995]. Whilst previously thought to 
be specific to the developing embryo, there is now evidence to support the existence 
of a post-natal haemangioblast in man [Bailey et al., 2003; Ribatti, 2008]. Efforts to 
define the haemangioblast have helped shape our understanding of the EPC. A 
variety of haematopoietic and endothelial surface markers have been used to identify 
putative EPC (Table 1.1). 
 22 
Endothelial progenitor cells have been predominantly defined by the 
expression of CD34 and the extracellular domain of vascular endothelial growth 
factor receptor-2 (VEGFR-2), as these cell surface markers are thought to indicate 
cellular naivety and a vascular phenotype respectively. The surface receptor CD34 is 
often regarded as a ‘stem cell’ marker and is widely used as an indicator of cellular 
naivety. CD34 is a cellular adhesion molecule necessary for normal haematopoiesis 
[Cheng et al., 1996], and is also expressed on vascular endothelium [Fina et al., 1990]. 
VEGFR-2 is one of a family of transmembrane cell surface receptors for vascular 
endothelial growth factor, a pro-angiogenic cytokine. VEGFR-2 is considered as a 
marker of endothelial lineage, being widely expressed on mature endothelial cells and 
is necessary for the normal development of the vascular system and haematopoiesis 
in-utero. Upon differentiation toward a haematopoietic lineage the VEGF and CD34 
receptors are lost, whilst those committed to an endothelial lineage retain expression 
[Civin et al., 1984; Matthews et al., 1991]. 
 
Asahara et al, demonstrated that both CD34+ and VEGFR-2+ fractions 
isolated from mononuclear cells when cultivated under angiogenic conditions up-
regulated endothelial surface antigens (CD31, Tie-2, E-Selectin, VEGFR-2), and 
were capable of homing to regions of ischaemia and appeared to participate in 
neovascularisation in an animal model of hind limb ischaemia [Asahara et al., 1997]. 
Whilst fuelling an intense period of research this study was far from definitive and 
indeed raised more questions than it answered. The purity of the cell populations 
used in the study was poor (CD34 ~ 15.7% and VEGFR-2 ~ 20%), and the infused 
cells were not specifically dual positive. CD34 and VEGFR-2 co-expression is also a 
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characteristic of mature endothelial cells therefore additional surface markers have 
been used in an attempt to distinguish EPC from mature endothelial cells sloughed 
from the vessel wall by vascular stress [Dignat-George et al., 2000]. The cell surface 
protein CD133 is a relatively novel surface receptor with unknown function that is 
expressed on most CD34+ cells. CD133 is quickly down regulated on differentiation 
and is therefore a reliable indicator of cellular naivety [Miraglia et al., 1997]. Whilst 
CD133 is generally considered to be a marker of haematopoietic lineage, on account 
of the ability of CD133+ cells to provide haematopoietic reconstitution by 
transplantation, CD133+ cells have also been reported to give rise to cells with an 
endothelial phenotype in culture [Gehling et al., 2000]. The co-expression of all three 
receptors has been used to identify a population of mononuclear cell capable of 
developing a mature phenotype [Peichev et al., 2000]. CD133 expression either in 
isolation, or in combination with CD34 and VEGFR-2 has been used in variety of 
studies to define EPC [Friedrich et al., 2006; Gill et al., 2001; Grisar et al., 2005; 
Kanayasu-Toyoda et al., 2003; Kipshidze et al., 2004; Mauro et al., 2007; Palange et 
al., 2006; Quirici et al., 2001; Valgimigli et al., 2005; Yang et al., 2004].  
 
CD34+CD133+VEGFR2+ cells are however extremely rare in the peripheral 
circulation and reliably measuring them in clinical studies is extremely difficult and it 
is questionable that they could be used in clinical practice. Furthermore although the 
expression of CD133 is a reliable indicator of cellular naivety, it still fails to 
adequately distinguish a vascular progenitor from a haematopoietic progenitor. Case 
et al, specifically compared the behaviour of CD34+CD133+VEGFR2+ cells when 
used in two widely employed endothelial colony forming assays, early and late EPC 
 24 
(discussed below), and a haematopoietic colony-forming assay [Case et al., 2007]. 
CD34+CD133+VEGFR2+ cells were incapable of forming colonies in the culture 
assays previously used to define EPC, but consistently formed colonies in 
haematopoietic assays. The majority of CD34+CD133+VEGFR2+ cells in fact 
expressed the common leukocyte antigen CD45, and the capacity to form an 
endothelial phenotype was confined to those CD34+ cells that were CD45-. These 
findings have been supported by Timmermans et al, who also demonstrated that 
CD45-CD34+CD133-VEGFR-2+ cells are capable of forming late outgrowth 
endothelial colonies (see below), and that a separate CD45+CD34+CD133+VEGFR-
2- population, formed haematopoietic colonies [Timmermans et al., 2007]. CD45+ is 
a powerful discriminator of pure haematopoietic and non-haematopoietic fractions 
and is beginning to be used to discriminate populations of EPC in clinical studies. It 
may transpire that the absence of CD45 may define a population of progenitor cell 
that ultimately forms true endothelial cells, as CD34+CD45- cells generate colonies 
that more closely resemble mature endothelial cells both functionally and 
phenotypically. However, as mature endothelial cells are CD45- and may also 
express CD34 [Delia et al., 1993; Fina et al., 1990], the detection of CD34+CD45- 
cells in the peripheral circulation may simply represent the presence of circulating 
mature endothelial cells rather than bone marrow derived progenitor cells. Late 
outgrowth colonies may represent the same phenomenon [Case et al., 2007]. 
 
 Just as endothelial function is integral to the maintenance of normal vascular 
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homeostasis [Ross, 1990], EPC regulation appears to be similarly important. 
Concentrations of circulating CD34+VEGFR-2+ cells are reduced in patients with 
traditional cardiovascular risk factors including cigarette smoking, elevated LDL 
cholesterol [Vasa et al., 2001b], diabetes mellitus [Fadini et al., 2005] and 
hypertension [Pirro et al., 2007]. CD34+VEGFR-2+ cell concentration is markedly 
reduced in patients with overt atherosclerotic disease of the coronary and peripheral 
circulation [Chironi et al., 2007]. Consistent with their putative vasculoprotective 
function, a high circulating concentration of CD34+VEGFR-2+ cells is associated 
with a lower risk of myocardial infarction, hospitalisation, revascularisation and 
cardiovascular death in patients with coronary artery disease [Schmidt-Lucke et al., 
2005; Werner et al., 2005]. CD34+VEGFR-2+ [Vasa et al., 2001b], CD133+VEGFR-
2+ [Thum et al., 2007b], and CD133+CD34+ populations fall with advancing age, 
and mobilisation in response to cardiovascular stress is reduced in older patients 
[Scheubel et al., 2003]. Matching for biological characteristics however, in particular 
angiographic severity of coronary artery disease, diminishes the importance of 
chronological age as a determinant of EPC concentration [Pelliccia et al., 2009], 
however EC-CFU are significantly higher in children compared to adults [Fabbri-
Arrigoni et al., 2012]. EPC biology is in part inherited, with apparently healthy 
offspring of patients with coronary artery disease having reduced levels of 
CD34+VEGFR-2+ cells compared with the offspring of healthy controls [Whittaker 
et al., 2008].  
 
 Even in healthy people CD34+ cells comprise a mere 0.05% of circulating 
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leukocytes. Circulating sub-populations co-expressing CD133 and VEGFR-2 are 
even more rare, and the capacity of such a small population to provide significant 
endovascular repair is questionable. CD14 is a membrane bound receptor primarily 
responsible for the detection of lipopolysaccharide [Wright et al., 1990]. It is 
expressed in abundance on monocytes, and also at low levels on mature endothelial 
cells [Jersmann et al., 2001]. CD14+ cells are involved in the response to vessel injury 
and new vessel formation, and share many antigenic characteristics with mature 
endothelial cells in culture. Importantly, CD14+ cells are approximately 10 times 
more abundant in the peripheral circulation than CD34+ cells. There has therefore 
been much speculation and investigation into whether CD14+ cells may be a source 
of clinically useful EPC [Rehman et al., 2003; Rohde et al., 2007; Yoder et al., 2007; 
Zhang et al., 2006]. Monocytes are highly plastic, having the capacity to differentiate 
into a variety of mature phenotypes depending on environmental cues [Zhao et al., 
2003]. In particular, monocytes will up-regulate a variety of endothelial 
characteristics in culture [Fernandez Pujol et al., 2000; Harraz et al., 2001; Rehman et 
al., 2003; Schmeisser et al., 2001; Urbich et al., 2003; Zhang et al., 2005; Zhang et al., 
2006; Zhao et al., 2003], and will form vascular structures in vitro under appropriate 
angiogenic stimulation [Rohde et al., 2007; Schmeisser et al., 2001; Zhang et al., 
2005]. Activated monocytes accumulate at sites of new vessel formation and adhere 
to injured endothelium, and under experimental conditions CD14+VEGFR-2+ and 
CD14+Tie-2+ cells accelerate re-endothelialisation with demonstrable improvements 
in endothelial function by enhanced acetylcholine-mediated vasodilatation in a NO-
dependent manner [Elsheikh et al., 2005; Nowak et al., 2004]. Such VEGFR-2 and 
Tie-2 expressing monocytes are also known to facilitate neo-angiogenesis in the 
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context of neoplasia [De Palma et al., 2005; Murdoch et al., 2007; Venneri et al., 
2007]. Numerous studies however indicate that whilst monocytes are pro-angiogenic, 
they do not incorporate directly into the vasculature [De Palma et al., 2005; O'Neill et 
al., 2005; Zentilin et al., 2006; Ziegelhoeffer et al., 2004]. CD14+ cells most likely 
accelerate vascular repair through the secretion of angiogenic growth factors rather 
than by differentiating into true endothelial cells [Rehman et al., 2003]. 
 
Both CD34+ and CD14+ populations therefore appear important in the 
regeneration of diseased and damaged arteries and it is likely that populations 
bearing the two receptors interact. CD34+ cells for instance augment the 
incorporation of CD34-CD14+ cells into the endothelium of blood vessels in mouse 
ischemic limbs [Harraz et al., 2001]. Drawing a firm distinction between CD14+ and 
CD34+ cells however is an over simplification, as several lines of evidence indicate 
that a proportion of CD14+ cells are in fact derived from the more naïve CD34+ 
population. CD34+ cells cultured on fibronectin in the presence of VEGF and basic 
fibroblastic growth factor differentiate into a CD14+ population before developing 
endothelial characteristics in-vitro, including the expression of Von Willebrand factor 
(vWF), eNOS and CD144 [Nakul-Aquaronne et al., 2003]. A study using a CD34+ 
acute myeloid leukemia cell line MUTZ-3, interrogated the differentiation of 
CD34+CD14–CD11b– progenitors through a CD34–CD14–CD11b+ stage, into non-
proliferating CD14+CD11bhi progeny [Santegoets et al., 2006]. The presence of 
CD34+CD14+ cells has been confirmed by Romagani et al, who used highly-sensitive 
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antibody-conjugated magneto-fluorescent liposomes to isolate a subset of CD14+ 
cells co-expressing CD34 [Romagnani et al., 2005]. In peripheral blood these 
CD14+CD34low cells constitute 0.6% to 8.5% of all peripheral-blood leukocytes and 
are the dominant population among circulating VEGFR-2+ cells. In the bone 
marrow virtually all CD14+ cells were CD14+CD34low double positive. Circulating 
CD14+CD34low cells, exhibit high expression of the embryonic stem cell markers 
such as Nanog and Oct-4, and are capable of differentiating into endothelial cells. 
Taken together these studies suggest that CD14+ cells are derived from CD34+ cells 
and have the ability to develop endothelial characteristics depending on the action of 
external cues. The interactions between these cell types require further investigation. 
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Table 1.1: Haematopoietic and endothelial surface markers  
Identifier Distribution Function  
CD45 Leukocytes A signalling molecule regulating 







Endotoxin receptor regulating 
inflammatory cytokine production 
such as TNF by monocytes 
CD 115 Monocytes 
Macrophages 
Receptor for macrophage-CSF 
regulating myeloid proliferation and 
differentiation 
CD117 (c-Kit) Haematopoietic stem 
and progenitor cells 
Receptor for stem cell factor.  
Stimulates cellular proliferation. 
CD133 Haematopoietic stem 
and progenitor cells 
Unknown 
CD34 Haematopoietic stem 
and progenitor cells 
Capillary 
endothelium 
Intracellular adhesion molecule. 
Binds E and L-Selectins and is 





Adhesion molecule thought to be 
important for trans-endothelial 







N/A - Phagocytic process occurring 
in myeloid and endothelial cells 
Ulex binding Macrophages 
Monocytes 
Endothelium 





Constituent of transforming growth 
factor-beta receptor 1. Important 
regulator of angiogenesis. 
CD 141 Endothelium, Smooth 
Muscle, Monocytes 
and Neutrophils 
Binds thrombin and activates protein 








Tie 2 (CD202) Endothelium 
Monocytes 
Stem cells 
Angiopoietin 1 receptor. 
Regulates vessel remodeling and 
maintains vascular integrity 
CD 146 Endothelium 
Melanoma cells 
Dendritic cells 
Intra-cellular adhesion molecule. 
E-Selectin 
(CD62E) 
Endothelium Adhesion molecule regulating 
leukocyte/endothelial interactions 
and cell trafficking to sites of 
inflammation  
CD 144 Endothelium 
 
Intracellular adhesion molecule 





Endothelium Regulation of endothelial adhesion 
and signalling. Essential for 


















































eNOS Endothelium Enzymatic generation of nitric oxide ENDOTHELIAL 
Ac-LDL = Acetylated low density lipoprotein; CD = cluster of differentiation; TNF = tumour 
necrosis factor; CSF = colony stimulating factor; eNOS = endothelial nitric oxide synthase; 
VEGFR-2 = vascular endothelial growth factor receptor-2 
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1.5  CULTURING ENDOTHELIAL PROGENITOR CELLS 
A widely used but largely inferential approach to the isolation and 
quantification of EPC has been through demonstrating the development of mature 
endothelial characteristics in mononuclear cells following a period of culture. Broadly 
speaking, there are 3 populations of cultured EPC or ‘functional’ EPC. 
 
1)  Endothelial Cell - Colony Forming Unit (EC-CFU), also referred to as EPC-
CFU, and as early outgrowth colonies on the basis of the time at which they 
appear in culture (five days).  
2)  Circulating angiogenic cells (CAC), also at times referred to as early 
outgrowth colonies.  
3)  Endothelial Colony Forming Cells (ECFC) or late outgrowth colonies based 
on their appearance in culture at two to three weeks. These have also been 
referred to as late outgrowth EPC, endothelial outgrowth colonies, and blood 
outgrowth endothelial cells. 
 
1.5.1 Endothelial Cell - Colony Forming Unit 
The EC-CFU or early outgrowth colony assay is a modified version of the 
method originally used by Asahara [Asahara et al., 1997]. Colonies are generated in 
endothelial growth medium on fibronectin. A pre-plating step at 2 days excludes 
initially adherent cells, in an attempt to remove circulating endothelial cells from the 
assay. Mature colonies form at around day 5, and are comprised of clusters of small 
round cells with peripheral spindle shaped cells (Figure 1.1) that express endothelial 
characteristics such as CD146, CD31, Tie-2, VEGFR-2, CD34, E-Selectin and 
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eNOS expression, Ulex Europeus agglutinin-1 (UEA-1) binding and acetylated low 
density lipoprotein uptake. Consistent with a vasculoprotective role, EC-CFU 
concentration is associated with improved brachial reactivity [Hill et al., 2003] and 
are increased in response to tissue ischaemia and vascular injury such as that 
occurring in patients undergoing coronary artery bypass surgery [Roberts et al., 
2007], the presence of myocardial ischaemia [George et al., 2004] or infarction 
[Massa et al., 2005; Shintani et al., 2001], and in patients undergoing angioplasty 
[Banerjee et al., 2006; Bonello et al., 2006; Chen et al., 2008; Marboeuf et al., 2008]. 
Impaired mobilisation of EC-CFU in response to ischaemic injury is also associated 
with an adverse outcome [Sobrino et al., 2007]. EC-CFU concentrations are lower in 
association with adverse cardiovascular risk profiles, such as in patients with type I 
[Loomans et al., 2004] and type II diabetes mellitus, hypercholesterolaemia [Hill et 
al., 2003], hypertension [Delva et al., 2007],  coronary artery disease [Heeschen et al., 
2004], cerebrovascular disease [Ghani et al., 2005], COPD [Palange et al., 2006], 
rheumatoid arthritis [Grisar et al., 2005], and heart failure [Valgimigli et al., 2004], 
although notably not in non-ischaemic cardiomyopathy [Zhou et al., 2008]. 
 
1.5.2 Circulating Angiogenic Cells 
Unlike EC-CFU, CAC are derived from an adherent population of 
mononuclear cells and do not form discrete colonies. They are thought to be derived 
from the bone marrow and have been defined as EPC on the basis of the expression 
of endothelial characteristics; UEA-1 binding and uptake of Ac-LDL, and expression 
of vWF, CD31, VEGFR-2, CD144, Tie-2 [Asahara et al., 1999; Dimmeler et al., 
2001; Dimmeler et al., 2000; Gehling et al., 2000; Kalka et al., 2000b]. They probably 
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represent a population of adherent monocyte. Similar to EC-CFU, CAC and are 
depressed in cardiovascular diseases such diabetes, coronary artery disease and 
rheumatoid arthritis [Adams et al., 2004; Grisar et al., 2005; Tepper et al., 2002; Vasa 
et al., 2001b], and are mobilised in response to acute stressors such as myocardial 
ischaemia [Shintani et al., 2001] and coronary artery bypass grafting [Roberts et al., 
2007]. They promote neovascularisation in animal models of acute myocardial 
infarction [Kawamoto et al., 2001], although they probably do this through the 
secretion of angiogenic cytokines as they have little proliferative capacity of their own 
[Kalka et al., 2000b; Kawamoto et al., 2001; Rehman et al., 2003]. 
 
1.5.3 Endothelial colony forming cell or late outgrowth colonies 
This population of cells is also generated from the culture of peripheral 
mononuclear cells, but in contrast to EC-CFU, endothelial colony forming cells 
(ECFC) are derived from an adherent fraction, grown on type I collagen. ECFC are 
morphologically described as flat clusters of cells with a cobblestone appearance 
(Figure 1.1). Whilst ECFC share many phenotypic characteristics with EC-CFU 
[Ingram et al., 2004], they do not express the haematopoietic markers CD45 or 
myeloid/macrophage markers such as CD115, and do not exhibit phagocytic 
function. ECFC arise from non-haematopoietic cells negative for CD133 and the pan 
leukocyte marker CD45, but positive for CD34 and VEGFR-2 [Timmermans et al., 
2007]. Enrichment of unsorted mononuclear preparations for CD45-CD34+ cells 
increases the frequency of ECFC by some 400% compared to an abolition of ECFC 
growth in the CD45+ fraction [Timmermans et al., 2007]. Of the populations so far 
identified, the CD45-CD34+ derived ECFC more closely fulfil the characteristics of a 
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true EPC. They conform to an endothelial phenotype and morphology, are derived 
from the bone marrow [Lin et al., 2000], have robust proliferative potential [Gulati et 
al., 2003a; Ingram et al., 2004], and are capable of forming perfusing vessels in vivo 
[Yoder et al., 2007]. ECFC are mobilised within the first few hours following 
myocardial infarction [Huang et al., 2007; Massa et al., 2009] and have been 
positively correlated with the severity of coronary artery disease in patients 
undergoing coronary angiography [Guven et al., 2006]. However, as previously 
discussed, mature endothelial cells may also express CD34 [Fina et al., 1990] and are 
also CD45-. The growth of late outgrowth colonies from the peripheral blood may 
therefore represent the presence of circulating mature endothelial cells sloughed from 
the vasculature, rather than circulating bone marrow derived progenitor cells. This 
important distinction has yet to be established. 
 
Unfortunately, across hundreds of different studies, the term EPC has been 
used interchangeably with reference to several different cell populations, bearing 
various permutations of surface markers and cultured under different conditions, and 
this has made it difficult to make reliable comparisons between studies. Erroneous 
conclusions regarding the phenotype of cell populations in culture as a result of the 
low specificity of given endothelial characteristics may provide some explanation for 





Figure 1.1 Endothelial cell-colony forming units (EC-CFU) and endothelial 
colony forming cells (ECFC): (A)EC-CFU are generated from a non-adherent 
population of mononuclear cells cultured on fibronectin and appear some 5-7 days into 
culture. EC-CFU exhibit endothelial surface characteristics but are composed of monocytes 
and angiogenic lymphocytes with little capacity to form perfusing vessels or incorporate 
directly into vascular structures. EC-CFU exhibit phagocytic activity and avidly secrete 
angiogenic growth factors. (B) ECFC are generated from adherent mononuclear cells grown 
on type I collagen and appear after 2-3 weeks of cell culture. ECFC are morphologically 
indistinguishable from mature endothelial cells and are derived from non-haematopoietic 
(CD45-) cells expressing CD34. ECFC have robust proliferative potential and the capacity to 
form perfusing blood vessels in vitro. 
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1.6 ENDOTHELIAL PROGENITOR CELLS AND IATROGENIC VASCULAR INJURY 
Using various animal models of vascular injury pre-clinical studies have 
amassed a significant body of evidence to indicate that bone marrow derived cells 
localise to regions of vascular injury and accelerate vascular healing by restoring 
endothelial function and the attenuation of neo-intimal hyperplasia (Table 1.2) 
[Kong et al., 2004a; Takamiya et al., 2006; Walter et al., 2002; Werner et al., 2003; 
Werner et al., 2002; Yoshioka et al., 2006]. Several clinical studies have specifically 
addressed the role of putative EPC populations following angioplasty (Table 1.3). 
Most of these studies have examined the behaviour of EC-CFU. These studies have 
been small, and have often lacked appropriate control groups for comparison. A 
study of patients undergoing peripheral angioplasty detected an increase in 
circulating mature endothelial cells immediately after angioplasty, followed by a two 
to three fold increase in EC-CFU at 24 hours [Bonello et al., 2006]. These findings 
were confirmed by Marboeuf et al, who also correlated EC-CFU with plasma C-
reactive protein (CRP) concentrations following angioplasty [Marboeuf et al., 2008]. 
Garg et al, described EC-CFU mobilisation following PCI in patients with acute 
coronary syndromes. However, it is impossible to determine whether EC-CFU were 
mobilised in response to myocardial infarction or discrete vascular injury in this study 
given the absence of a control group of patients (i.e. patients not undergoing PCI) 
[Garg et al., 2008a]. However mobilisation of EC-CFU type cells within the first 24-
hours of angioplasty has been observed, suggesting a role for these cells in the 
immediate response to vascular injury [Banerjee et al., 2006; Bonello et al., 2006; 
Garg et al., 2008a; Marboeuf et al., 2008].  
 36 
 Few studies have addressed whether EC-CFU mobilisation influences the 
development of ISR and a need for target vessel revascularisation and the available 
data are poor. In a retrospective study, George et al., demonstrated that in patients 
presenting with proliferative, as opposed to focal ISR, EC-CFU were reduced both in 
number and adhesive capacity, suggesting that a deficiency in EC-CFU might 
predispose to aggressive neointimal hyperplasia [George et al., 2003]. This study did 
not detect a difference in the number of EC-CFU between those patients with and 
without angiographic restenosis, however subsequently two other groups have 
reported a reduction in EC-CFU in patients presenting with restenosis, and these 
patients had reduced EC-CFU proliferative and migratory capacity as well as 
increased cellular senescence [Lei et al., 2007; Matsuo et al., 2006]. 
 
A strong association exists between reduced CD34+VEGFR-2+ cells and 
those risk factors predictive of ISR, i.e. cigarette smoking [Vasa et al., 2001b], 
diabetes mellitus [Fadini et al., 2005], and endothelial dysfunction [Herbrig et al., 
2006]. Two small clinical studies demonstrated a fall in CD34+VEGFR-2+ cells 
within the first few hours of coronary angioplasty, although interpretation of these 
studies is limited as neither used a control group [Lee et al., 2009; Thomas et al., 
2008a]. In a moderate sized study of 102 patients, CD34+CD133+ concentrations 
were significantly lower in patients undergoing PCI for stable anginal symptoms than 
in matched controls without angina, however the peripheral concentration was 
similar at 24 hours following PCI [Arao et al., 2010]. Egan et al., measured a variety 
of surface markers expressed on mononuclear cells including CD34, CD133, 
VEGFR-2, CD117, CD31 and CXCR4+ in patients undergoing PCI, diagnostic 
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coronary angiography alone and healthy controls. In this small study, patients with 
CAD had lower resting levels of CD34+, CD133+, CD117+, CD34+CD117+, 
CD34+CD31+ and CXCR4+ cells compared to healthy controls. Following PCI, 
they observed an increase in those cells expressing CD133, CD117, CD34/CD31, 
CD34/CD117 and CXCR4 within 6-12 hours [Egan et al., 2009]. As CXCR4 is 
thought to be integral to EPC homing and integration, it is of interest to note that 
reduced levels of CXCR4 correlated with the incidence of angina at one year. Whilst 
underpowered to address clinical outcomes, this study suggests a role for CXCR4 in 
EPC homing and integration at the site of vascular injury following PCI. 
 
Mobilisation of ECFC and CD45-CD34+ has been detected within hours of 
acute myocardial infarction in small preclinical and clinical studies. One may 
speculate that PCI would exert a similar effect although no studies have specifically 
examined ECFC or CD45-CD34+ cells following PCI. Several studies have 
documented an increase in CD34+CD45+ cells following PCI [Bonello et al., 2006; 
Inoue et al., 2007; Schober et al., 2005]. Importantly there is an indication that this 
might be associated with the development of neo-intimal hyperplasia. Schober et al., 
found that CD34+CD45+ mobilisation following PCI was significantly correlated 
with, and independently predictive of, late lumen loss at 6 months [Schober et al., 
2005]. Inoue et al., performed a similar study and combined coronary and peripheral 
venous sampling to detect a local inflammatory response within the coronary 
circulation in response to PCI [Inoue et al., 2007]. The magnitude of inflammation 
within the coronary circulation correlated with CD34+CD45+ mobilisation, and 
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both were significantly greater in patients who subsequently developed ISR. 
Interestingly the use of DES in this study was associated suppression of both coronary 
inflammation and circulating CD34+CD45+ cell concentrations, suggesting that in 
addition to a local anti-proliferative action, DES may also reduce ISR by suppressing 
inflammatory signalling to the bone marrow. Inoue et al., demonstrated that 
circulating mononuclear cells of patients with ISR exhibited a propensity to develop 
a smooth muscle phenotype over that of an endothelial phenotype in culture. The 
potential role of circulating smooth muscle progenitor cells (SMPC) in the 
development of ISR has been supported in other pre-clinical studies [Sata et al., 
2002]. It is interesting to note that SMPC are also reported to express CD34 and 
VEGFR-2 [Simper et al., 2002]. Furthermore both CD34 and CD133 are expressed 
at higher concentrations in the neo-intima of re-stenotic lesions compared to de-novo 
lesions [Skowasch et al., 2003]. These populations may indeed potentiate neo-intimal 





Table 1.2.  Preclinical studies of putative EPC following vascular injury 
Reference Model Number  Putative EPC  Effect 
[Walter et al., 
2002] 
Murine Tie2/lacZ BM 
transplant recipients 
subjected to balloon 
mediated arterial injury 
and pretreatment with 





Simvastatin enhanced EPC mobilisation 
following vascular injury and increased 
their adhesive capacity. Re-
endothelialisation was accelerated by 
BM derived cells and neo-intimal 
hyperplasia was reduced. 
[Werner et al., 
2002] 
Murine GFP BM 
transfection followed by 
wire mediated arterial 
injury and pretreatment 




Sca 1+KDR+ cells of 
BM origin 
 
Rosuvastatin enhanced BM derived EPC 
mobilisation following vascular injury. 
Re-endothelialisation was accelerated by 
BM derived cells and neo-intimal 
hyperplasia was reduced. 
[Werner et al., 
2003] 
Intravenous cell therapy 
following wire mediated 
murine arterial injury 
6 vascular injury Spleen derived Dil-Ac-
LDL+lectin+ MNCs 
with or without a period 
of culture in endothelial 
growth medium  
Cell therapy enhanced re-
endothelialisation in splenectomised 
animals and was associated with a 
reduction of neointima formation but 
MNC were more effective than EPC.  
[Fujiyama et al., 
2003] 
Intravenous cell therapy 
vs saline following balloon 
mediated murine arterial 
injury  








Compared to saline placebo, BM 
derived CD34+ cells and both PB and 
BM derived CD14+ cells upregulated 
endothelial markers, accelerated neo-
endothelialisation and inhibited neo-
intimal hyperplasia following activation 
with MCP-1 
[Kong et al., 
2004a] 
G-CSF vs control prior to 




CD34+KDR+ G-CSF enhanced EPC mobilisation 
following vascular injury. Re-
endothelialisation was accelerated by 
BM derived cells and neo-intimal 
hyperplasia was reduced. 
[Nowak et al., 
2004] 
Intravenous cell therapy 
following balloon injury 
in mice using 
CD14/CD11b cells 
expressing, Tie 2+, Tie2-, 
KDR+, KDR-, or saline 
control 
6 cell therapy 
6 controls 
Myeloid cells (CD14, 
CD11b) expressing 
KDR+ or Tie2+ 
 
CD14+KDR+ and CD14+Tie-2+ 
displayed endothelial characteristics in 
culture and enhanced re-
endothelialisation of denuded arteries 
with an associated reduction in neo 
intimal hyperplasia. 
[Elsheikh et al., 
2005] 
Intravenous cell therapy 
using GFP transduced 
cells following balloon 
mediated arterial injury in 
mice 
10 CD14+KDR+  
10 CD14+KDR- 




Unlike CD14+KDR- cells, CD14+KDR+ 
cells exhibited an endothelial phenotype 
in culture and contributed to neo-
endothelialisation. 
[Yoshioka et al., 
2006] 
G-CSF following wire 
mediated arterial injury in 
mice 
 
Treatment pre- and post-
arterial injury vs post-
arterial injury alone 
22 G-CSF  
20 controls 
 
CD34+KDR+ G-CSF reduced neo-intimal hyperplasia 
in association with mobilisation of bone 
marrow derived EPC and accelerated re-
endothelialisation compared to control. 
The effect was enhanced if administered 
prior to injury. Few BM derived cells 
contributed to neo-endothelium. 
[Takamiya et 
al., 2006] 
1) G-CSF prior to balloon 
mediated arterial injury in 
rats 
2) GFP BM transfected 
mice subjected to balloon 
mediated arterial injury 
10 G-CSF  
5 placebo 
CD117+KDR+ 1) G-CSF enhanced EPC mobilisation 
following vascular injury. Re-
endothelialisation was accelerated and 
neo-intimal hyperplasia was reduced. 
2) GFP expressing BM derived cells 
contribute to neo-endothelialisation. 
BM = bone marrow; Dil-Ac-LDL= Di acetylated low-density lipoprotein; EPC = endothelial progenitor cell; G-CSF = granulocyte-colony 
stimulating factor; GFP = green fluorescent protein; KDR = kinase domain receptor; MCP-1 = monocyte chemoattractant protein – 1; 




Table 1.3. Clinical studies of putative EPC following PCI 
Reference Study 
design 
Number Putative EPC Effect of Angioplasty 
[George et al., 
2003] 
Retrospective 






EC-CFU No difference in EC-CFU in those presenting 
with or without angiographic restenosis, but EC-
CFU lower in those presenting with diffuse vs 
focal restenosis and reduced adhesive capacity in 
restenosis. 
[Schober et al., 
2005] 
Prospective  
Elective PCI with 
no control group 
17 PCI CD34+ Mobilisation of CD34+ following PCI predicts 
restenosis and correlates with late lumen loss. 
[Bonello et al., 
2006] 
Prospective 
Elective PCI with 
no control group 
 
15 PCI CEC 
CD45+CD34+ 
EC-CFU 
CEC were increased 6.-fold at 6 hours, 
CD45+CD34+ cells increased 2.6-fold at 6hrs 
and EC-CFU increased 2.6-fold at 24 hours. 
[Matsuo et al., 
2006] 
Retrospective 






EC-CFU EC-CFU 2-fold greater in patients without ISR 
and increased senescence in EC-CFU of patients 
with ISR. 
[Banerjee et al., 
2006] 
Prospective 
PCI in elective 




20 elective PCI 




No change in CD34+CD31+with PCI in ACS or 
diagnostic angiography but 1.4-fold increase in 
EC-CFU with elective PCI. 
 











EC-CFU 3.5 fold greater in patients without 
ISR. 
Reduced proliferative and migratory capacity in 
EC-CFU of patients without ISR but no 
difference in adhesive capacity. 
[Inoue et al., 
2007] 
Prospective 
Elective PCI with 
no control group 
40 PCI CD34+ CD34+ increased 3-fold following BMS at 7 
days, 






no control group 
14 angioplasty EC-CFU EC-CFU increased 2.5-fold at 24 hours. 
[Garg et al., 
2008b] 
PCI in NSTEMI 
with no control 
group 
20 PCI EC-CFU EC-CFU increased 1.3-fold at 24 hours. 
[Thomas et al., 
2008a] 
Prospective 
Elective PCI with 
no control group 






Transient fall in all populations at 6 hours post 
PCI. 
[Egan et al., 
2009] 
Prospective 











Compared to angiography, CD133+, CD117+, 
CD34+CD117+, CD34+CD31+, and 
CXCR4+cells increased 6–12 hours following 
PCI. No difference in CD34+, VEGFR-2+, or 
CD34+VEGFR-2+ cells. CXCR4 expression 
correlated with freedom from angina at 1 year. 
[Lee et al., 
2009] 
Prospective 
Elective PCI in 
diabetics 
No control group 
8 patients CD34+VEGFR-2+ Transient fall of ~50% in first 4 hours following 
PCI. 
ACS = acute coronary syndrome; CD = cluster of differentiation; CXCR-4 = chemokines receptor 4; EC-CFU = endothelial cell 
colony forming unit; NSTEMI = non-ST-segment elevation myocardial infarction; PCI = percutaneous coronary intervention 
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1.7 THERAPEUTIC ENDOTHELIAL PROGENITOR CELLS FOR PCI 
ASSOCIATED VASCULAR INJURY 
 Current strategies to reduce the incidence of complications following 
percutaneous intervention are based on suppressing neo-intimal cellular proliferation 
rather than enhancing endovascular repair. Drug-eluting stents have dramatically 
reduced the incidence of early in-stent restenosis, but local anti-proliferative therapy 
may interfere with vascular healing and prevent formation of a functional endothelial 
layer [Muldowney et al., 2007]. Therapies designed to mobilise endothelial 
progenitors or to increase their ability to home to the site of stent implantation and 
facilitate vascular repair are attractive, and have the potential to improve clinical 
outcomes following PCI. These approaches fall into three broad categories; 
pharmacological, stent-based and cellular therapies.  
 
1.7.1 Pharmacological mobilisation of endothelial progenitor cells 
 Mobilisation of precursors from the stem cell niche occurs via 
phosphatidylinositol-3-kinase/Akt/eNOS (PI3K/Akt/eNOS) activation.  The 
PI3K/Akt/eNOS pathway is responsible for the regulation of cellular apoptosis, 
proliferation, and migration in a variety of biological systems, including the 
cardiovascular system [Shiojima et al., 2002]. Activation of the PI3-Akt pathway by 
angiogenic factors such as VEGF, fibroblastic growth factor and angiopoietin 
stimulates nitric oxide synthesis by bone marrow stromal cells [Dimmeler et al., 2001; 
Llevadot et al., 2001]. Increased nitric oxide bioavailability leads to cleavage of intra-
cellular adhesions between stem cells and stromal cells of the bone marrow by 
proteinases, such as elastase, cathepsin G, and matrix metalloproteinases [Heissig et 
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al., 2002]. A high stromal derived factor -1 (SDF-1) gradient across the bone marrow 
generated by bone marrow stromal cells acts through its cognate receptor CXCR-4 
to force mobilised stem cells into the peripheral circulation such that they may home 
to regions of vascular injury [Asahara et al., 1999; Seeger et al., 2009; Yla-Herttuala et 
al., 2007]. Mobilisation of EPC is therefore heavily reliant on nitric oxide synthesis 
via PI3K/Akt/eNOS activation [Aicher et al., 2003; Landmesser et al., 2004]. 
Reduced NO bioavailability is evident in patients with cardiovascular risk factors and 
is integral to the development of atherosclerosis and disordered function of eNOS is 
thought to be in part responsible for impaired mobilisation of EPC in these patients 
[Huang, 2009; Thum et al., 2007a]. Bone marrow cells treated with an eNOS 
transcription enhancer in order to increase eNOS activity exhibit enhanced 
migratory and neovascularisation capacity and when administered in a model of 
hind-limb ischaemia can improve organ function. Furthermore this beneficial effect is 
reversed by the use of an eNOS inhibitor, strongly implicating nitric oxide in the 
process of vascular repair and neovascularisation [Sasaki et al., 2006]. Detailed 
mechanistic data regarding EPC mobilisation in the context of discrete vascular 
injury are limited, although there are numerous factors thought to induce EPC 
mobilisation including VEGF, fibroblastic growth factor, growth hormone, insulin-
like growth factor, angiopoietin, SDF-1, erythropoietin, eostrogens, granulocyte 
colony-stimulating factor, statins, angiotensin receptor blockers, peroxisome 
proliferator-activated receptor antagonists and physical exercise. Several of these 
have been examined in the context of discrete vascular injury as potential therapeutic 
strategies for the mobilisation of EPC. 
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3-Hydroxy-3-methylglutaryl coenzyme-A reductase inhibitors 
3-Hydroxy-3-methylglutaryl coenzyme-A reductase inhibitors (statins) 
mobilise CD34+ and VEGFR-2+ cells to the peripheral circulation in a dose-
dependent manner via the PI3/Akt pathway [Leone et al., 2008; Park et al., 2008; 
Vasa et al., 2001a]. Statins also stimulate EC-CFU and ECFC formation and 
augment the quantity, migratory and proliferative capacity of a variety of putative 
EPC in culture [Deschaseaux et al., 2007; Landmesser et al., 2004; Llevadot et al., 
2001; Walter et al., 2002; Walter DH, 2001], and also induce differentiation of 
CD14+ and CD34+ cells toward an endothelial phenotype [Dimmeler et al., 2001]. 
The reduced rate of ISR following PCI in patients treated with statins may in part be 
explained by enhanced mobilisation and function of EPC [Walter et al., 2001b]. 
Walter et al., demonstrated an accelerated rate of re-endothelialisation and a 
reduction in neo-intimal hyperplasia in rats treated with simvastatin subjected to 
balloon mediated arterial injury, associated with an increase in quantity and adhesive 
capacity of Ac-LDL+BS-1-Lectin+ cells in culture. Although this definition of EPC is 
non-specific, the neo-endothelium in statin treated animals was confirmed to be of 
bone marrow origin by the use of a Tie2/LacZ bone marrow transplant model 
[Walter et al., 2002]. Werner et al, obtained similar results using rosuvastatin [Werner 
et al., 2002]. Fluvastatin ameliorates impaired re-endothelialisation caused by 
sirolimus coated stents, however this effect does not appear to be mediated through 
mobilisation of bone marrow derived progenitors, rather by enhancing the 
traditionally recognised mechanism of re-endothelialisation; proliferation of mature 
endothelial cells adjacent to the stented segment [Fukuda et al., 2009]. The 
stimulatory effects of statins on re-endothelialisation may not be sustained. Hristov et 
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al., demonstrated a reduction of both EC-CFU and CD34+VEGFR-2+ cells in 
patients with coronary artery disease on chronic statin therapy [Hristov et al., 2007]. 
The authors speculated over the possible exhaustion of EPC reserves, desensitisation 
of the bone marrow to the effects of statins, or possible enhanced recruitment of 
circulating EPC to peripheral sites of endothelial disrepair. Whilst another small 
study concurred with the finding of reduced colony formation (similar to EC-CFU) 
on chronic statin therapy, ECFC were increased [Deschaseaux et al., 2007]. 
Stimulation of EC-CFU may therefore represent an initial haematopoietic effect of 
statin therapy as opposed to the long-term angiogenic effects of chronic therapy 
reflected by the increased quantity of ECFC. Statin therapy is of course already well 
established as a treatment for primary and secondary prevention for atherosclerotic 
events, however novel effects of statins on enhanced EPC mobilisation and function 
may support an argument for intensive statin therapy prior to PCI. 
 
Renin-angiotensin-aldosterone antagonism 
Activation of the renin-angiotensin-aldosterone system (RAAS) occurs in a 
variety of cardiovascular disorders, with associated deleterious long-term 
consequences, and antagonism of the RAAS is recognised to be beneficial in the 
setting of conditions such as heart failure, myocardial infarction, atherosclerosis and 
hypertension. The mechanism of action is thought to be partly via amelioration of 
the endothelial dysfunction that characterises these conditions, and hypothetically 
such benefits may occur through enhanced endogenous vascular repair via EPC. 
Treatment with ACE inhibitors augments the mobilisation of bone marrow-derived 
progenitors and enhances the proliferative and migratory capacity of CAC in vitro 
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[Muller et al., 2009]. Similarly, treatment with angiotensin receptor blockers causes 
circulating EC-CFU to increase [Bahlmann et al., 2005], probably through a 
reduction in cellular senescence by reducing oxidative stress caused by angiotensin II 
[Imanishi et al., 2005]. Paradoxically, angiotensin II has also been shown to stimulate 
VEGF receptor expression in a dose-dependent manner, and increase proliferation of 
EC-CFU and tube formation in Matrigel® when co-treated with VEGF [Imanishi et 
al., 2004]. Aldosterone itself has an inhibitory effect on the progenitor cell maturation 
in bone marrow cells ex-vivo in a PI3K/Akt-dependent manner [Marumo et al., 
2006] and aldosterone antagonism with either spironolactone and eplerenone 
increase circulating EPC with an associated increase in capillary density in animal 
models of ischaemia [Kobayashi et al., 2010; Ladage et al., 2011]. The effect of 
antagonising the RAAS on EPC mobilisation and function remains poorly 
understood, however the behaviour of putative EPC populations in response to 
RAAS antagonism in small experiments has largely mirrored the beneficial effects 
observed in clinical practice. 
 
Granulocyte colony stimulating factor 
 Granulocyte colony stimulating factor (G-CSF) has no established role in the 
treatment of cardiovascular disease but is routinely used to mobilise progenitor cells 
in the context of bone marrow transplantation. G-CSF induces release of elastase and 
cathepsin G from neutrophils, leading to the release of progenitors from the stem cell 
niche into the blood stream. G-CSF mobilises a variety of EPC phenotypes including 
CAC [Honold et al., 2006], EC-CFU [Korbling et al., 2006; Powell et al., 2005], 
CD34+CD133+ and CD133+VEGFR-2+ [Powell et al., 2005], c-Kit+VEGFR-2+ 
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[Takamiya et al., 2006], CD34+VEGFR-2+ [Yoshioka et al., 2006] and 
CD34+CD133+VEGFR-2+ [Korbling et al., 2006]. Several studies have 
demonstrated a positive effect of G-CSF on re-endothelialisation [Kong et al., 2004a; 
Mei et al., 2008; Shi et al., 2002; Takamiya et al., 2006; Yoshioka et al., 2006]. Kong et 
al, treated rats with G-CSF and demonstrated accelerated re-endothelialisation and 
reduced neointimal hyperplasia following endovascular balloon injury, associated 
with increased expression of CD34, eNOS, VEGFR-2, stem cell factor receptor-c-kit, 
and E-selectin on circulating MNC [Kong et al., 2004a]. Takamiya et al showed 
similar effects of G-CSF on arterial repair associated with the mobilisation of c-
Kit+VEGFR-2+ cells and enhanced endothelial coverage [Takamiya et al., 2006]. A 
green fluorescent protein bone marrow transplant model was used to confirm that a 
significant proportion of the neo-endothelium was derived from the bone marrow. 
This contrasts with the findings of Yoshioka et al, who found that although G-CSF 
mobilised CD34+VEGFR-2+ cells and accelerated re-endothelialisation, very few 
BM derived EPC contributed to re-endothelialisation [Yoshioka et al., 2006]. The 
mechanism through which G-CSF reduces neo-intimal hyperplasia is therefore 
unclear. Yoshioka et al, speculate that G-CSF may increase proliferation and 
migration of adjacent endothelial cells either directly or through stimulation by 
attaching EPC. Even a marginal increase in attaching EPC might be enough to 
increase the secretion of angiogenic factors [Gulati et al., 2003b; Kocher et al., 2001]. 
Shi et al. used G-CSF to accelerate endothelialisation of Dacron grafts implanted in 
the aortas of dogs, but despite enhanced endothelialisation, animals treated with G-
CSF had considerably more neo-intimal formation than controls [Shi et al., 2002]. 
Concordant with this pre-clinical study, intra-coronary G-CSF administered to 
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patients with myocardial infarction was associated with an increased incidence of 
ISR, despite improvements in left ventricular ejection fraction (LVEF%) [Kang et al., 
2004]. This effect may have been mediated through G-CSF’s non-specific pro-
inflammatory actions and the mobilisation of smooth muscle progenitors from the 
bone marrow. The non-specific nature of G-CSF’s effects hampers its translation into 
a targeted therapy for vascular repair. Ongoing studies using G-CSF in combination 
with sitagliptin, an anti-diabetic dipeptidylpeptidase IV –inhibitor, known to cleave 
SDF-1 and augment progenitor cell mobilisation will address whether the effects of 
G-CSF may be honed and make it clinically useful in the context of cardiovascular 
disease [Theiss et al., 2010]. 
 
Peroxisome proliferator–activated receptor agonists 
 Peroxisome proliferator–activated receptor (PPAR) agonists inhibit vascular 
smooth muscle proliferation and migration, and accelerate re-endothelialisation and 
improve endothelial function. This can attenuate neo-intimal formation in mice 
subjected to femoral angioplasty. Wang et al. attributed this effect to the ability of 
roziglitazone to drive pleuripotent bone marrow-derived vascular progenitors toward 
an endothelial phenotype, and away from a smooth muscle phenotype [Wang et al., 
2004]. PPAR agonists may therefore have a role to play in augmenting a 
maladaptive response to iatrogenic vascular injury although concerns remain 
regarding the safety profile of these drugs in patients with ischaemic heart disease 






 The effects of erythropoietin on the response to discrete vascular injury are 
similarly favorable in terms of re-endothelialisation. Erythropoietin significantly 
increases CD34+VEGFR-2+, and enhances neovascularisation in response to 
ischaemia cells in mice. Serum erythropoietin concentration correlates tightly with 
progenitor cells expressing CD34+VEGFR-2+, CD34+CD133+ CD34+Lin+ and 
cultured EPC similar to CAC in patients with coronary artery disease [Heeschen et 
al., 2003], and Erythropoietin therapy causes acute mobilisation of CD34+VEGFR-
2+ [Bahlmann et al., 2004] and increases the proliferative and adhesive capacity of 
cultured EPC in a PI3-Akt dependent manner [George et al., 2005]. Chronic 
erythropoietin therapy in patients with congestive cardiac failure (CCF) however had 
no effect on circulating CD34+, CD34+CD45+, CD34+CD133+, CD34+VEGFR-2+ 
or CD34+CD133+VEGFR-2+ progenitor cells. The acute effects of erythropoietin 
may therefore be attenuated over time, although bone marrow suppression related to 
CCF may explain these differences [Westenbrink et al., 2010]. In an animal model of 
endovascular injury, erythropoietin treatment enhanced proliferation of resident 
endothelial cells and reduced apoptosis of the injured artery, in association with 
eNOS dependent mobilisation of Sca-1+VEGFR-2+ cells [Urao et al., 2006]. 
Erythropoietin has also been associated with an increased incidence of neo-intimal 
proliferation despite adequate re-endothelialisation in animal studies, possibly as a 
result of the non-specific mobilisation of smooth muscle progenitors and pro-
inflammatory effects [Reddy et al., 2007]. In the HEBE-III trial, a single dose of 
erythropoietin therapy had a favourable impact on clinical outcomes following acute 
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myocardial infarction, however the mechanism of this benefit is uncertain as this 
effect appeared to be independent of improvement in LV function [Voors et al., 
2010]. Similarly in the REVEAL trial patients with AMI treated with erythropoietin 
showed now improvement in infarct size however of concern, sub-group analyses in 
older patients suggested an increased infarct size and erythropoietin therapy was 
associated with increased adverse events [Najjar et al., 2011]. Whether erythropoietin 
has a role in cardiovascular remodelling remains unknown. 
 
Oestrogens 
 Oestrogens have also been shown to enhance vascular repair in models of 
arterial injury, in part through eNOS dependent mobilisation and proliferation of 
bone marrow-derived EPC which exhibited enhance migratory and mitogenic 
activity [Iwakura et al., 2003], and reduced apoptotic signaling through the actions of 
caspase-8 [Strehlow et al., 2003]. 
 
Physical exercise  
Physical exercise is a known stimulus of EC-CFU [Rehman et al., 2004], and 
using running wheels has been shown to enhance vascular repair in mice subjected to 
vascular injury in association with enhanced progenitor cell mobilisation [Laufs et al., 
2004]. 
 
1.7.2 Stent-based Therapy 
Technological advances and the evolution of intra-coronary stents provide a 
potential vehicle to deliver novel therapies directly to the site of vascular injury. 
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Attempts to coat intra-coronary stents with endothelial mitogens, such as VEGF, 
have not been encouraging in terms of re-endothelialisation [Swanson et al., 2003]. 
However, gene-eluting stents directly delivering naked plasmid DNA encoding for 
VEGF-2 can accelerate re-endothelialisation and reduce lumen loss in animal models 
[Walter et al., 2004]. The Genous bioengineered R-stent is coated with monoclonal 
antibodies directed against CD34 and designed to attract EPC and encourage re-
endothelialisation. Genous stents have already progressed to phase II and III clinical 
trials and have been deployed in over 5,000 patients. Preliminary data from small 
registries reported major adverse cardiovascular event (MACE) rates ranging from 
7.9% to 13% [Aoki et al., 2005; Co et al., 2008; Duckers et al., 2007; Lee et al.; 
Miglionico et al., 2008]. The e-HEALING registry involving 4,939 patients, reports 
target vessel failure rate of 8.4% with a target lesion revascularisation rate of 5.7% 
and a MACE rate of 7.9%, with a low incidence of stent thrombosis (1.1%) [Silber et 
al.]. Although underpowered, the HEALING II registry reported that patients with 
normal CD34+VEGFR-2+ titers had lower rates of in-stent restenosis in comparison 
to those patients with reduced circulating EPC (late luminal loss 0.53±0.06 versus 
1.01±0.07 mm). Furthermore, a subgroup of 30 patients in this non-randomised 
study underwent serial evaluation using intravascular ultrasound, and regression of 
neointimal volume was observed in patients with higher concentrations of EPC 
[Duckers et al., 2007]. The first randomised controlled trial in a small cohort of 
patients with ST-segment elevation myocardial infarction reported a trend toward 
increased restenosis with the Genous stent when compared to a standard chromium-
cobalt stent [Cervinka, 2009]. The Tri-stent Adjudication Study (TRIAS) compared 
the Genous stent with tacrolimus eluting, Taxus stents in 193 patients with lesions 
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carrying a high risk of restenosis, i.e chronic total occlusions, small caliber vessels 
(<2.8mm), long lesions (>23mm) or diabetic patients. At 1 year there was a highly 
significant increase in restenosis in the Genous stent group. Target vessel failure was 
also increased (17.3% versus 10.5%) although this was not statistically significant, 
possibly due to the relatively small number of patients in the trial. The Genous stent 
does however have a favorable safety profile with respect to stent thrombosis; no stent 
thromboses occurred in the Genous stent group compared to 4 stent thromboses in 
the Taxus stent group and this was despite a significantly lower use of clopidogrel in 
patients randomised to receive the Genous stent [Beijk et al., 2009]. It is difficult 
however to envisage a role for the Genous stent, as the early discontinuation of 
clopidogrel it allows, which would be favourable in patients at higher risk of 
developing bleeding complications, is provided to a similar extent by bare metal 
stents, yet BMS may have more favourable profile with respect to ISR.  
 
Restenosis may be increased with CD34 capture stents for a variety of 
reasons. As discussed CD34 is not specific for EPC, being common to a number of 
progenitors including smooth muscle progenitor cells [Simper et al., 2002]. 
Circulating smooth muscle progenitor cells are poorly characterised, but are thought 
to contribute to neo-intimal hyperplasia [Sata et al., 2002]. Both CD34 and CD133 
are detected at increased levels in the neo-intima of re-stenotic lesions compared to 
de-novo lesions [Skowasch et al., 2003]. The effect of indiscriminate binding of 
CD34+ cells to intra-coronary stents could theoretically amplify the re-stenotic effect 
due to proliferation of smooth muscle progenitors, particularly if exposed to the pro-
inflammatory micro-environment of patients susceptible to ISR. As our 
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understanding of EPC biology improves, so too will our ability to use intra-coronary 
stents to modulate the cellular response to vascular injury and directly enhance re-
endothelialisation following iatrogenic vascular injury through gene and drug 
delivery or progenitor cell capture. 
 
1.7.3 Infusion of endothelial progenitor cells in acute vascular injury 
As an alternative to pharmacological mobilisation, direct intravenous, and 
also intra-arterial infusion of ‘EPC’ have also been used in an attempt to accelerate 
vascular healing in the context of discrete vascular injury. In animal models of 
endovascular injury, transfusion of mononuclear cells cultured in angiogenic medium 
to produce endothelial like cells have successfully accelerated re-endothelialisation 
and attenuated neointimal hyperplasia [Griese et al., 2003; Gulati et al., 2003b; 
Werner et al., 2003; Zhao et al., 2008]. Generally these studies have used unselected 
cell populations as ‘EPC’, so it is therefore uncertain through what mechanism 
infused cells exerted their effect. Beneficial effects may have been mediated through 
the paracrine influence of angiogenic monocyte and lymphocyte populations. The 
restoration of endothelial function may be best imparted by the synergy exists 
between unselected mononuclear cell sub-populations [Wassmann et al., 2006]. 
 
Concerns that infusion of mononuclear cells may increase inflammatory 
signalling and smooth muscle proliferation are well founded theoretically and there 
are some reports of an increased incidence of coronary events including restenosis 
and thrombosis following such treatment. Circulating progenitor cells have also been 
implicated in the progression of atherosclerotic plaques in the context of ischemia 
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[Silvestre et al., 2003]. Mononuclear cells cultured in endothelial growth medium 
genetically engineered to over express endothelial nitric oxide synthase (eNOS) were 
effective in accelerating re-endothelialisation with an associated reduction of neo-
intimal hyperplasia and thrombosis [Kong et al., 2004b]. There have been no clinical 
studies using infused progenitor cells specifically to influence restenosis. Data 
regarding the transfusion of progenitor cells in human studies are derived largely 
from studies examining the effect of mononuclear cell infusion on left ventricular 
dysfunction and myocardial ischaemia in the context of acute myocardial infarction 
[Padfield, 2012]. 
 
1.8 AIMS AND HYPOTHESES 
Delayed re-endothelialisation following vascular injury permits persistent 
vascular inflammation and the potentiation of neo-intimal hyperplasia that may lead 
to restenosis and myocardial ischaemia. Circulating EPC may play a critical role in 
vascular healing following PCI however putative EPC expressing CD34+VEGFR-2+ 
are not known to be mobilised by discrete vascular injury or specifically affect 
vascular healing following PCI. The EC-CFU assay was once widely regarded as a 
measure of circulating EPC, but emerging evidence would suggest that EC-CFU are 
in fact composed of activated leukocytes, providing possible explanation for their 
association with acute systemic inflammation. Although systemic inflammation is 
closely associated with a maladaptive response to vascular injury, the impact of 
systemic inflammation on the various putative EPC populations remains poorly 
understood. A better understanding of the role of putative EPC following vascular 
injury may allow a targeted cellular approach to reduce the complications of PCI. 
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This thesis aims to determine whether putative EPC are related to atherosclerotic 
vascular injury and whether they are mobilised in response to iatrogenic vascular 
injury and how systemic inflammation impacts on EPC mobilisation and function.  
 
I hypothesise that EC-CFU and bone marrow derived vascular progenitors 
will be mobilised in response to PCI mediated vascular injury in order to contribute 
to effective re-endothelialisation and the restoration vascular homeostasis. A robust 
response by these populations may therefore lead to rapid reconstitution of the 
endothelial monolayer thereby facilitating rapid recovery of normal endothelial 
function and vascular homeostasis (Figure 1.2). Mobilisation of EPC following 
vascular injury is likely to be mediated by cytokines and growth factors induced by 
endothelial denudation and vessel injury. However, vascular injury is also associated 
with a more generalised acute phase systemic inflammatory response. I wish to 
establish whether EPC mobilisation occurs as part of a non-specific inflammatory 
response or is a specific response to vascular endothelial injury. Rather than 
mobilising EPC following PCI, systemic inflammation may exert deleterious effects 
on EPC function, and impair progenitor cell engraftment at the site of vascular 
injury.  In addition I aim to relate circulating concentrations of putative EPC 
populations to the severity of coronary atheroma to further interrogate the 




The following hypotheses will be addressed: 
 
1. Vascular injury during PCI mobilises putative EPC (Chapters three and 
seven). 
2. EC-CFU are composed of leukocytes, formed through the proliferation and 
migration of peripheral blood monocytes and lymphocytes (Chapter four). 
3. Acute systemic inflammation will not mobilise putative EPC in the absence of 
vascular injury in healthy volunteers (Chapter five). 
4. Circulating putative EPC are diminished in patients with coronary artery 
disease but are mobilised following acute myocardial infarction (Chapter six). 
5. Increased concentrations of EPC are associated with less atheroma and better 
clinical outcomes (Chapter six). 
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Figure 1.2 Hypothetical role of circulating progenitor cells following iatrogenic 
vascular injury: (A) Under resting conditions circulating concentrations of EC-CFU 
precursors and circulating EPC are low. (B) Intra-coronary stent deployment relieves 
obstruction, but damages the endothelium and underlying artery, exposing collagen and tissue 
factor, activating platelets and the coagulation cascade. In the absence of an intact endothelium, 
local platelet/platelet and platelet/leukocyte complexes form and intense local inflammatory 
infiltrate ensues with detectable systemic inflammation. I hypothesise a biphasic response to 
vascular injury caused by PCI. (C) The early response consists of mobilisation of the precursors 
of EC-CFU involving angiogenic monocytes and lymphocytes. EC-CFU precursors home to the 
site of injury and avidly secrete angiogenic factors encouraging resident endothelial cell 
proliferation and migration, and the mobilisation and homing of bone marrow derived and local 
endothelial progenitors to the site of vascular injury. (D) Subsequently progenitor cells proliferate 
and contribute to effective re-endothelialisation and the restoration vascular homeostasis. (E) An 
inadequate EC-CFU/EPC response following PCI may lead to delayed re-endothelialisation and 
persistent inflammation, smooth muscle hypertrophy and extra-cellular matrix deposition leading 
to restenosis and symptoms of myocardial ischaemia. (F) A robust response by the bone marrow 
leads to rapid homing of EC-CFU precursors to sites of vascular injury with recruitment and 
integration of EPC to the endothelial monolayer, facilitating rapid re-endothelialisation and 
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2.1.1 Ethical Considerations 
All studies were undertaken in accordance with the regulations of the Lothian 
and London Research Ethics Committee, and with the Declaration of Helsinki of the 
World Medical Association. Specific ethical approval was obtained from Lothian 
local research ethics committees and research and development office for each of the 
clinical studies that follows (Chapter four, 06/S1102/42; Chapter five & seven, 
06/S11ADMIN/108; Chapter six, 06/S1103/44) and all subjects partaking in the 
following studies provided written consent. For all participating subjects, the 
registered General Practitioner and the responsible Consultant Cardiologist was 
informed of the patient’s participation in the study. 
 
2.1.2 Subject Recruitment 
Healthy Volunteer studies 
Healthy non-smoking male volunteers (aged between 18 and 35 years) were 
recruited through an advertisement distributed using the University of Edinburgh’s 
electronic mailing list. Subjects were required to have no significant past medical 
history or an inter-current illness likely to be associated with an inflammatory 
response. Subjects were excluded if they had previously undergone typhoid 
vaccination, or had received any vasoactive or non-steroidal anti-inflammatory drugs 





Patients undergoing coronary angiography and angioplasty 
Elective patients 
 Patients undergoing elective coronary angiography for the investigation of 
suspected angina or as part of an evaluation prior to surgery for valvular heart 
disease were identified prospectively from elective angiography lists at the Royal 
Infirmary of Edinburgh by members of the research team in conjunction with the 
express permission of the physician clinically responsible for the patients care. 
Patients were then contacted by a member of the research team (GJP or LF) by 
means of an invitation letter and a patient information sheet posted to their home 
address. This was followed by a telephone call in order to further elaborate on the 
study details and answer any questions prospective participants might have.  
 
Patients with acute coronary syndrome 
 Patients undergoing coronary angiography following an acute coronary 
syndrome (ACS) were identified by daily review of patients scheduled for coronary 
angiography at Edinburgh Royal Infirmary (ERI) with either an increase in plasma 
troponin concentration above 0.2ng/mL or evidence of myocardial ischemia on a 
12-lead electrocardiogram in the context of unstable anginal symptoms. Patients 
were provided with a brief description of the study rationale and protocol and were 
provided with an information leaflet and were given at least 24 hours to consider 
participation in the study. Patients were excluded given the presence of a significant 
co-morbid illness such as any haematological or internal malignancy, acute ST-
segment elevation myocardial infarction, significant ventricular arrhythmia or 
haemodynamic instability, hepatic or renal failure, intercurrent infection or a 
clinically active inflammatory disorder. Patients were excluded in the event of 
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systemic corticosteroid treatment within 30-days of study enrolment. All volunteers 
underwent baseline evaluation including documentation of clinical characteristics, 
cardiovascular risk factors, and medication. Hyperlipidemia and hypertension were 
defined as either a documented history or the use of a lipid lowering or anti-
hypertensive medication respectively. 
 
2.1.3 The Steroids Against ReStenosis - STARS trial 
In the absence of an intact endothelium persistent inflammation encourages 
smooth muscle hypertrophy and in-stent restenosis [Toutouzas et al., 2004]. Elevated 
pre-procedural serum CRP concentrations predict adverse outcome after coronary 
stent implantation and are associated with a greater degree of angiographic 
restenosis. In vitro data supports the hypothesis that CRP is detrimental to EPC 
function [Fujii et al., 2006]. This would suggest that systemic inflammation inhibits 
vascular repair and is associated with an adverse proliferative response [Walter et al., 
2001a].  
 In collaboration with Dr Mark de Belder at James Cook University Hospital 
Middlesbrough (JCUH), we are participating in the STeroids Against Re-Stenosis 
(STARS) Trial, 2x2 randomised controlled trial examining the effect of oral 
Prednisolone and two different types of BMS design (Zeta™ or Vision™; Abbott 
Vascular; UK) on the development of in-stent restenosis following PCI. This study 
population will undergo protocol driven repeat coronary angiography and 
intravascular ultrasound at six months following stent insertion, and therefore 
provides the ideal vehicle to prospectively test the hypothesis that increased 
circulating numbers of EPC and mobilisation following angioplasty will encourage 
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early endothelialisation and prevent persistent vascular inflammation and in-stent 
restenosis. This study also provides an opportunity to explore the effect of anti-
inflammatory treatment on EPC mobilisation and function. 
 
2.1.4 Randomisation procedures 
Healthy volunteer studies 
 In a double-blind fashion, subjects were randomly allocated by the nursing staff 
of the Wellcome Trust Clinical Research Facility, Edinburgh Royal Infirmary to 
receive intramuscular Salmonella Typhus polysaccharide vaccination 0.025 mg 
(Typhim Vi, Aventis-Pasteur MSD, UK) or saline placebo given by intramuscular 
injection. Subjects received the alternate treatment following a two-week wash out 
period. 
 
Patients undergoing coronary angiography 
 Patients undergoing coronary angiography with a view to follow on PCI 
underwent baseline evaluation of clinical, biochemical and putative EPC 
concentration. The decision to proceed to coronary intervention in all cases was 
determined by clinical need at the operator’s discretion. For studies using PCI as a 
model of vascular injury discussed in chapters three and seven, potential recruits 
undergoing coronary angiography were selected by an augmented method of 
minimisation in order to minimise between group differences and potential 
confounding effects between those undergoing PCI or diagnostic angiography alone 
[Treasure et al., 1998]. For example, if during recruitment the mean age of one group 
were to be become significantly different from the other this would be taken into 
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account when inviting subsequent patients to take part in the study. Age, gender, and 
traditional risk factors for CAD; diabetes; smoking history; hypercholesterolaemia 
and hypertension were taken into consideration. 
 
 The STARS trial 
 Although the results of the STARS trial are not reported within this thesis, the 
patients recruited for chapter 6 comprise the STARS cohort recruited at ERI. Follow 
up data is not yet available for these patients, as the data regarding their treatment 
allocation remains blinded. However, the STARS trial is discussed here and in 
further detail in chapter eight.  
 Following informed consent, patients undergoing coronary angiography with a 
view to follow on PCI underwent baseline evaluation of clinical, biochemical and 
putative EPC concentration. Patients were then randomised in a double blind 
fashion to receive oral prednisolone 40 mg or placebo in addition to empirical proton 
pump inhibition with lansoprazole 30mg, 24 hours (no earlier than 8 hours) prior to 
angiography. The study medications were prepared at James Cook University 
Hospital (JCUH) Pharmacy, and were presented as reddish brown capsules in plain 
white containers identifiable only by a study reference code. In the event of the 
decision to proceed to treatment with a BMS, of a de novo lesion affecting a native 
coronary artery with a reference diameter of > 3mm (single or multiple PCI to simple 
or ostial/bifurcation lesions included), patients were then randomised by sealed 
envelope in a single blind fashion to receive either Zeta or Vision BMS. Patients were 
excluded in the event of the use of drug eluting stent, primary PCI for AMI, re-
stenotic lesions, vein graft lesions and any unprotected left main stem PCI. Oral 
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prednisolone 40mg daily, was continued for a total of 28-days, and aspirin 75mg and 
clopidogrel 75 mg daily, were given to all patients for at least three months following 
PCI. Prescription of other pharmacological agents was at the discretion of the 
attending physician. Patients were re-evaluated at 24 hours and at one and four 
weeks in order to assess clinical status and perform serial assays of haematological 
and biochemical assays and EPC measures. Patients returned at 6-months for repeat 
coronary angiography and intra-vascular ultrasound examination. Patients treated 
with drug eluting stents (DES), or those not undergoing PCI received no further 
study medication, but were invited to return for further phlebotomy for assessment of 





Figure 2.1. Protocol for patients enrolled in to the STARS trial at ERI 
 
 64 
2.2 INVASIVE VASCULAR PROCEDURES 
 All invasive procedures took place in the cardiac catheterisation laboratory at 
ERI. Baseline procedures formed part of the patient’s routine clinical management 
and were conducted by the responsible Physician caring for the patient.  
 
2.2.1 Diagnostic coronary angiography 
 Diagnostic coronary angiography was performed via a 6 French sheath placed 
in the femoral or radial artery using appropriate 6 French arterial catheters following 
the administration of 200µg of intra-coronary glyceryl trinitrate (GTN). Standard 
angiographic projections were employed in addition to specific evaluation of target 
lesions in at least two orthogonal views, before and immediately following PCI. 
 
2.2.2 Percutaneous coronary intervention.  
 PCI was performed using standard techniques on flow limiting coronary 
stenoses (>50%) thought to be clinically relevant at the operator’s discretion, given 
ECG changes at presentation, and lesion characteristics. Briefly, an appropriate 
guide catheter is advanced to the coronary ostium. A guide wire of suitable weight is 
then advanced through the obstructive lesion. Balloon angioplasty is performed in 
order to optimise stent delivery at the operator’s discretion. A balloon-mounted 
intracoronary stent of a suitable length and diameter necessary to effectively address 
the obstructive lesion is then advanced to the point of maximal stenosis and deployed 
at a pressure necessary to evenly appose the stent with the vessel wall. Further 
dilatation of the stent by balloon angioplasty in order to optimise stent deployment is 
performed at the operator’s discretion. Artery closure is performed by manual 
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pressure, or by device closure (RadistopTM or AngiosealTM) at the operator’s 
discretion.  
 
2.3 IMAGE ANALYSIS AND GENSINI SCORING 
 The severity of coronary disease was quantified offline by observers blinded to 
the patient’s clinical profiles through visual inspection of the angiographic 
appearance of each epicardial arterial segment. Coronary artery disease severity was 
graded using a modified version of the Gensini scoring system [Gensini, 1983; 
Ringqvist et al., 1983]. Fourteen pre-determined arterial segments of the major 
epicardial arteries are graded according to a visual estimate of severity of stenosis and 
allocated a weighting score according to the lesion’s location (Table 2.1; Figure 2.2). 
The original Gensini score does not discriminate between minor grades of atheroma, 
i.e. normal, plaque disease and stenoses of <25% which all score 0. In order to 
discriminate between the presence of minor degrees of atheroma and normal arteries 
the score was modified to discriminate between these gradations of atheroma (table 
2.1). This provides a continuous variable quantifying atheroma burden accounting 
for proximal versus distal disease. The median intra-observer variability as assessed in 
twenty randomly selected coronary angiograms was 11% (IQR=7-32%). 
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Table 2.1: Gensini scoring system. 
Disease severity Segment scores Arterial Segment Weighting 
Occluded 32 Left main stem 5 
Sub-total occlusion 16 
Proximal left anterior 
descending 
2.5 
Stenosis >95% 8 Mid left anterior descending 2.5 
Stenosis 75-95% 4 Distal left anterior descending 1 
Stenosis 50-74% 3 First diagonal 1 
Stenosis 25-50% 2 Second diagonal 1 
Stenosis <25% 1 Proximal circumflex 2.5 
Plaque Disease only 0.5 
Mid and atrioventricular 
circumflex 
1 
Nil 0 First obtuse marginal 1 
Second obtuse marginal 1 
Proximal right coronary artery 1 
Mid right coronary 1 


























































































































2.4 CLINICAL FOLLOW UP 
Clinical event monitoring and follow up 
The nature and timing of clinical events were determined by reference to 
medical records using the TrakCare® software application (InterSystems 
Corporation, Cambridge, MA, USA), an electronic patient record system used by the 
Acute Hospitals Division of Lothian National Health Service (NHS) Health Board, 
United Kingdom. Deaths due to cardiovascular causes included any sudden death, 
and death from acute myocardial infarction, coronary artery disease, or congestive 
heart failure. Acute myocardial infarction was defined as any increase in plasma 
concentration above the 99th centile in the presence of symptoms or ECG changes 
indicative of myocardial ischaemia. Revascularization procedures included all 
percutaneous or surgical coronary artery procedures. Hospitalisation for 
cardiovascular causes included any planned or unplanned hospitalisation for acute 
coronary syndromes, heart failure, stroke or uncontrolled arrhythmia, or any 
coronary or peripheral vascular revascularization occurring from the date of 
enrollment. Major adverse clinical events were a composite of cardiovascular death, 
recurrent myocardial infarction, revascularization or hospitalisation for a 
cardiovascular cause. 
 
2.5 FLOW CYTOMETRIC ANALYSES 
All laboratory bench procedures were performed in the Centre for 
Regenerative Medicine at the Little France site, Edinburgh Royal Infirmary or at 
King’s Buildings, Edinburgh University in class II laboratories by trained laboratory 
personnel adhering to standard safety procedures (GJP, EF, MW, OT-C). 
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2.5.1 Immunostaining of putative EPC and angiogenic monocytes: 
Using Gilson® PIPETMAN Classic™ pipettes, and disposable pipette tips, 
5µL of antibody solution at the dilutions described (Table 2.2) were transferred to 
polyurethane tubes according to the following table (Table 2.3). Optimal antibody 
dilutions were determined by titration of antibody concentrations to achieve the 
lowest possible concentration producing maximal separation of populations of 
interest with minimal non-specific staining. Compensation was performed using 
commercially available flow cytometry compensation beads (Miltenyi Biotec, UK). 
 
Table 2.2: Immunofluorescence staining materials for flow 
cytometric analyses 
Antibody Manufacturer Dilution  
CD3-PerCP R&D systems, Minneapolis, USA 1:10 
CD14-FITC Caltag Systems, Buckingham, UK  1:10 
CD14-PE Caltag Systems, Buckingham, UK 1:10 
CD18-PE R&D systems, Minneapolis, USA 1:10 
CD19-APC R&D systems, Minneapolis, USA Undiluted 
CD34-FITC Becton Dickinson, Oxford, UK  Undiluted 
CD45-PerCP Becton Dickinson, Oxford, UK  1:3 
CD133-PE Miltenyi Biotec Ltd, Surrey, UK  1:2 
CXCR-4-APC R&D systems, Minneapolis, USA 1:10 
Tie-2-APC R&D systems, Minneapolis, USA  1:5 
VEGFR-2-APC R&D systems, Minneapolis, USA  1:2 
VEGFR-2-PE R&D systems, Minneapolis, USA  Undiluted 
APC = allophycocyanin; CD = cluster of differentiation; FITC = Fluorescein 
isothiocyanate; PBS = phosphate buffered saline; PE = phycoerythrin; PerCP=Peridinin-
chlorophyll-protein complex; VEGFR-2 = vascular endothelial growth factor receptor-2 
 
200µL of peripheral blood was then transferred to each tube, with care taken to 
avoid smearing of blood on the walls of the tube. All tubes were then briefly agitated 
with a mechanical vortex mixer and incubated at room temperature in the dark. At 
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20 minutes, according to the manufacturer’s instructions, 200µL of lysing reagent A, 
from the UtilyseTM (Dako/BioStat; UK) kit was transferred to each tube followed 
again by a brief agitation. A further period of incubation at room temperature in the 
dark for 10 minutes was performed at which time 2mL of lysing reagent B was added 
Table 2.3: Flow cytometric protocol 
Tube Antibodies 
1 Primary negative control 
2 CD45-PERCP    
3  CD34-FITC   
4 CD45-PERCP CD34-FITC   
5 CD45-PERCP CD34-FITC VEGFR-2-APC  
6 CD45-PERCP CD34-FITC VEGFR-2-APC CD133-PE 
7 CD45-PERCP CD14-FITC   
8 CD45-PERCP CD14-FITC Tie-2-APC  
9 CD45-PERCP CD14-FITC Tie-2-APC VEGFR-2-APC 
10 CD45-PERCP CD34-FITC CD18-PE  
11 CD45-PERCP CD34-FITC CD18-PE CXCR4-APC 
APC = allophycocyanin; CD = cluster of differentiation; FITC = Fluorescein isothiocyanate; PBS = 
phosphate buffered saline; PE = phycoerythrin; PerCP=Peridinin-chlorophyll-protein complex; 
VEGFR-2 = vascular endothelial growth factor receptor-2 
 
followed by a final agitation. Erythrocyte lysis was evident by the solution becoming 
transparent. In the event of an incomplete lysis, as evidenced by persisting 
opacification of the solution, a further period of incubation was occasionally required 
to ensure complete lysis of red blood cells and avoid contamination of the sample 
with excessive cellular debris. Balanced samples were then centrifuged for 10 minutes 
at 250 x g in a desktop centrifuge (Jouan BR3-11). The supernatant was then 
discarded and the samples subjected to two further washing steps entailing 
suspension of the cell residue in 2mL of phosphate buffered saline solution (PBS; 
pH7.4; Sigma-Aldrich; UK), and centrifugation for 10 minutes at 250 x g. The cell 
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residue was finally resuspended in 450µL of CellFixTM (Becton Dickinson; UK), cell 
fixative agent at a 1:10 dilution in PBS and analyzed immediately. 
  
2.5.2 Flow cytometric data analyses.  
Flow cytometry was performed on a Becton Dickinson FACS CaliberTM using 
CellquestTM software on an Apple Macintosh desktop computer. Standard 
maintenance procedures were performed prior to and following analysis of cell 
samples to ensure proper working order of the FACS CaliberTM. Acquisition gates 
were applied to encompass the total leukocyte population and specifically the 
lymphocyte population according to the characteristic forward side scatter 
appearance. For each sample, 80,000 events were acquired in the lymphocyte region, 
equating to approximately 500,000 total events. Data were analysed using FlowJo 
(Treestar, USA). Analyses involved first identifying leukocytes by their characteristic 
forward and side scatter profile. For CD34+, CD45+, CD133+, VEGFR-2+, CD18+, 
and CXCR-4+ quantification, the proportion of leukocytes cells bearing each epitope 
was determined individually by using the side scatter profile plotted against the 
appropriate fluorescence channel. Permutations of co-expression were determined 
automatically using Boolean principles (AND, NOT, OR etcetera.). Although 
opinion remains divided, iso-type controls are considered by many to be unnecessary 
in flow-cytometric analyses, particularly for rare event haematopoietic populations 
[Keeney et al., 1998]. I therefore used the autofluorescence of unstained samples to 
establish positive stain boundaries (the fluorescence minus one technique) as depicted 
below Figure 2.5) [Tung et al., 2004]. Control gates were set within the leukocyte 
population of an unstained sample to include events with autofluorescence in the 
 72 
appropriate channel at an arbitrarily predefined level (0.005% for CD34 and 0.01% 
for other populations. CD14+ cells were gated and VEGFR-2 and Tie2 expression 
was assessed using quadrant analysis (Figure 2.5). Quadrants were set on unstained 
negative controls to include approximately 0.5% autofluorescence. The absolute 
concentration of cells per mL of blood was calculated by equating the total number 
of events in the lymphocyte, monocyte, neutrophil and eosinophil regions by forward 
and side scatter to the total leukocyte count from the full blood count. The intra-
assay coefficients of variation for the phenotypic markers used are tabulated below 
(Table 2.4). 
 
Table 2.4 Intra-assay co-efficient of variation for the 
phenotypic markers used to identify EPC and 
angiogenic monocytes 
 





CD34+CD45-  19% 






Values expressed are the median CV% for duplicate samples where CV% is 




Figure 2.5 Flow cytometric analysis of putative progenitor cells and angiogenic 
monocytes: Representative dot plots of negative controls and stained samples are shown in red and 
blue respectively. First leukocytes were identified on the basis of their characteristic forward and side 
scatter profile (A). CD34-FITC (B&C) expression and the proportion of CD34+ events expressing 
CD18 (D&E) and CXCR-4 (F&G) were determined. Similarly CD133-PE+ (H&I), CD45-PercP+ 
(J&K), and VEGFR-2-APC+ (L&M) events were identified. Co-expression of surface markers was 
determined using Boolean principles. In separate analyses CD14-FITC+ events were identified (N), and 
those expressing Tie-2-APC and or VEGFR-2-PE were determined using quadrant analysis (O&P). 
Gates were set on single or unstained stained negative controls where appropriate. 
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2.5.3 Cell sorting 
 In order to specifically isolate 
monocytic and lymphocytic fractions of a 
mononuclear preparation and specifically 
interrogate the behaviour of these cells 
when placed in close proximity to 
maturing EC-CFU, mononuclear 
preparations underwent fluorescent 
activated cell sorting (FACS). Sixty mL of 
peripheral blood was collected into 
ethylene-diamine tetra-acetic acid (EDTA) 
and diluted 3:1 with Ca2+ and Mg2+ 
deficient PBS (2% fetal calf serum). Diluted blood was layered on 10mL of 
Histopaque-10771 (Sigma-Aldrich; UK) in 50mL falcon tubes (Beckton Dickinson; 
UK). Density gradient centrifugation was performed at 1000 x g for 25 minutes. The 
‘buffy coat’ of mononuclear cells was aspirated and washed three times with PBS. 
Approximately 8x107 cells were obtained and resuspended in 4mL of 2% FCS and 
then stained using antibodies directed against the T-cell marker CD3 pre-conjugated 
to PE, the B-cell marker CD19 pre-conjugated to APC, and the monocyte marker 
CD14 pre-conjugated to PE (Invitrogen, UK) for 20 minutes at 37°C, 5% CO2. Cell 
clumps were removed by agitation followed by sedimentation at 37°C, 5% CO2. The 
single cell suspension was transferred to a fresh tube, centrifuged at 300 x g for 5 
minutes, and re-suspended in 
Figure 2.6 Isolation of mononuclear 
cells: Whole blood collected in EDTA is 
diluted with PBS and layered on 
Histopaque and centrifuged. Mononuclear 
cells collect on the surface of the 
histopaque to form a ‘buffy coat’ that is 




fresh culture medium supplemented with 100U/mL penicillin and 100g/mL 
streptomycin. Data were acquired on a FACSAria cell sorter (Becton-Dickinson, UK) 
equipped with an argon laser and standard filter set using a 70-µm nozzle at a sheath 
pressure of 70 PSI and flow rate setting of 1. The sort rate was less than 1000 
events/sec. Cell separation and analyses were performed using CellQuestPro 
software (Becton Dickinson; UK). Acquisition gates were set to exclude cellular debris 
on the basis of the characteristic FSC against SSC profile. In order to avoid cellular 
Figure 2.7 Fluorescence activated cell sorting: Mononuclear cells were considered ‘intact’ 
on the basis of their FSC-A against side scatter-area (SSC-A) appearance (A1). To minimize 
cellular aggregates populations were then selected on the basis of their FSC-A against FSC-H 
profile (A2). Populations were sorted on the basis of their fluorescence in the relevant channel 
(A3&A4). Following cell sorting samples were reacquired to confirm purity (B-D). 
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aggregates, events were included on the basis of a forward scatter – area (FSC-A) 
against FSC-width bivariate plot [Tzur et al., 2011]. Myeloid and lymphoid gates 
were set using forward and side scatter. From these sub-populations of viable events, 
lymphocyte (CD3 and CD19) and monocytic (CD14) populations were collected 
using gates set on the basis of immunofluorescence in the appropriate channel 
corresponding to the fluorochrome (Figure 2.7). Cells were collected into 5mL 
polystyrene sterile tubes (Falcon; UK), primed with 1mL of endocult medium and 
antibiotics (penicillin 100U/mL and streptomycin 100g/mL). An aliquot of each 
sorted sample was reacquired in order to assess purity. Finally, recovered cells were 
resuspended in complete medium. 
 
2.6 CELL CULTURE AND FUNCTIONAL ANALYSES 
2.6.1 EC-CFU generation  
Endothelial cell colony forming units were generated using a commercially 
available assay. Whole peripheral blood collected in EDTA was diluted with PBS at 
1:1 dilution and layered on 10mL of Histopaque 10771 (Sigma-Aldrich; UK) in 50ml 
falcon tubes (Beckton Dickinson; UK). Density gradient centrifugation was 
performed at 1000 x g for 25 minutes. The resulting mononuclear buffy coat was 
aspirated and transferred to fresh tube and the volume made up to 50ml in PBS.  
The cell suspension was centrifuged at 200 g for 10 minutes and the supernatant 
discarded. The pellet was transferred to a 15mL centrifuge tube and subjected to two 
further washing steps using PBS and centrifugation at 200g. This was repeated and 
 77 
  
the remaining cell residue was supended in 2mls of PBS. Using a Multisizer™ 3 
Coulter counter® (Beckman-Coulter; UK) the cellular concentration was 
determined, and 5 x 106 mononuclear cells were transferred to 6 well fibronectin 
coated plates. Two mL of complete endothelial culture medium, EndocultTM (Stem 
Cell Technologies) were added to each well and plates were incubated at 37°C and 
5% CO2. After two days, non-adherent cells were removed and three to four aliquots 
of 8x105 cells were replated, each in 1mL of complete EndocultTM on fibronectin. 
EC-CFU colonies were defined as a central core of round cells with associated 
elongated spindle-like cells at the periphery (Figure 1.2A). Colonies were counted by 
visual inspection using an inverted light microscope on day five.  
 
The quantity of EC-CFU colonies generated by an individual at any given 
time point was determined from three to four separate wells. Variation between wells 
is displayed in the form of a Bland-Altman plot (Figure 2.8) demonstrating the level of 
Difference between wells versus the average






























level of agreement 
between 260 pairs 
of wells from 
healthy volunteers. 
The level of 
disagreement 




Level of bias = 
3.26 ± SD 15.35. 
95% CI  = -26.8 
to 33.34 (dashed 
lines). 
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agreement between 260 pairs of wells from healthy volunteers. The level of disagreement 
increased with greater EC-CFU concentrations. Level of bias = 3.26 ± SD15.35 (95% 
CI = -26.8 to 33.34). The median co-efficient of variation between wells was 33% (IQR: 
20-61%).  
 
2.6.2 EC-CFU characterisation 
Much of the debate regarding the phenotype of EC-CFU, has revolved 
around their haematopoietic, versus the endothelial characteristics. I wished to verify 
the phenotypic characteristics of EC-CFU that I would be using in these studies. EC-
CFU were therefore characterised using a battery of surface and intracellular stains 
(Table 2.5) described as follows. 
 
Stains and cellular markers 
Acetylated low-density lipoprotein (Ac-LDL) and Ulex Uropeaus binding are 
classical endothelial characteristics but both also identify phagocytic cells such as 
macrophages. VEGFR-2 is considered a marker of endothelial lineage, being widely 
expressed on mature endothelial cells and is necessary for the normal development of 
the vascular system. Similarly the tyrosine kinase receptor Tie-2 is expressed on 
mature endothelial cells and is necessary for normal vascular development. CD146 
and CD144 are endothelial intercellular adhesion molecules that facilitate the 
formation of a confluent layer of endothelial cells. CD105, or endoglin is a 
constituent of the transforming growth factor-beta receptor is thought to be limited to 
proliferating cells and is expressed on activated endothelium and smooth muscle cells 
but also extensively on macrophages. Endothelial nitric oxide synthase is an enzyme 
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responsible for the production of nitric oxide by endothelial cells in response to sheer 
stress. Von Willebrand factor (vWF) allows intercellular adhesion, primarily between 
platelets and exposed collagen following tissue injury to facilitate coagulation, and 
receptors for vWF are expressed on activated endothelial cells. CD31 is a platelet 
endothelial cell adhesion molecule also expressed on activated endothelial cells. 
CD45, also known as the common leukocyte antigen, is a protein tyrosine 
phosphatase expressed on all haematopoietic cells and leukocytes. CD4 is expressed 
primarily on helper T-cells and is broadly a lymphocyte marker but it is also 
expressed to an extent on myeloid cells. CD8 is another glycoprotein expressed on T-
cells. CD68 is a surface protein instrumental in phagocytosis and is expressed 
strongly on macrophages. The lipopolysaccharide receptor CD14 is widely expressed 
on monocytes. 
 
Colony immunostaining method 
Day five EC-CFU grown on fibronectin-coated chambered cover slips (BD 
Biosciences) were fixed with ice-cold methanol, permeabilised with 0.02% MP40 
(Sigma-Aldrich; UK) and blocked with blocked with 10% Goat serum, 1% bovine 
serum albumin (BSA), prior to immunostaining with the primary antibody. After 
three washes, cells were incubated with the secondary antibody and incubated for an 
hour, for stains where the primary step used a murine monoclonal antibody (MAB), 
the secondary step involved incubation with a biotinolated anti-mouse MAB directed 
against the primary antibody. A tertiary step using Streptavadin, pre-conjugated to a 
fluorochrome excitable at 546nm, directed against biotin was then employed. Nuclei 
were counterstained with 4',6-diamidino-2-phenylindole (DAPI) and incubated in the 
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dark for 10 minutes and then washed twice in PBS. Colonies were then mounted 
with PermaFluorTM (Thermo Scientific). After three final washes, cells were 
photographed using confocal microscopy. Secondary antibodies were titrated such 
that controls lacking primary antibodies were routinely negative.  
 
Positive and negative control cell populations  
 Human umbilical vein endothelial cells (HUVEC) served as positive controls 
for endothelial markers. Having undergone no more than three passages, HUVEC 
were cultured in EGM-2 (Lonza; UK) on glass chamber slides until a confluent cell 
monolayer was achieved. Mononuclear cell (MNC) preparations served as positive 
controls for haematopoietic markers. 100µl of MNC at a density of 4x105 cells/mL in 
1% BSA solution were spun onto glass slides and fixed with methanol for five 
minutes before being stained as above. The human adenocarcinoma cell-line, HT-29 
(courtesy of Dr S. Bader, ERI) served as a universal negative control population. HT-
29 cells were cultured in RPMI (Gibco/Invitrogen; UK) supplemented with 5% FCS 
until confluency was achieved. Cells were fixed and stained as described above. 
 
Confocal microscopy and image analysis  
 Stained EC-CFU, MNC preparation, HUVEC and HT-29 were all visualized 
using a Zeiss ‘LSM 510 Meta’ confocal fluorescent microscope at x40 or x20 
magnification with an oil immersion objective lens. Fluorescent intensity on EC-CFU 




Table 2.5: Immunofluorescent staining materials for EC-CFU 
characterisation 
Primary Antibodies Manufacturer Dilution in PBS 
Polyclonal rabbit/antihuman   
eNOS  BD Transduction Laboratories 1:500 
CD146 Springbioscience 1:200 
CD34 BD Biosciences; Santa Cruz 1:100 
Tie-2 BD Transduction Laboratories 1:200 
CD8 Springbioscience undiluted 
Monoclonal mouse/anti-human   
CD4 BD Transduction Laboratories 1:500 
CD45 BD Transduction Laboratories 1:500 
CD14 Caltag 1:100 
CD31 BD Transduction Laboratories 1:200 
CD68 Dako 1:200 
CD105 BD Transduction Laboratories 1:200 
CD144 BD Transduction Laboratories 1:200 
VEGFR-2 R&D 1:200 
vWF Dako 1:200 
Secondary Antibodies   
Biotinolated anti-mouse Dako 1:500 
Streptavadin 546 Molecular Probes 1:500 
Anti-rabbit Alexafluor 488 Invitrogen 1:200 
Nuclear stain   
DAPI Sigma 1:1000 
Primary antibodies are directed against the relevant cellular component. Alexafluor 488 is a 
monoclonal antibody (MAB) directed against rabbit primary antibodies pre-conjugated to a 
fluorochrome excitable at 488nm. Streptavadin was pre-conjugated to a fluorochrome excitable at 
546nm, and binds to biotinolated anti-mouse MABs directed against the primary antibody. CD = 
cluster of differentiation; eNOS = endothelial nitric oxide synthase; VEGFR-2 = vascular 
endothelial growth factor receptor-2 
 
2.6.3 EC-CFU functional assays 
Proliferation 
Cellular proliferation within EC-CFU was assessed by the detection of 
incorporation of the thymidine analogue bromodeoxyuridine (BrdU) (Sigma-Aldrich; 
UK). Mononuclear cells replated on fibronectin at day two were incubated with 
BrdU at a 100 µmol concentration. On day five colonies were fixed with 4% 
paraformaldehyde at room temperature for 30 minutes and permeabilised using 
0.25% tween 20 (Caltag) for 12 hours. Colonies were then incubated with DNAse 
(Perbio; UK) at 500Uml-1 in 50mM Tris buffered deionised water, MgCl210mM, 
BSA 100ugml-1 pH 7.4) at 37°C for 30 minutes. Colonies were rinsed well with PBS 
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and incubated with anti-BrdU conjugated to alexafluore-488TM (Invitrogen) at a 
1:100 dilution. Colonies were examined with an inverted microscope at 488nm. 
Proliferation was expressed as the proportion of BrdU positive cells per unit volume 
of colony. Colony volume (V) was calculated using the formula: V = (πr2h)/3. Where 




The ability of EC-CFU to migrate toward a high VEGF concentration was 
assessed using 8µm pore transwell plates (Costar). On day five of culture EC-CFU 
were rinsed twice with Hepes buffered calcium and magnesium free saline solution 
(Sigma-Aldrich; UK) and then detached from the wells using non-enzymatic 
dissociation solution (Sigma-Aldrich; UK) at 37°C for 5-10 minutes. Complete 
growth medium was returned to the well and the cell suspension was pipetted 
repeatedly to dissociate cellular aggregates. Recovered cells were washed, 
resuspended in 1mL of serum free medium at a concentration of 2x106 cells/mL 
using a coulter counter (Beckman Coulter; UK). Using five wells of a plastic transwell 
migration kit (Costar; UK), 600µL of serum free medium was placed in the lower 
chamber of each transwell, with VEGF (Peprotech; UK) at a concentration of 
50ng/ml. Transwell chambers were gently placed into the wells with the porous 
membrane just submerged in the medium. 2x105 cells (100µL of 2 x106/mL) were 
then pipetted into each transwell. Using a Beckman Coulter counter the cell 
concentration in wells 1-5 were then counted at three hours 
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2.7 VENOUS SAMPLING AND LABORATORY ASSAYS  
2.7.1 Peripheral Venous Sampling  
 Venous blood was withdrawn from the antecubital fossa in a standard fashion 
collected into trisodium citrate for cytokine analysis, potassium EDTA for 
mononuclear cell preparation, flow cytometric analysis and full blood count, and 
serum gel tubes for CRP and clinical biochemistry (Monovette®, Sarstedt, 
Nümbrecht, Germany).  
  
2.7.2  Sample Preparation  
 Citrate and acidified buffered citrate samples were centrifuged at 2,000 g for 30 
minutes at 4°C, EDTA samples at 1000g for 10 minutes at 20°C. Serum samples 
were centrifuged at 2,000 g for 20 minutes after being allowed to clot on ice. Platelet 
free plasma or serum was decanted and stored at -80ºC before assay.  
  
2.7.3 Cytokine and circulating biomarker detection 
 Plasma troponin I concentrations were measured using an automated 
immunometric assay; ARCHITECT STAT troponin I assay (Abbott Laboratories, 
Chicago, IL). Plasma IL-6, vascular endothelial growth factor A (VEGF-A), 
measured with commercially available enzyme linked immunosorbant assays 
(ELISAs) (Quantikine, R&D Systems; UK). Intra-assay, and inter-assay coefficients of 
variability were 5.25% and 9.5% for IL-6 and 2.4% and 7.6% for plasma VEGF-A 
respectively. Serum CRP concentrations were determined using a validated, highly 
sensitive assay (Department of Clinical Biochemistry; Fife NHS Trust, UK), using the 
method of particle-enhanced immunonephelometry (Behring BN II nephelometer, 
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Dade Behring Inc.). Intra-assay and inter-assay coefficients of variability for hs-CRP 
were 3.7% and 4.2% respectively. All assays were performed in duplicate and the 
mean value taken. Differential leukocyte count, haemoglobin and standard routine 
biochemical assays were undertaken on fresh venous samples (Departments of 
Haematology and Clinical Biochemistry, Lothian NHS University Hospitals Trust; 
UK). 
 
2.7.4 RNA extraction and quantitative real-time polymerase chain reaction 
 Total leukocyte ribonucleic acid (RNA) extraction from 1mL of whole blood 
was performed using QIAGEN’s RNeasy Mini Kit (QIAGEN Ltd., Crawley, UK). 
One microgram of total RNA was transcribed into cDNA in each reverse 
transcription reaction with 200U of M-MLV reverse transcriptase for 60 minutes at 
37oC in 20µL reactions containing 1µL (0.5µg/µL) of random hexamer primers, 
with 0.625µL (40U/µL) of RNAse inhibitor, 5µL of dNTP mix, and 5µL of 5X RT 
reaction buffer. Real-time polymerase chain reaction (PCR) was carried out using the 
ABI Prism 7900HT system (Applied Biosystems, Warrington, UK) to determine the 
relative quantity of mRNA. PCR primers and probes for amplification of cDNA 
derived from CD34 and CD14 transcripts were obtained from Applied Biosystems 
(Foster City, CA, USA). Each assay contained forward and reverse PCR primers and 
one Taqman MGB probe. In each PCR reaction, 4µL of the reverse transcription 
reaction was analysed. The PCR reactions were run in triplicate. Analysis was 
performed using ABI 7900HT SDS software in order to obtain the relative quantities 
of mRNA compared to a calibrator. 
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2.8  DATA ANALYSIS AND STATISTICS 
Flow cytometric analysis, EC-CFU enumeration, and Gensini scoring were 
performed by an observer blinded to the patients’ clinical profiles. Statistical analyses 
were performed with SPSS version 17 (SPSS Inc, Chicago, USA). The D'Agostino & 
Pearson test was used to test for normality of distribution. Continuous variables are 
reported as the mean ± standard error, or the median and inter-quartile range where 
appropriate. Independent two-tailed Student’s t-test, Mann-Whitney U tests and 
Pearson’s Chi-Square tests were used for comparison between groups where 
appropriate. Spearman’s test was used to test for correlation between variables. For 
partial correlation analyses controlling for covariates, data were normalised where 
appropriate. For the evaluation for associations between the various cell populations 
and clinical endpoints, cell concentrations were categorised into tertiles after natural 
logarithmic transformation. Multivariate Cox-regression analysis was performed to 
determine associations between progenitor cells and event-free survival with 
adjustment for the diagnosis of ACS on enrollment and cardiovascular risk factors 
including; age, gender, diabetes, hypertension, hyperlipidemia, a history of 
myocardial infarction, left ventricular systolic dysfunction, previous revascularisation, 
the severity of coronary artery disease, and use of cardiac medication. Hazard ratios 
represent the predicted change in the hazard between the lowest and the highest 
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3.1 SUMMARY 
Endothelial progenitor cells are circulating mononuclear cells with the capacity to 
mature into endothelial cells and contribute to vascular repair. The aim of this study 
was to assess the effect of PCI related local vascular injury on putative circulating 
EPC in patients with coronary artery disease. Putative phenotypic EPC were 
quantified by flow cytometry (CD34+VEGFR-2+) complemented by real-time PCR, 
and the endothelial cell colony forming unit (EC-CFU) assay, before and during the 
first 24 hours after elective diagnostic angiography (n=27) or PCI (n=27). 
Percutaneous coronary intervention, but not diagnostic angiography, caused a 
systemic inflammatory response, increasing the circulating neutrophil (P<0.001) and 
C-reactive protein concentrations (P=0.001) without causing significant myocardial 
necrosis. Twenty-four hours after PCI, EC-CFU increased by three fold (median 
[IQR], 4.4 [1.3-13.8] versus 16.0 [2.1-35.0]; P=0.01), although circulating 
CD34+VEGFR-2+ cells (1.31 ± 0.28 versus 1.34 ± 0.22 x106/L; P=0.35) and 
leukocyte CD34 mRNA (relative quantity 2.3±0.5 versus 2.1±0.4; P=0.21) did not. 
There was no correlation between EC-CFU and CD34+VEGFR-2+ cells either 
before (r=-0.24, P=0.10) or at 24 hours (r=-0.09, P=0.61) after angiography. 
Therefore discrete local vascular injury inflicted by PCI causes a systemic 
inflammatory response and increases EC-CFU, however traditional phenotypic 
CD34+VEGFR-2+ putative EPC are not mobilised in the first 24 hours following 
vascular injury. This suggests that that unlike EC-CFU, CD34+VEGFR-2+ cells are 
not involved in the immediate response to vascular injury.
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3.2 INTRODUCTION 
Ischaemic heart disease is a major cause of morbidity and mortality 
worldwide. Despite advances in percutaneous coronary intervention (PCI), major 
adverse cardiac events occur in up to 30% of patients following balloon angioplasty 
and 20% following stenting [Serruys et al., 1994]. Vascular trauma, induced by PCI, 
initiates the release of cytokines and growth factors resulting in the proliferation of 
smooth muscle and deposition of platelets and leukocytes at the site of injury in order 
to accelerate vascular repair. Endothelialisation is necessary to prevent mural 
thrombus formation and neointimal hyperplasia that may otherwise lead to 
ischaemic complications and restenosis. 
 
The traditional paradigm of vascular repair is based on the proliferation and 
migration of pre-existing mature endothelial cells from the adjacent vasculature 
[Risau, 1995]. In an animal model of hind limb ischaemia Asahara and colleagues 
found that mononuclear cells from peripheral blood might have the potential to 
differentiate into endothelial cells [Asahara et al., 1997]. Endothelial progenitor cells 
(EPC) have been characterised by their expression of both haematopoietic (CD34+) 
and endothelial cell antigens (VEGFR-2+), and by their ability to proliferate, migrate 
and differentiate into mature cell types. These putative EPC form vascular structures 
in vitro and are incorporated into the vessel wall in experimental models of 
neovascularisation [Murohara et al., 2000]. These cells may therefore play an 
important role in the maintenance and repair of the vascular endothelium, and in the 
pathogenesis of atherosclerotic plaque formation and its consequences. Although 
putative EPC have been isolated and cultured from a variety of cell populations in 
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peripheral blood and bone marrow, the EPC remains undefined. Comparisons 
between clinical studies have been limited by the use of a variety of phenotypic 
markers to discriminate EPC and by the lack of comparable functional assays. In 
order to circumvent this problem, the endothelial cell colony forming unit assay (EC-
CFU) was developed as an alternative means of enumerating circulating EPC [Hill et 
al., 2003]. Although now recognised not to be a measure of ‘EPC’, the relationship 
between EC-CFU and cardiovascular stress is well recognised. 
 
In peripheral blood CD34+VEGFR-2+ cells are infrequent, but numbers 
increase rapidly in response to myocardial ischaemia and acute myocardial infarction 
[Adams et al., 2004; Massa et al., 2005], and are reduced in cigarette smokers [Vasa et 
al., 2001b], patients with diabetes mellitus [Fadini et al., 2005], and in those with 
evidence of endothelial dysfunction [Herbrig et al., 2006]. These patients are at high 
risk of complications following PCI. Patients with diffuse in-stent restenosis have 
reduced concentrations of EC-CFU like cells in comparison with matched controls at 
the time of presentation [George et al., 2003]. Inadequate EPC number and function 
prior to angioplasty, as well as inadequate early and sustained EPC recruitment, may 
favour a maladaptive response to arterial injury and result in an increased incidence 
of in-stent thrombosis, restenosis and ischaemic complications. The immediate effects 
of local vascular injury during angioplasty and stenting on the mobilisation of EPC 
are unknown. The aim of this study was therefore to measure circulating phenotypic 




Fifty-four patients undergoing elective coronary angiography participated in 
this study, which was performed with the approval of the local research ethics 
committee, in accordance with the Declaration of Helsinki, and the written informed 
consent of all volunteers. All patients were recruited following referral for 
angiography to investigate symptoms suggestive of stable angina. Patients with a 
recent acute coronary syndrome or coronary intervention (<3 months), renal or 
hepatic failure, or a systemic inflammatory disorder or malignancy were excluded 
from the study. Twenty-seven patients underwent diagnostic coronary angiography 
alone, and 27 required balloon angioplasty and stenting because of flow limiting 
luminal stenosis of a major epicardial vessel (Table 3.1). 
 
3.3.2 Coronary angiography and PCI 
All patients were treated for two weeks with 75 mg clopidogrel prior to 
angiography or PCI. Coronary angiography was performed via the right femoral or 
radial artery with 6F arterial catheters. Elective PCI was performed in all patients 
after the administration of 5,000 IU of intravenous heparin, and in one patient after 
intravenous glycoprotein IIb/IIIa inhibitor. Coronary stents (Liberté, Boston 
Scientific) were implanted in all patients after balloon predilatation of the lesion. 
 
3.3.3 Blood sampling and assays 
Venous blood was sampled before, immediately after and at 6 and 24 hours 
following the procedure. EDTA anti-coagulated blood (Sarstedt-Monovette, 
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Germany) was collected for flow cytometry, and for preparation of plasma for storage 
in all subjects. Whole blood was analysed for total cells, differential count and 
platelets using an autoanalyzer (Sysmex, UK). Plasma troponin I concentrations were 
measured using an automated immunometric assay (Ortho-clinical Diagnostics, High 
Wycombe, UK). Serum C-reactive protein (CRP) concentrations were measured 
using an immunonephelometric assay (Behring BN II nephelometer, Marburg, 
Germany). In 40 subjects (20 diagnostic angiograms and 20 PCI), 20 mL of whole 
blood was drawn at baseline and 24 hours for mononuclear cell preparation, cell 
culture and real-time PCR. 
 
3.3.4 Flow cytometry 
Whole blood cells were phenotyped by flow cytometry. Cells were directly 
stained and analysed for phenotypic expression of surface proteins using pre-
conjugated anti-human monoclonal antibodies including anti-CD34-FITC, and anti-
VEGFR-2-PE (R&D systems, Minneapolis, USA). Appropriate negative controls 
were used to establish positive stain boundaries as described. Undiluted samples 
(100mL) were stained with antibodies for 30 minutes in the dark. Erythrocytes were 
lysed (lysing solution, Becton Dickinson), and samples were centrifuged at 200 g for 
10 minutes, washed with phosphate buffered saline (PBS), and fixed (Cell Fix 
solution, Becton Dickinson). For each sample, 80,000 events were acquired in the 
lymphocyte region (as determined by characteristic forward and side scatter profile) 
using a FACS Calibur flow cytometer (Becton Dickinson) and data were analysed 
using FCS Express (DeNovo Software). The number of leukocytes per mL of blood 
was measured using an automated cell counter in our regional haematology 
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laboratory. EPC were quantified based on the percentage of CD34+VEGFR-2+ 
double positive leukocytes and expressed as number of cells per mL of blood. 
 
3.3.5 Endothelial cell colony forming units 
Endothelial cell-colony forming units (EC-CFU) [Hill et al., 2003] were 
generated from circulating mononuclear cells isolated by density gradient separation 
as described above (Section 2.6.1. EC-CFU were counted in a minimum of four wells 
on day five. 
 
3.3.6 RNA extraction and quantitative real-time PCR 
Total leukocyte ribonucleic acid (RNA) extraction and real-time polymerase 
chain reaction (rt-PCR) were carried out as described. Briefly, RNA extraction from 
1mL of whole blood was performed and 1µg of total RNA was transcribed into 
cDNA. Real-time PCR was carried out to determine the relative quantity of mRNA. 
PCR primers and probes for amplification of cDNA derived from CD34 and CD14 
transcripts were obtained from Applied Biosystems (Foster City, CA, USA). Each 
assay contained forward and reverse PCR primers and one Taqman MGB probe. 
The PCR reactions were run in triplicate. Analysis was performed using ABI 
7900HT SDS software in order to obtain the relative quantities of mRNA compared 
to a calibrator. 
 
3.3.7 Data analysis and statistics 
Analysis was performed by an observer blinded to whether patients had 
undergone angiography or PCI. Statistical analyses were performed with GraphPad 
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Prism (Graph Pad Software, USA) using two-tailed Student’s t-test, repeated 
measures ANOVA, Mann-U Whitney or Wilcoxon paired tests where appropriate. 
D'Agostino & Pearson omnibus normality test was used to assess whether parameters 
were normally distributed with continuous variables are reported as mean ± SEM or 
median [IQR]. Statistical significance was taken at a two sided P value of <0.05.
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3.4 RESULTS 
3.4.1 Subjects and procedures 
Twenty-seven patients underwent diagnostic coronary angiography alone and 
27 underwent PCI using intracoronary stents to treat 36 lesions with an average 
vessel diameter of 2.9±0.1 mm at the point of stent deployment. Patients were well 
matched in terms of age and sex and with respect to their cardiovascular risk profile 
and baseline medications (Table 3.1). There were no complications arising from 
angiography or PCI and all patients were discharged home 24 hours after the 
procedure. 
 
3.4.2 Inflammation and myocyte necrosis 
Diagnostic angiography did not increase peripheral blood leukocyte count or 
serum C-reactive protein concentrations (Table 3.2). Coronary intervention 
increased circulating neutrophil (∆ 0.9±0.3 x109/L, P<0.001) and serum C-reactive 
protein concentrations (∆ 1.5 [0.4-2.0] mg/L, P=0.001) at 24-hours. There was a 
transient reduction in monocyte count immediately following PCI (∆ -0.07±0.02 
x109/L, P=0.004) and cardiac catheterisation alone (∆ -0.10±0.03 x109/L, P=0.006). 
Monocyte count returned to pre-procedure levels by 24 hours. There was little 
evidence of myocyte necrosis following diagnostic angiography or PCI, with plasma 
cardiac troponin I at 24 hours increased in 2 patients following angiography and 4 
patients following PCI: median concentration 0.2 [0.2-0.69] ng/mL and 0.2 [0.2-1.6] 




3.4.3 Endothelial cell – colony forming units 
Although unaffected by diagnostic angiography (median [IQR], 4.7 [0-21.5] 
versus 3.2 [1.1-9.7]; P=0.70), the number of EC-CFU increased three fold 24 hours 
after PCI (median [IQR], 4.4 [1.3-13.8] versus 16.0 [2.1-35.0], P=0.01; Figure 3.1). 
 
3.4.4 Phenotypic endothelial progenitor cells 
CD34+ and CD34+VEGFR-2+ cells were similar at baseline and unaffected 
by either procedure (Table 3.3). There was no correlation between EPC identified by 
phenotype (CD34+VEGFR-2+ cells) and the number of EC-CFU either before (r=-
0.24, P=0.10) or 24 hours (r=-0.09, P=0.61) after angiography. Similarly, no increase 
in leukocyte CD34 mRNA occurred following diagnostic angiography or PCI. There 
was however, a reduction in leukocyte CD14 mRNA immediately after 
catheterisation in both diagnostic and interventional studies that coincided with the 
reduction in circulating monocytes (Table 3.3). Relative quantities of leukocyte CD14 
mRNA increased significantly 24 hours following PCI (P<0.05).  
 
Figure 3.1 EC-CFU 
concentration in 
response to local 
vascular injury: The 
number of EC-CFU 
increased following PCI 
compared to baseline 
(median [IQR], 4.4 [1.3-
13.8] versus 16.0 [2.1-
35.0], P=0.01), but were 
not changed following 
diagnostic angiography 
alone (median [IQR], 
4.7 [0-21.5] versus 3.2 
[1.1-9.7], P=0.70). 






























Table 3.1.  Baseline characteristics of study population 
 Angiography (n=27) PCI (n=27) P Value 
Demographics and clinical characteristics 
Age (years) 62 ± 2 61 ± 2 0.71 
Male gender (%) 15/12 17/10 0.69 
Cigarette smokers  5 5 0.98 
Diabetes mellitus  8 3 0.18 
Hypertension 15 19 0.52 
Previous MI 4 6 0.69 
Previous PCI 5 8 0.55 
Prior CABG 4 4 0.95 
Biochemistry 
Total cholesterol (mg/dL) 186 ± 11 168 ± 7 0.18 
LDL-cholesterol (mg/dL) 97 ± 10   90 ± 7 0.60 
HDL-cholesterol (mg/dL) 46 ± 2  42 ± 3 0.18 
Triglycerides (mg/dL) 206 ± 19  193 ± 25 0.68 
Medical therapy 
Aspirin 21 21 0.99 
Clopidogrel 27 27 0.99 
Statin 18 24 0.15 
ß-blocker 18 22 0.33 
ACE inhibitor/ARB 13 15 0.83 
Angiographic findings 
Normal/minor disease 13 0 0.001 
1 vessel disease 2 11 0.03 
2 vessel disease 5 9 0.33 
3 vessel disease 7 7 0.99 
Stent implantation 
De novo lesions 0 24 - 
Restenosis 0 3 - 
Grafts 0 1 - 
Stents per patient 
1 stent 0 19 - 
2 stents 0 7 - 
3 stents 0 1 - 
Values are presented as number or mean ± SEM or number; an unpaired Student’s t-test was used 
for comparisons involving parametric data and a Mann-U Whitney test for non-parametric data. 
ACE = angiotensin converting enzyme; ARB = angiotensin II receptor blocker; CABG = coronary 



























































































































































































































































































































































































































































































































































































































































This study demonstrates that PCI, but not diagnostic angiography, is 
associated with a systemic inflammatory response and an increase in circulating EC-
CFU in the first 24 hours, however this is not associated with a change in either 
circulating CD34+VEGFR-2+ cell concentrations or leukocyte CD34 mRNA levels 
following PCI. Therefore, the immediate cellular response to vascular injury involves 
mobilisation of EC-CFU rather than putative CD34+VEGFR-2+ EPC. Circulating 
CD34+VEGFR-2+ cells may be capable of endothelial cell differentiation, but are 
rare in peripheral blood and are not mobilised rapidly in the early response to acute 
local vascular injury.  
 
Asahara et al., originally described a population of peripheral adult cells 
containing CD34+ cells that could differentiate into cells with endothelial-like 
characteristics in vitro. ‘Functional’ colony assays such as the EC-CFU assay were 
subsequently developed in an attempt to enumerate these cell populations. However, 
coronary intervention increased the number of EC-CFU but was not associated with 
a mobilisation of CD34+VEGFR-2+ cells. These findings are superficially discordant 
with Asahara’s original description and require exploration. The exact origin and 
phenotype of the progenitors identified by Asahara remains speculative in part 
because the purity of CD34+ cells used in this initial study was only 15%, and did not 
employ specifically CD34+VEGFR-2+ cells [Asahara et al., 1997]. Nevertheless the 
co-expression of transmembrane glycoproteins CD34 and VEGFR-2 has been used 
in an increasing number of clinical studies to phenotype and quantify circulating 
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EPC. Previous studies have demonstrated early mobilisation of CD34+VEGFR-
2+cells following vascular injury in patients with acute myocardial infarction [Massa 
et al., 2005], and CD133+VEGFR-2+cells following major burns and CABG surgery 
[Gill et al., 2001]. However, these clinical events involve extensive damage to a 
number of tissues in addition to the vasculature that may contribute to the 
mobilisation of progenitors and may explain the absence of CD34+ EPC mobilisation 
in the present study. EC-CFU are diminished in patients with cardiovascular risk 
factors and impaired vascular function [Hill et al., 2003], suggesting they fulfil a 
function in the maintenance of vascular homeostasis, and protect against the 
development of atheroma. Mobilisation of EC-CFU in response to discrete vascular 
injury caused by PCI is consistent with this hypothesis, and given the endothelial 
phenotype of EC-CFU it is plausible that quantification of EC-CFU may provide a 
measure of the capacity of circulating mononuclear cells to form endothelial cells. 
However, it is doubtful whether these colonies arise directly from the circulating 
CD34+ stem cells. Consistent with previous findings [Tura et al., 2007] and those of 
George et al., [George et al., 2006] I found no correlation between the number of 
peripheral blood CD34+ cells and the number of EC-CFU. Studies addressing the 
origin of endothelial progenitor lineage in adult peripheral blood have demonstrated 
that monocytes also express endothelial lineage markers such as VEGFR-2 and can 
differentiate into mature endothelial cells [Schmeisser et al., 2001]. Rehman et al. 
found that the majority of EC-CFU expressed monocyte markers such as CD14, 
Mac-1, and CD11c, suggesting that they are derived from monocyte-like cells 
[Rehman et al., 2003]. These findings are confirmed in the elegant studies by Rohde 
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et al in which they demonstrate formation of colony forming units by mononuclear 
cells depleted of CD34+ cells and report that the EC-CFU are primarily composed of 
monocytic and lymphocytic cells [Rohde et al., 2007]. The role of EC-CFU remains 
unclear and further studies are required to address what in-vivo processes they 
represent. 
 
The concept that functional endothelial cells may originate from a CD14 
expressing progenitor is supported by reports that mature endothelial cells isolated 
from human umbilical vein express CD14 [Jersmann et al., 2001]. Furthermore, 
Urbich et al. demonstrate that isolated CD14+ cells also have the capacity to improve 
neovascularisation after hind-limb ischaemia [Urbich et al., 2003]. CD14+ monocyte-
like cells are more abundant in normal peripheral blood than in bone marrow and 
are therefore capable of rapidly homing to sites of vascular injury. Whilst 
CD34+VEGFR-2+ cells may ultimately give rise to endothelial cells, they are much 
less prevalent in peripheral blood than in bone marrow, and are not mobilised 
following PCI. The findings of this study are consistent with those recently published 
by Thomas et al., [Thomas et al., 2008a] and together these studies do not suggest an 
important role for CD34+VEGFR-2+ cells in the early response to vascular injury. 
 
Whilst I did not specifically measure CD14+ cells by flow cytometry, I did 
quantify circulating monocytes, and total leukocyte CD14 mRNA. I identified a 
significant decrease in both variables immediately after cardiac catheterisation. This 
fall in circulating monocytes may be explained by immediate localisation of 
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monocytes to the site of vessel damage: both at the site of arterial puncture and at the 
site of coronary angioplasty and stenting, although adherence of monocytes to the 
plastic catheters used during the procedure might explain the rapid but transient fall 
in circulating monocytes. The number of peripheral blood monocytes returned to 
pre-procedural levels by 24 hours, and CD14 mRNA levels increased 24 hours after 
PCI. Mobilisation of CD14+ monocyte-like cells or a change in the function of these 
cells through up-regulation of surface protein expression may explain the increase in 
EC-CFU in peripheral blood observed 24 hours after arterial injury. These cells may 
contribute to vascular repair either through formation of mature endothelial cells and 
incorporation into the vessel wall, or through the release of angiogenic growth factors 
at the site of vessel injury.  
 
As it may take up to three months for a complete functional endothelial layer 
to form following percutaneous coronary intervention [Grewe et al., 2000], I cannot 
discount a role for CD34 derived progenitors, perhaps released in response to 
secondary angiogenic factors, in the later stages of vascular repair. It is also possible 
that other putative EPC populations not measured in the present study, such as those 
expressing the stem cell marker CD133, may have a role in the response to vascular 
injury. Further studies are required to explore specifically the role of CD14+ and 
CD133+ subpopulations, to define the time course of this response to vascular injury, 






Acute local vascular injury following angioplasty and stenting results in a 
systemic inflammatory response and increases the number of EC-CFU. Circulating 
CD34+VEGFR-2+ cells are rare in peripheral blood, and are not mobilised rapidly 
in the early response to vascular injury. The acute response to injury is mediated by 
EC-CFU, probably derived from circulating monocytic cells rather than the 
primitive CD34+VEGFR-2+ cells that have hitherto been considered as the major 
endothelial progenitor cell source in blood and bone marrow. It is unclear what EC-
CFU represent. A better understanding of the cellular response to vascular injury is 
necessary to allow a more sophisticated approach to reducing the complications of 
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4.1 SUMMARY 
 The formation of endothelial cell-colony forming units (EC-CFU) is increased 
by cardiovascular stress, although their function in-vivo is unclear. I therefore 
examined the constituents of EC-CFU and the mechanisms of their generation. The 
expression of endothelial and haematopoietic antigens on EC-CFU was assessed 
using immunofluorescent confocal microscopy and flow-cytometry. Colony growth 
was examined using time-lapse microscopy. In order to interrogate leukocyte/colony 
interactions, wells containing mature EC-CFU were inoculated with autologous 
monocytic and lymphocytic cells isolated by fluorescence activated cell sorting. 
Cellular proliferation within EC-CFU was assessed using the nucleotide analogue 
bromodeoxyuridine (BrdU) and the inhibitor of cellular proliferation, mitomycin-C. 
EC-CFU expressed typical endothelial characteristics [CD146, CD105, Tie-2 and 
eNOS], however several endothelial markers were only weakly expressed or absent 
[CD31, CD144, von Willebrand factor and vascular endothelial growth factor 
receptor-2]. EC-CFU strongly expressed the pan-leukocyte marker CD45, the 
macrophage marker CD68, and also the lymphocyte markers CD4 and CD8. 
Expression of CD14 on EC-CFU was progressively down-regulated over time from 
14.4±3.6% at baseline to 10.9±0.9%, 5.2±0.4%, 3.8±1.2 and 2.5±0.6% on days two 
to five respectively (P<0.001; N = 6). Time-lapse microscopy revealed migration of 
characteristic spindle cells toward mature colonies. Both monocytic and lymphocytic 
fractions migrated toward mature colonies. Colonies exhibited punctate 
incorporation of BrdU that progressively increased during colony maturation 
sequentially from a median of 2.2 (0.0-4.0) x103cells/µm3 on day two to 35.2 (18.7-




EC-CFU exhibit endothelial characteristics, but are predominantly CD14+ derived 
macrophages and are a potent stimulus for lymphocyte migration. Proliferation is 
necessary for EC-CFU generation, however colony growth also occurs as a result of 
leukocyte migration. Although confirmatory in-vivo studies are required, EC-CFU 
formation likely reflects leukocyte activation as a reparatory response to vascular 
denudation or tissue ischaemia.
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4.2 INTRODUCTION 
 Endothelial progenitor cells (EPC) offer promise as a therapeutic target in 
cardiovascular medicine. Unfortunately, our understanding of EPC biology has been 
slow to progress, and even a precise definition of an EPC has been lacking. In the 
absence of a robust phenotypic definition, ‘functional’ endothelial colony forming 
assays have been developed, whereby mononuclear cells isolated from the peripheral 
circulation are cultured under angiogenic conditions in order to generate colonies 
that exhibit mature endothelial cell characteristics. Formation of ‘endothelial’ 
colonies has been interpreted as inferential evidence that circulating endothelial 
progenitor cells exist in the peripheral circulation. Based on the premise that colonies 
arise via clonal expansion of a single cell, the enumeration of such colonies has been 
used to estimate the concentration of endothelial progenitors in the peripheral blood. 
Such assays have subsequently been used in a huge number of pre-clinical and 
clinical studies in order to determine the relationship between putative EPC and 
cardiovascular disorders.  
 
 The endothelial cell – colony forming unit (EC-CFU) assay described by Hill et 
al, has been used most extensively [Hill et al., 2003]. In support of their 
vasculoprotective role, EC-CFU are reduced in patients with overt atherosclerosis 
[Heeschen et al., 2004], and in cardiovascular disorders such as diabetes mellitus 
[Loomans et al., 2004], and hypertension [Delva et al., 2007], and an increased 
capacity to generate EC-CFU is associated with better vascular function as measured 
by flow mediated arterial dilatation [Hill et al., 2003]. EC-CFU are mobilised in 
response to cardiovascular stress, such as coronary artery bypass surgery [Roberts et 
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al., 2007], myocardial ischaemia [George et al., 2004] and infarction [Massa et al., 
2005; Shintani et al., 2001], and as demonstrated in the previous chapter, discrete 
endovascular injury caused by percutaneous coronary intervention [Mills et al., 
2009]. Several other studies have reported similar findings following angioplasty both 
in the coronary and peripheral vasculature [Banerjee et al., 2006; Bonello et al., 2006; 
Garg et al., 2008b; Marboeuf et al., 2008]. These studies were conducted under the 
specious impression that EC-CFU were a quantitative measure of circulating EPC, 
however we now appreciate this not to be the case. EC-CFU are related to normal 
cardiovascular homeostasis, however lack the capacity to form perfusing vessels in 
animal models of neovascularisation, and widely express hematopoietic markers 
[Rohde et al., 2007; Yoder et al., 2007]. The pathophysiological significance of EC-
CFU therefore remains unclear, although it is plausible that EC-CFU formation 
reflects leukocyte activation in response to cardiovascular stress. Although 
presumptively regarded as a proliferative assay this has never been demonstrated, 
and furthermore the presence of mature leukocytes within EC-CFU indicates cell 
migration is important in their development. These studies were conducted to 
confirm the phenotypic characteristics of EC-CFU and test the hypothesis that EC-
CFU form by cellular migration rather than proliferation.  
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4.3 MATERIALS AND METHODS 
4.3.1 Immunostaining of endothelial cell-colony forming units 
Following informed consent, circulating mononuclear cells isolated by density 
gradient separation (Histopaque 1.077 g/ml; Sigma-Aldrich, UK) of peripheral 
blood from healthy volunteers was used to generate EC-CFU as described above 
(Chapter 2.6.1) Endothelial cells-colony forming units (EC-CFU) (Stem Cell 
Technologies) were defined as a colony of cells consisting of multiple thin, spindle 
cells in association with a central cluster of rounded cells [Hill et al., 2003]. The 
phenotypic characteristics of EC-CFU were determined as described above in 
chapter 2. Briefly, day five EC-CFU were fixed and permeabilised and blocked with 
blocked with 10% Goat serum/ 1% bovine serum albumin (BSA), prior to 
immunostaining with by immunostaining using a battery of surface and intracellular 
stains including endothelial nitric oxide, CD146, CD34, CD31, CD105, CD144, 
Tie-2 and VEGFR-2, in addition to the leukocyte markers CD45, CD4, CD8, CD14 
and CD68.  
 
Positive and negative controls 
 Human umbilical vein endothelial cells (HUVEC) served as positive controls 
for endothelial markers. Having undergone no more than three passages, HUVEC 
were cultured in EGM-2 (Lonza; UK) on plain glass chamber slides until confluency 
was acheived. Mononuclear cell (MNC) preparations served as positive controls for 
haematopoietic markers. 100µl of MNC at a density of 4 x 105 cells/mL in 1% BSA 
solution were cytospun onto glass slides and fixed using methanol for 5 minutes 
before being stained as above.  
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The human adenocarcinoma cell-line, HT-29 served as a negative control 
population. HT-29 cells (courtesy of Dr S. Bader’s group, University of Edinburgh) 
were cultured in RPMI (Gibco/Invitrogen; UK) supplemented with 5% FCS until 
confluency was achieved. Cells were fixed in methanol and stained as described 
above. 
 
Confocal microscopy and image analysis  
Stained colonies were visualized using a Zeiss ‘LSM 510 Meta’ confocal 
fluorescent microscope at x40 with an oil immersion objective lens. Fluorescent 
intensity was compared qualitatively against the positive and negative controls. 
 
4.3.2 Time-lapse microscopy 
 For time-lapse analysis developing colonies were identified 24 hours following 
the replating step. Developing colonies were imaged using an inverted confocal 
microscope (Leica), situated in an environmentally controlled chamber with an 
integrated digital camera (Nikon). Colonies were incubated at 37°C at 5% CO2. 
Images were captured at a frequency of six per hour for approximately 72 hours. 
 
4.2.3 Fluorescence activated cell sorting.  
 Cell sorting was performed as described in chapter two. Briefly, mononuclear 
cells were isolated from the whole blood of healthy volunteers by density gradient 
centrifugation. Aliquots of mononuclear cells were stained for lymphocytes with anti-
CD3 PE-mouse and anti-CD19 APC-mouse pre-and another stained for monocytes 
using anti-CD14 Cy5-5PE. Cell clumps were removed by agitation followed by 
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sedimentation and the cell suspension was transferred to fresh culture medium 
supplemented with 100 U/mL penicillin and 100g/mL streptomycin. Cell sorting 
was performed by a FACSAria cell sorter (Becton-Dickinson, UK) using 
CellQuestPro software (Becton Dickinson; UK). Acquisition gates were set using the 
protocol as described.  
 
4.3.4 Cellular migration 
 FACS sorted mononuclear cells were stained green (CD14+ monocytes) or red 
(CD3+ and CD19+ lymphocytes) by incubating sorted fractions for 20 minutes at 
37°C at a density of 0.5x106/mL in complete endocult medium with cell-labeling 
solution (Vybrant™ Di cell-labeling solution; Molecular Probes, UK) at a 
concentration of 2.5 µL/mL, mixed by gentle pipetting. Cell suspensions were 
centrifuged at 1500 rpm for five minutes at 37°C to form a cell pellet. The 
supernatant was gently removed and the cell pellet was resuspended in complete 
medium. Fluorescently labeled sorted cell fractions containing approximately 5x105 
cells were combined with autologous EC-CFU approaching maturity at day four. 
Cell populations were delivered via an 8µm transwell migration chamber (Co-
star;UK) in order to demonstrated active cellular migration and prevent cell clumps 
contaminating the pre-existing colonies. Colonies were assessed over the following 24 
hours using an inverted microscope equipped with an argon laser in order to assess 
leukocyte/colony interactions. 
 
4.3.5 Colony proliferation  
 Mononuclear cells from healthy volunteers were used to generate EC-CFU 
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colonies as described above. At the replating step on day two, four separate wells 
were prepared and from day two to five an individual well was pulsed with 
Bromodeoxyuridine (BrdU) (Sigma-Aldrich) at a 100 µmol concentration for six 
hours at 37°C, 5% CO2. Following each pulse, unincorporated BrdU was removed 
by rinsing unattached cells and the well itself twice with fresh medium. Resuspended 
cells were returned to the well and incubation was allowed to continue thereby 
providing a ‘snapshot’ of the amount of proliferation occurring for a six hour period 
on each day. On day six the supernatant was removed and colonies were fixed and 
permeablised with 4% paraformaldehyde at room temperature for 30mins. Colonies 
were then immersed in 0.25% tween-20 for 12hrs before being rinsed with PBS. 
Permeabilised colonies were incubated with DNAse (Perbio science; United 
Kingdom) at 500U/mL in 50mMol Tris buffered deionised water; MgCl210mMol; 
bovine serum albumin 100µgml-1 pH 7.4) at 37°C for 30 minutes. Colonies were 
then rinsed well with PBS and incubated with anti-BrdU conjugated to alexafluore 
488 (Invitrogen; Paisley, UK) at a 1/100 dilution.  
 Wells were visualised using an inverted fluorescent microscope and integrated 
digital camera (Nikon Eclipse TS100-F). Proliferation was expressed as the 
proportion of BrdU positive cells per cubic micron of colony, where colony volume 
(V) was calculated using the formula V = (πr2h)/3 where r = the radius of the base of 
the colony and h = the height of the colony was assumed to be equal to r. For control 
experiments, lymphocytes were obtained by gently decanting the non-adherent 
population of a mononuclear cell preparation exposed to plastic [Elkord et al., 2005]. 
Lymphocytes either fresh, or stimulated to proliferate with phytohaemagglutinin 
(PHA; Wellcome, Kent, UK.) at concentration of 5 µg/mL [Aldhous et al., 2008] 
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were treated as above in order to obtain negative and positive controls for BrdU 
incorporation respectively. In separate experiments EC-CFU were cultured in the 
presence of the anti-proliferative agents, mitomycin C and Actinomycin D, in order 
to assess the effect of blocking proliferation on colony formation. 
 
Statistical analysis 
 All experiments were performed at least in triplicate to ensure reproducibility. 
Continuous variables are reported as mean ± SEM or median and inter-quartile 
range where appropriate. Statistical analyses were performed with GraphPad Prism 
(Graph Pad Software, USA) using two-tailed Student’s t-test, Mann-U Whitney or 
Wilcoxon paired tests where appropriate. Spearman’s test was used to test for 




4.4.1 Phenotypic characteristics of EC-CFU 
EC-CFU expressed a variety of surface antigens considered typical of 
haematopoietic/leukocytic cells, endothelial cells or both (Figure 4.2). The intensity 
of immunofluorescence was compared to HUVEC, uncultured MNC and as a 
universal negative control, the human adenocarcinoma cell line HT29. Of the typical 
leukocyte markers examined, the common leukocyte antigen CD45 and the 
macrophage marker CD68 were most intensely expressed. Both were increased 
compared to MNC and were absent on HUVEC. The lymphocyte markers CD8, 
and to a lesser extent CD4, were expressed on EC-CFU at a similar level of intensity 
as uncultured MNC. HUVEC were negative for lymphoid markers. Notably, the 
monocyte marker CD14 was only very weakly expressed on mature colonies, as 
compared to uncultured MNC. Consistent with previous reports [Jersmann et al., 
2001] very faint CD14 expression was also seen on isolated HUVEC, but otherwise 
expression of these more typical leukocyte markers was absent on HUVEC and HT-
29. Flow-cytometric quantification of CD14 expression on cells retrieved from the 
EC-CFU assay demonstrated a fall in CD14 expression from 14.4±3.6% at baseline 
to 10.9±0.9%, 5.2±0.4%, 3.8±1.2 and 2.5±0.6% on days two to five respectively 
(ANOVA P<0.001; N = 6) (Figure 4.3). Of the more typical endothelial markers 
inspected, CD146 and Tie-2 were most intense and were expressed to a comparable 
degree on both EC-CFU and HUVEC. The vascular endothelial cadherin, CD144 
was absent on EC-CFU yet strongly positive on HUVEC. The intensity of expression 
of eNOS on EC-CFU was weakly expressed though similar to that of HUVEC. Von-
Willebrand factor was relatively faintly expressed on both EC-CFU and HUVEC. 
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VEGFR-2 expression was virtually absent on EC-CFU and was only very faintly 
expressed on HUVEC. CD31, an endothelial marker that is also expressed on 
monocytic cells was faintly expressed on EC-CFU, but very brightly on HUVEC. All 
of the more typical endothelial markers were absent on MNC and HT-29. CD105, a 
surface protein expressed on both monocytic macrophages and activated endothelial 
cells, was very intensely expressed. CD105 expression was similarly intense on 
HUVEC. CD34 was expressed on EC-CFU but to a similar level as MNC and HT-
29. There was faint expression of CD34 on HUVEC. Finally Ac-LDL uptake and 
lectin binding, classical but non-specific characteristics of endothelial cells were 
present EC-CFU and HUVEC but absent on HT-29. 
 
 



















Figure 4.3 Down 
regulation of CD14 in 
culture 
CD14 expression on cells in 
the EC-CFU assay was 
assessed by flow cytometry. 
There was progressive 
down regulation of CD14 
expression in culture over 
time from 14.4±3.6% at 
baseline to 10.9±0.9%, 
5.2±0.4%, 3.8±1.2 and 
2.5±0.6% on days two to 
five respectively (ANOVA 











































































Figure 4.2 EC-CFU phenotypic characterisation: With the exception of Ac-LDL and 
Ulex Europeaus, colonies were stained using primary antibodies followed by a secondary step. 
Cells are imaged at either x20 or x40 magnification. Mononuclear cells (MNC) and human 
umbilical vein cells (HUVEC) served as positive and negative controls depending on the antigen 
in question. The human adenocarcinoma cell line HT-29 served as a universal negative control. 
Expression of CD45, CD68, and CD105 were most intense. CD4 and CD8 were present 
throughout EC-CFU. The monocyte marker CD14 was only weakly expressed on EC-CFU. 
Colonies displayed classical, but non-specific endothelial characteristics; uptake of acetylated 
low-density lipoprotein and Ulex Uropeaus binding and expressed Tie-2, CD146, CD105 and 
eNOS. von Willebrand factor, VEGFR-2 and CD31 expression was weak and the vascular 





















4.4.2 Fluorescence activated cell sorting 
 Mononuclear cells were sorted into monocytic and lymphocytic fractions on 
the basis of CD14, CD3 and CD19 expression. Approximately 33±19% of MNC 
were intact, and approximately 77±11% of these events were singlets (i.e. not cell 
aggregates). Of the intact singlets, 66±15% fell within the lymphoid gate and 27±8% 
fell within the myeloid gate. Within the lymphoid and myloid gate cells were further 
selected on the basis of CD19 or CD3 and CD14 respectively. Such stringent 
acquisition criteria produced a high purity of cell phenotype. With respect to the T-
lymphocyte sort, 80±4% of intact events were CD3+ and 0.3±<0.15% were CD14+. 
For the B-lymphocyte sort, 87±6% of intact events were CD19+ and 0.4±<0.2% 
were CD14+. For the monocyte sort, 73±11% of intact events were CD14+ and 
0.4%±<0.15% were either CD3+ or CD19+. The absolute quantities of cells 
recovered from sorts were as follows; 1.0±0.5 x106, 3.3±0.8 x106 and 0.8±0.2 x106 
for CD14+, CD3+ and CD19+ cells respectively. 
 
4.4.3 Cellular Migration 
Cellular migration time-lapse 
 Colonies were observed using time-lapse microscopy for approximately 72 
hours. Avid migration of both ‘round’ and ‘spindle’ cells toward colonies occurred 
with an associated enlargement of the colony. Cells migrated by rolling or by the 
projection of cytoplasmic extensions followed in turn by movement of the cell body. 
Small satellite colonies could be seen to form but these subsequently dissipated. 
Ultimately colonies began to degrade and disintegrate, adopting an ill-defined and 





Cellular Migration – Inoculation experiments 
 Via a transwell insert, 5x105 cells from each population were added to a 
respective well. Within eight hours of inoculation, stained mononuclear cells had 
migrated through the transwell insert and had settled on the base of the well. Both 
round and spindle shaped morphology were evident within both monocytic and 
lymphocytic populations. However, within the first eight hours stained spindle cells 
were randomly positioned, unlike unstained spindle cells closely associated with 
colonies that adopted a radial distribution around mature colonies. Definite 
Figure 4.4 Mononuclear cells migrate to and incorporate into EC-CFU: Time-lapse 
microscopy revealed that both round and spindle shaped cells migrated toward developing EC-
CFU. A still image is shown here of a large central colony attracting cells. The direction of cell 
migration is depicted by the black arrows. A small satellite colony was seen to form at the 2 o’clock 
position, which also attracted a stream of spindle cells. The number of cells occupying the surface 
of the well between colonies could clearly be seen to diminish over the period of colony 
maturation (see time-lapse movies). 
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incorporation into colonies was evident by 12 hours by both monocytic and 
lymphocytic cells with dense staining of colonies, predominantly at the periphery of 
the colonies (Figure 4.5). CD3+ and CD19+ cells behaved similarly. Distinct 
populations of stained and unstained cells were present throughout, indicating that 
staining of colonies after 12 hours was not due to contamination of the wells with 
cellular stain. In order to provide added confirmation of this, EC-CFU were co-
incubated with supernatant of washed mononuclear cells following staining. No dye 
uptake occurred. 
 
4.4.4 EC-CFU proliferation  
 Freshly adhered MNC on fibronectin showed only very sparse and scattered 
BrdU uptake (data not shown). EC-CFU exhibited marked BrdU uptake, indicating 
that cellular proliferation was indeed taking place (Figure 4.6A). As a positive control, 
MNC stimulated to proliferate with PHA[Inman et al., 1963] formed multiple 
colonies, all of which exhibited marked BrdU uptake (Figure 4.6B). As a negative 
control, EC-CFU unexposed to BrdU were stained with anti-BrdU as above. The 
absence of immunofluorescence confirmed that staining was specific (Figure 4.6C). 
The proportion of BrdU+ cells in EC-CFU varied directly with the size of a colony 
(r=0.66; 95% confidence intervals (CI) 0.53-0.76, P<0.0001; N = five subjects and 
109 colonies). The median concentration of BrdU+ cells increased sequentially from 
a median of 2.2 (0.0-4.0) x103 cells/µm3 on day two to 35.2 (18.7-55.6) x103 
cells/µm3 on day 5 (P<0.0001; N=5; Figure 4.7A). After day five, colonies 
degenerated, and exhibited a diffuse and granular morphology with little definition of 
cell membranes and nuclei, making the determination of BrdU concentration 
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unfeasible. BrdU incorporation was also evident in EC-CFU generated form MNC 
enriched for CD14+ to a purity of >99%. When treated with the cell cycle arrest 
agent mitomycin C, colony formation was significantly reduced from a median of 21 
(5-48) to 2 (0.3-10) colonies per well; P=0.003; N=12: Figure 4.7B). Cells did 
however remain alive and acquired spindle-shaped morphology, indicating a sub-
lethal, anti-proliferative dose of Mitomycin-C. Cells treated with actinomycin D 
(which ultimately inhibits both cell division and protein synthesis) remained rounded 
and began to die after one day in culture. 
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Figure 4.5 Monocytes and lymphocytes migrate and incorporate into EC-CFU: 
Day 5 EC-CFU cultures inoculated with stained mononuclear cells are displayed. Wells with 
added CD14+ monocytes stained green are displayed on the right, and CD3+ lymphocytes 
stained red are displayed on the left. Stained and unstained cells can be readily distinguished 
from each other. Both cells types adopted a spindle shape morphology but round cells can also 
be seen (A and B; x40 magnification). Stained mononuclear cells migrated toward and 
incorporated into EC-CFU (C-D with phase-contrast; E-F without phase-contrast; 
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 These studies confirm the haematopoietic nature of EC-CFU, and for the first 
time demonstrate that EC-CFU colonies are a potent stimulus for the migration of 
monocytes and lymphocytes in-vitro. Furthermore, I demonstrate conclusively that 
cellular proliferation occurs within EC-CFU colonies and that this may be necessary 
in order for EC-CFU to form. 
 
 Consistent with previous reports [Hur et al., 2007; Rohde et al., 2007; Yoder et 
al., 2007], I found that EC-CFU exhibit a variety of endothelial characteristics. 
These included the uptake of acetylated low-density lipoprotein and UEA-1 binding, 
and the expression of Tie-2, CD146, CD31, CD105 and endothelial nitric oxide 
synthase. Other typical endothelial markers such VEGFR-2 and Von Willebrand 
factor were only very weakly expressed, or in the case of CD144, not at all. Although 
often described as classical endothelial characteristics, Ac-LDL uptake, lectin binding 
and surface expression of CD31, CD144 and CD105 are actually non-specific, and 
can also a be expressed on cells of myeloid lineage such as monocytes and 
macrophages [Rohde et al., 2006]. Indeed the most intensely expressed antigens of all 
were the pan-leukocyte marker CD45, and the macrophage markers CD68 and 
CD105. The lymphocyte markers CD4 and CD8 were also expressed widely 
throughout colonies. Of particular note was the fact that the monocyte marker CD14 
was expressed only very weakly despite being expressed relatively intensely on 
uncultured monocytes. Further interrogation of mononuclear cells plated in the EC-
CFU assay using flow-cytometric analysis confirmed that CD14 expression is 
progressively down-regulated in the EC-CFU assay over time. In contrast, the 
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markers CD68 and CD105 were expressed very weakly on uncultured monocytes but 
became very intensely expressed on mature EC-CFU. It is recognised that monocytes 
will up-regulate a variety of endothelial characteristics in culture [Fernandez Pujol et 
al., 2000; Harraz et al., 2001; Rehman et al., 2003; Schmeisser et al., 2001; Urbich et 
al., 2003; Zhang et al., 2005; Zhang et al., 2006; Zhao et al., 2003] and will also readily 
differentiate into macrophages under appropriate environmental cues [Becker et al., 
1987]. CD14 expression diminished as CD68 and CD105 expression increased, and 
it is therefore likely that monocytes differente into macrophages in the EC-CFU 
assay, consistent with previous studies demonstrating that colonies possess phagocytic 
function and are unable form perfusing vessels in vivo [Yoder et al., 2007]. It is now 
recognised that proteins may be transferred between cell types, leading to erroneous 
conclusions regarding gene expression and phenotype. For instance, platelet derived 
micro-particles are readily taken up by monocytes leading to apparent ‘expression’ of 
such antigens as CD31 and vWF. This may well explain the phenotypic 
characteristics of EC-CFU [Prokopi et al., 2011]. 
 
EC-CFU colonies were thought to be derived from single cells undergoing 
clonal expansion, and the assay was used as a means of quantifying the concentration 
of circulating putative EPC [Asahara et al., 1997; Hill et al., 2003]. As a result the 
spindle cells assumed to be ‘emanating’ from each colony, were thought to be neo-
endothelial cells. Using time-lapse microscopy I have confirmed that, contrary to 
popular belief, cells do not emerge from EC-CFU, but in fact migrate toward them 
with a commensurate increase in colony size. Inoculating the EC-CFU assay with 
immunofluorescently labeled monocytic and lymphocytic fractions, allowed tracking 
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of specific CD14+, CD3+ and CD19+ cell populations, confirming that both 
monocytes and lymphocytes may adopt a spindle shape morphology and undergo 
avid migration toward, and incorporation into, EC-CFU. Having demonstrated that 
cellular migration was a significant component of colony growth, I wished to 
determine the significance of cellular proliferation on colony growth, particularly as 
EC-CFU were originally assumed to be proliferating colonies.  
 
Bromodeoxyuridine (BrdU) is an analogue of the nucleotide thymidine that 
incorporates into the DNA of actively dividing cells, and serves as a means of 
identifying the presence of cellular proliferation. Incubation of maturing EC-CFU 
with immunofluorescently labeled BrdU demonstrated that cellular proliferation 
occurs throughout EC-CFU, with the concentration of proliferating cells increasing 
substantially by three, four and 16 fold, on days three four and five respectively. In 
the presence of mitomycin-C, the number of colonies formed was markedly reduced, 
indicating that cellular proliferation is necessary to initiate colony formation. 
Mitomycin-C can have deleterious effects on cell viability, and this may have effected 
colony formation, however at the low concentrations used in the present study, 
cytotoxic effects are likely to have been very limited [Sadeghi et al., 1998]. 
Furthermore, cells were still able to form spindle cells indicating retention of viability, 
unlike cells treated with actinomycin-D, where cells remained rounded and began to 
disintegrate after a day in culture. Proliferation therefore appears to be the initiating 
event in colony formation. The mass of proliferating cells may then serve as a 
stimulus for further cell migration. Further studies are required to elucidate precisely 
which cells are proliferating.  
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In parallel studies (working with Dr Olga Tura-Ceide et al, Scottish Centre 
for Regenerative Medicine working in the same laboratory as myself) we showed that 
EC-CFU potential is associated with CD14+ cells and that CD14 cells that are 
proliferating (see appended manuscript; The constituents and mechanisms of 
generation of EC-CFU). In these studies enriching for CD14+ cells increased EC-
CFU formation. The CD14 depleted fraction did not form colonies. Neither CD133 
or CD34 enriched fractions could generate EC-CFU. CD133 and CD34 deplete 
fractions could generate EC-CFU but to a lesser extent than unfractionated cells. 
Interestingly CD34+ cells could generate cells if first differentiated into CD14+ cells. 
CD14 cells therefore appear to be the precursor for EC-CFU however we did not 
definitively phenotype the BrdU+ cells in the assay. 
 
Leukocytes accumulate at sites of tissue injury as crucial mediators in the 
inflammatory response necessary for wound healing. This is similarly the case 
following vascular injury, and the roles of monocyte derived macrophages, and 
lymphocytes following vascular injury have been well described [Farb et al., 1999; 
Fujiyama et al., 2003; Inoue et al.]. Endothelial injury leads to the release of 
chemotactic factors such as monocyte chemo-attractive protein-1 (MCP-1) [Ito et al., 
1997] and stromal derived factor-1 (SDF-1)[Garg et al., 2008b] and increased 
expression of various intercellular adhesion molecules on the endothelium. 
Monocytes attach to sites of vascular injury migrate into the vascular wall, and 
secrete chemotactic factors that drive further cellular migration to the site of vascular 
injury and activate endothelial cells in order to enhance re-endothelialisation. 
Monocytes differentiate into phagocytic macrophages in order to remove noxious 
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agents and amplify the inflammatory response through antigen presentation to 
invading lymphocytes attracted by increased SDF-1 production. Activated T-cells 
similarly regulate the inflammatory response and endothelial cell activation 
facilitating the restoration of normal vascular homeostasis. EC-CFU and closely 
aligned populations mobilize to regions of vascular injury in animal models [Asahara 
et al., 1997; Werner et al., 2003].  
 
In the last chapter I described an increase in EC-CFU following 
cardiovascular stress in the form of discrete vascular injury (Chapter 3), [Mills et al., 
2009]. I shall go on to decribe a similar increase following acute myocardial 
infarction (Chapter 6) [Padfield et al., 2013], and also provide some evidence to 
suggest that this is a relatively specific inflammatory response to vascular injury 
(Chpater 5) [Padfield et al., 2010b]. Although not specifically measured in the present 
study, EC-CFU are known to secrete a variety of angiogenic cytokines (VEGF, 
interleukin-8, matrix metalloproteinases, G-CSF, and GM-CSF) [Hur et al., 2007; 
Rehman et al., 2003] that are capable of inducing leukocyte migration and 
proliferation, suggesting an active influence by EC-CFU on these processes. In the 
present study I have observed that the in-vitro behaviour of EC-CFU closely mirrors 
the known in-vivo cellular response to vascular injury. I therefore suggest that EC-
CFU formation reflects in-vivo leukocyte activation, predominantly by monocytes 
which undergo proliferation and differentiation into macrophages, accompanied by 
avid cytokine production and the attraction of further monocytes and lymphocytes to 
amplify a vasculoprotective inflammatory response to vascular injury. The close 
relationship between EC-CFU and cardiovascular health, combined with their 
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‘endotheloid’ phenotype led to the specious conclusion that EC-CFU were vascular 
progenitors. This study contributes to the growing body of evidence that refutes the 




 EC-CFU express endothelial characteristics, but are predominantly CD14+ 
derived macrophages that act as a potent stimulus for lymphocyte migration. 
Proliferation is necessary for EC-CFU generation, however colony expansion 
predominantly occurs as a result of leukocyte migration. EC-CFU formation likely 
reflects a vasculoprotective inflammatory response to vascular denudation or tissue 
ischaemia. Further studies of the in-vivo behaviour of EC-CFU are needed to confirm 
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5.1 SUMMARY 
Vascular injury causes acute systemic inflammation and mobilises endothelial 
cell colony forming units (EC-CFU). Whether such mobilisation occurs as part of a 
non-specific acute phase response or is a phenomenon specific to vascular injury 
remains unclear. I aimed to determine the effect of acute systemic inflammation on 
EC-CFU and putative EPC mobilisation in the absence of vascular injury. In a 
double-blind randomised cross-over study, 12 healthy volunteers received Salmonella 
typhus vaccination or placebo in order to generate an acute systemic inflammatory 
response. Phenotypic EPC populations enumerated by flow cytometry 
(CD34+VEGFR-2+CD133+, CD14+VEGFR-2+Tie2+, CD45-CD34+, as a 
surrogate for late outgrowth EPC and CD34+CXCR-4+), EC-CFU and serum 
cytokine concentrations [C reactive protein (CRP), interleukin-6 (IL-6), vascular 
endothelial growth factor (VEGF-A) and stromal derived factor-1 (SDF-1] were 
quantified during the first 7 days. Vaccination increased circulating leukocyte (9.8 ± 
0.6 versus 5.1 ± 0.2 x109/L; P<0.0001), serum IL–6 [0.95 (0–1.7) versus 0 (0–0) ng/L; 
P=0.016] and VEGF-A [60 (45–94) versus 43 (21–64) pg/L; P=0.006] 
concentrations at 6 hours, and serum CRP at 24 hours [2.7 (1.4–3.6) versus 0.4 (0.2–
0.8) mg/L; P=0.037]. Vaccination caused a 56.7 ± 7.6% increase in CD14+ cells at 
6 hours (P<0.001) and a 22.4 ± 6.9% increase in CD34+ cells at 7 days (P=0.04). 
EC-CFU, putative vascular progenitor and serum SDF-1 concentrations were 
unaffected throughout the study period (P>0.05 for all). Acute systemic inflammation 
causes non-specific mobilisation of CD34+ cells though does not selectively mobilise 
putative vascular progenitors. Systemic inflammation per se is not the primary 
stimulus for EC-CFU mobilisation following acute vascular injury. 
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5.2 INTRODUCTION 
A close relationship between cardiovascular disease and systemic 
inflammation is now well recognised. Elevated C-reactive protein (CRP) 
concentrations predict the occurrence of adverse cardiovascular events, 
independently of ‘traditional’ cardiovascular risk factors, even in apparently healthy 
individuals with apparently ‘normal’ CRP concentrations [Ridker et al., 2000]. Acute 
inflammation such as that occurring in the context of respiratory and urinary tract 
infections is temporally associated with adverse cardiovascular events, namely 
myocardial infarction and stroke [Smeeth et al., 2004]. Similarly the incidence of 
cardiovascular disease in patients with chronic inflammatory conditions, such as 
rheumatoid arthritis [del Rincon et al., 2001] and systemic lupus erythematosis is 
disproportionately high, even after adjusting for traditional cardiovascular risk factors 
[Svenungsson et al., 2001]. These effects may, in part be attributed to a deleterious 
effect of inflammatory signalling on endogenous vascular repair mechanisms such as 
EPC function. 
 
Although largely defined by the expression of haematopoietic markers, 
CD34+ and CD133+, and VEGFR-2 [Asahara et al., 1997; Peichev et al., 2000; Vasa 
et al., 2001b], Non-haematopoietic, CD45-CD34+ cells, have also recently been 
identified as a putative EPC on the basis of their ability to form “late outgrowth” 
colonies phenotypically and functionally indistinguishable from mature endothelial 
cell colonies in culture [Case et al., 2007; Timmermans et al., 2007; Yoder et al., 
2007]. In addition to CD34+ EPC, other circulating leukocytes have been identified 
has having regenerative capacity. In particular monocytes expressing VEGFR-2 and 
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the tyrosine kinase receptor, Tie-2 enhance endothelial regeneration and accelerate 
restoration of vascular function in animal models of vascular injury [Elsheikh et al., 
2005; Nowak et al., 2004]. The EC-CFU assay [Hill et al., 2003], although widely 
used as a measure of circulating EPC, is now thought not to have capacity to form 
perfusing vessels [Rohde et al., 2007; Yoder et al., 2007], but rather stimulates vessel 
growth and repair through the secretion of growth factors [Rehman et al., 2003]. In 
chapters three and four I demonstrated that EC-CFU, predominantly composed of 
monocytes and lymphocytes [Padfield et al., 2013], are mobilised in response to 
vascular injury in the context of an acute systemic inflammatory response [Mills et al., 
2009]. Although not true EPC there is compelling clinical evidence that EC-CFU are 
an important component in the cellular response to vascular injury [Hill et al., 2003; 
Sobrino et al., 2007; Werner et al., 2005].  
 
The effect of inflammation on the various putative EPC populations is poorly 
understood with contrasting effects seen during acute and chronic inflammation. 
Recombinant C-reactive protein (CRP) depresses EC-CFU function in-vitro [Verma et 
al., 2004], and conversely therapy directed against tumour necrosis factor-alpha 
therapy enhances the mobilisation and function of progenitor cells in patients with 
rheumatoid arthritis [Ablin et al., 2006]. Chronic inflammatory conditions such as 
ulcerative colitis, rheumatoid arthritis and systemic lupus erythematosis are also 
associated with depressed concentrations of circulating EPC [Grisar et al., 2005; 
Masuda et al., 2007; Moonen et al., 2007; Palange et al., 2006], suggesting that EPC 
dysfunction is a potential mechanism underlying the accelerated rate of 
atherosclerosis observed in these conditions. In contrast, acute inflammation may 
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have the effect of increasing EPC concentrations, for instance following an acute 
coronary syndrome or tissue ischaemia [Adams et al., 2004; George et al., 2004; 
Massa et al., 2005], or discrete vascular injury caused by PCI [Banerjee et al., 2006; 
Mills et al., 2009]. However, it is unclear whether the stimulus for the mobilisation of 
these populations arises from the systemic inflammatory response or from vascular 
injury per se. It may be that acute systemic inflammation potentiates EPC 
mobilisation, or indeed acts in a counter regulatory or inhibitory manner so suppress 
EPC mobilisation.  
 
 The aim of this study was therefore to investigate the behaviour of a range of 
putative EPC populations and EC-CFU, and the factors responsible for their 
mobilisation in response to an isolated inflammatory stimulus in the absence of 
denuding endothelial injury. I used an established model of acute systemic 
inflammation, Salmonella Typhus vaccination [Chia et al., 2003], to study the effects of 
inflammation on the behaviour of EPC in healthy volunteers. 
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5.3 METHODS AND MATERIALS 
 The study was performed with the approval of the local research ethics 
committee, in accordance with the Declaration of Helsinki, and with the written 
informed consent of all participants. All procedures were performed in accordance 
with the guidelines of our institution. 
 
5.3.1 Subjects 
 As described, twelve healthy, non-smoking, non-obese male volunteers were 
enrolled into the study. All subjects were normotensive without a history of diabetes 
mellitus, peripheral vascular or coronary artery disease. None of the subjects had 
undergone typhoid vaccination in the year prior to the study nor had they received 
vasoactive or non-steroidal anti-inflammatory drugs in the week before the study.  
 
5.3.2 Study design 
 Using a randomised balanced block double-blind crossover study design, the 
polysaccharide Salmonella Typhus vaccination 0.025 mg (Typhim Vi, Aventis Pasteur 
MSD, UK) was compared with saline placebo given by intramuscular injection at 
least 2 weeks apart [Chia et al., 2003]. Subjects attended between 8 and 10 am for 
venesection and were randomly assigned to vaccine or placebo injection into the 
deltoid muscle of the non-dominant arm. As previous studies have reported a peak 
inflammatory response occurring at 6 hours following Salmonella Typhus vaccination, 
subjects were asked to return 6 hours later for repeat blood sampling [Chia et al., 
2003]. In order to evaluate the late effects of vaccination on EPC, subjects returned 
at 24, and 168 hours for further blood sampling. Subjects were advised to maintain 
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adequate fluid intake of at least 2 L over the first 24 hours and avoid alcohol during 
the study period. In order to avoid confounding EPC mobilisation, subjects were also 
asked to abstain from strenuous exertion during the study period [Rehman et al., 
2004]. 
 
5.3.3 Blood sampling and assays 
 Venous blood samples (20 mL) were collected into EDTA and serum gel for 
flow cytometry, mononuclear cell preparations and culture, and separation of plasma 
and serum. Whole blood was analysed for total cells, differential count and platelets 
using an autoanalyzer (Sysmex, UK). ELISAs were used to quantify serum 
interleukin-6 (Invitrogen, UK), VEGF-A (Invitrogen, UK), and stromal derived 
factor-1 (SDF-1) (R&D systems, UK) concentrations according to the manufacturer’s 
instructions. Serum high sensitivity-CRP was quantified using an 
immunoturbidimetric method (Dade-Behring Marburg, Germany). 
 
5.3.4 Flow cytometric identification of EPC 
 Endothelial progenitor cells and angiogenic monocytes were identified using 
flow cytometry and analysed as described above (section 2.5.2),  
 
5.3.5 Endothelial cell - colony forming units 
Endothelial cell-colony forming units (EC-CFU) [Hill et al., 2003] were generated as 




5.3.6 Assays of EC-CFU function 
In order to assess the in-vitro effects of an inflammatory milieu on functional 
aspects of cultured EC-CFU, randomly selected subjects were recalled at the end of 
the study for repeat venesection. EC-CFU were again generated from peripheral 
blood, but on this occasion co-incubated with autologous stored serum samples (5% 
concentration) obtained at either baseline, 6 and 24 hours following exposure to 
either vaccine or placebo during the initial part of the study. On day five, mature 
colonies were retrieved using non-enzymatic dissociation solution (Sigma-Aldrich; 
UK) and underwent functional assays assessing cellular migration and adhesion as 
described above (Section 2.6.3) and briefly below. 
 
Migration 
EPC migratory capacity was assessed using 8µm pore transwell inserts 
(Corning-Costar; UK). Harvested EC-CFU were resuspended in chemotaxis buffer 
(EBM-2; Lonza; UK) at a concentration of 2x106 cells/mL. 200µL of cell solution 
was added to the upper chamber. 600µL of chemotaxis buffer containing 50ng/mL 
of VEGF (Peprotech; UK) was added to the lower chamber. Cells were incubated at 
37°C, 5% CO2, 95% humidity. At 3 hours the quantity of migrated EPC in the lower 




EC-CFU were harvested and re-suspended in EBM2 (Lonza; UK). 5x104 
cells were re-plated on Fibronectin and incubated as above. At 30 minutes non-
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adherent cells were removed and wells were washed gently with PBS. Adherent cells 
were visualised under direct focal microscopy. Cellular adhesion was expressed as a 
function of the density of adherent cells in 10 random fields. 
 
Proliferation 
 Cellular proliferation within EC-CFU was assessed by the detection of 
incorporation of the thymidine analogue bromodeoxyuridine (BrdU) (Sigma-Aldrich; 
UK) as described above (Section 2.6.3). Briefly, mononuclear cells replated on 
fibronectin at day two were incubated with BrdU. Colonies were fixed and 
permeabilised on day five and incubated with DNAse (Perbio; UK) for 30 minutes. 
Colonies were rinsed and incubated with anti-BrdU conjugated to alexafluore-488TM 
(Invitrogen; UK). Colonies were examined with an inverted microscope at 488nm. 
Proliferation was expressed as the proportion of BrdU positive cells per unit volume 
of colony. Colony volume (V) was calculated under the assumption of a conical 
geometry using the formula: V = (πr2h)/3 where r = the radius of the base of the 
colony and the height (h) of the colony is assumed to be equal to r. 
 
5.3.7 Data analysis and statistics 
 Continuous variables are reported as mean ± standard error of the mean or 
median and interquartile range (IQR) where appropriate. Because of the cross-over 
design, data were analysed to confirm the absence of a carry over effect prior to 
comparisons. Statistical analyses were performed with GraphPad Prism (Graph Pad 
Software, USA) using 2-way analysis of variance (ANOVA) and two-tailed Student’s 
t-test or Mann-U Whitney paired tests where appropriate. In previous studies 
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vascular injury following percutaneous coronary intervention had resulted in an 
approximately 300% increase in both circulating EC-CFU and serum C-reactive 
protein concentration [Mills et al., 2009]. Assuming that smaller changes in EC-CFU 
than those detected following PCI might still be clinically relevant, I aimed to detect 
at least a 75% increase in EC-CFU. Pilot data from healthy volunteer studies 
suggested a mean colony count of approximately 17 colonies per well with a standard 
deviation 16. Therefore given that: N = (z0.5α + zβ)2 (σ/δ) 2. Where zβ = 0.84 and z0.5α 
= 1.96, in order to provide an 80% power at a two-sided significance level of 5%. 
The approximate number of subjects (N) required to detect a difference of δ given a 
standard deviation of σ, is 12. Therefore 12 subjects were used in order to detect a 




5.4.1 Study participants 
 The characteristics of the study population are tabulated below. Total 
leukocyte concentrations were slightly higher prior to placebo (table 5.1). 
 
Table 5.1.  Baseline characteristics of study population 
 Placebo Vaccine P value 
Demographics and basic observations 
Age (years) 26±1.2 - 
Male gender (%) 100 - 
Temperature (°C) 36±0.2 36±0.1 0.90 
Blood Pressure (mmHg) - Systolic 136±2 130±4 0.13 
                                                  - Diastolic 79±3 73±3 0.13 
Pulse rate (bpm) 76±4 71±9 0.16 
Haematological and biochemical measures 
Total Leukocytes x109/L 5.6±0.3 5.1±0.2 0.02 
Neutrophils x109/L 3.1±0.2 2.7±0.2 0.06 
Lymphocytes x109/L 1.9±0.1 1.7±0.2 0.90 
Monocytes x109/L 0.45±0.02 0.45±0.04 0.90 
Interleukin – 6 ng/L 0.3±0.2 0.5±0.4 0.10 
VEGF-A pg/L 55.8±10 47.6±10 0.07 
SDF-1 ng/L 2040±56 2036±45 0.95 
CRP mg/L 0.4 (0.2-0.9) 0.4 (0.2-0.8) 0.40 
Angiogenic cell populations  
CD34+  3.38±0.28 2.92±0.24 0.16 
CD34+VEGFR-2+  0.51±0.09 0.38±0.04 0.17 
CD34+CD133+VEGFR-2+  0.14±0.04 0.15±0.06 0.85 
CD45-CD34+  0.48±0.06 0.39±0.04 0.23 
CD34+CXCR-4+  0.67±0.1 0.97±0.16 0.13 
CD14+  390±30 350±30 0.43 
CD14+VEGFR-2+  50±10 60±10 0.51 
CD14+Tie-2+  2.0±0.5 1.0±0.2 0.25 
CD14+Tie-2+VEGFR-2+  0.6±0.2 0.7±0.2 0.42 








Values are median and interquartile range or the mean ± standard error. Statistical 
comparisons are made using paired a Student’s t-test or Wilcoxon test where appropriate. 
Angiogenic cell populations quantified by flow cytometry are expressed as x106/L. bpm = beats 
per minute; CD = cluster of differentiation; CRP = C reactive protein; EC-CFU = endothelial 
cell – colony forming unit; SDF-1 = stromal derived factor –1; VEGF(R-2) = vascular 
endothelial growth factor (receptor-2). 
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5.4.2 Salmonella Typhus vaccination induces an inflammatory response 
 Following vaccination, subjects reported mild flu-like symptoms although these 
were not associated with any change in temperature, heart rate or blood pressure. No 
major adverse events occurred. Salmonella Typhus vaccination induced a leukocytosis 
in all subjects that was maximal at 6 hours (Δ 4.6±1.1x109/L, P<0.0001) and 
remained at 24 hours (P=0.037). This was driven predominantly by a neutrophilia (Δ 
4.3±1.1x109/L, P<0.0001) and to a lesser extent by a monocytosis (Δ 
0.19±0.03x109/L, P=0.004). Saline placebo injection had no effect on the differential 
cell counts (table 5.2). Following vaccination, there was an increase in serum IL–6 
[0.95(0–1.7) versus 0(0–0) ng/L; P=0.016] and VEGF-A [60(45–94) versus 43(21–64) 
pg/L; P=0.006] concentrations at six hours that returned to baseline levels by 24 
hours. Serum CRP concentrations increased later, peaking at 24 hours [2.7(1.4–3.6) 
versus 0.4(0.2–0.8) mg/L; P<0.001], returning to baseline at one week. Saline placebo 
injection had no effect on the cytokine profile (P>0.2; Figure 5.2).  
 
5.4.3 CD34+ Endothelial Progenitor Cell Phenotype 
 Six hours following saline placebo, CD34+, CD34+VEGFR-2+ and CD34+ 
CD133+VEGFR-2+ cell concentrations had fallen by 19.5±8.5% (P=0.033), 
42±9.5% (P=0.001) and 53.6±12.5% (P=0.037; figure 5.3) respectively. 
Concentrations were comparable to baseline at 24 hours and one week. Six hours 
following vaccination, CD34+ populations did not fall (P>0.2), and by 1 week 
circulating CD34+ cells had increased by 22.4±6.9% (P=0.04). CD34+VEGFR-2+ 
and CD34+CD133+VEGFR-2+ sub-populations did not change during the study 
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period (P>0.2; figure 4.4). The late outgrowth precursor CD45-CD34+ similarly fell 
at 6 hours following placebo by 7.4%±11, however this did not reach statistical 
significance. There were no differences in CD45-CD34+ cells following vaccination 
compared to placebo (P>0.2; figure 5.4). Circulating CD34+CXCR-4+ cell 
concentrations were similar prior to vaccination and placebo. Whilst CD34+CXCR-
4+ cell concentration followed a trend similar to that of CD34+ cells, the proportion 
of CD34+ cells expressing CXCR4 was not significantly changed throughout the 
study period (P=0.78; figure 5.4). Serum SDF-1 concentrations were similarly 
unaffected by vaccination or placebo (Figure 5.2). 
 
5.4.4 CD14+ Angiogenic monocyte 
 Following vaccination, I observed an increase in circulating CD14+ cells with a 
peak of 54.8±4.8% at 6 hours (P<0.005). A median of 0.18% (IQR, 0.08-0.24%) of 
CD14+ cells expressed Tie-2 and VEGFR-2, although the levels of this population 
did not change in response to vaccination (P>0.2). Similarly CD14+Tie2+ and 
CD14+VEGFR-2+ populations were unaffected by vaccination (P>0.2; Figure 5.5). 



























































































































































































































































































































































































































































































































































































































































































































































































































































































































































































5.4.5 Endothelial Cell - Colony Forming Units 
 Mean baseline numbers of CFU were similar prior to vaccination and saline 
placebo (33±11 versus. 24±6; P=0.6), and remained unchanged throughout the study 
period (P=0.7) (figure 5.4).  
 
EC-CFU function 
Co-incubation with stored serum inhibited EC-CFU generation and almost 























































































Figure 5.5 Effect of vaccination on circulating CD14+ populations. 
Vaccination resulted in a significant mobilisation of CD14+ cells compared to placebo (P<0.001) (A). 
CD14+ subpopulations bearing Tie-2 and or VEGFR-2 were not significantly different from placebo 
throughout the study period (P>0.2) (B-D). Data are presented as the absolute median and IQR 
change from baseline. 
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In order not to excessively inhibit EC-CFU formation, a 5% dilution was used to 
compare the effects of serum from vaccinated versus non-vaccinated subjects. EC-
CFU were generated under normal conditions or in the presence of serum obtained 6 
hours following intramuscular injection. Eighteen wells were seeded from six subjects. 
Consistent with the initial dose ranging study, serum caused a mild but non-significant 
reduction in the number of EC-CFU that were generated; 13 (9-28) colonies per well 
with no serum added, versus 7 (3.7-29) and 12 (5-19) colonies per well (ANOVA, P=0.49) 
with serum obtained following saline placebo or vaccination respectively. Migration 
towards VEGF-A were similar under all three conditions; 2796 (2333-4000) cells 
migrated with no serum added, 4008 (2890-5738) in the presence of serum obtained 
following placebo injection, and 2850 (2548-4333) cells with serum obtained following 
vaccination (ANOVA, P=0.25). Adhesion to fibronectin was similar without the addition 
Co-incubation with serum vs PBS














































medians ± IQR. 
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of serum or following the addition of serum obtained following placebo injection or 
vaccination (17(9-26) versus 10(8-38) versus 20(9-44) colonies per well; P=0.59). 
Proliferative capacity of EC-CFU was significantly reduced by the addition of serum, 1.4 
(1.02-2.01) versus 0.77 (0.42-1.20) and 0.90 (0.52-1.35) BrdU +ve cells/µm3 with serum 
obtained following saline placebo or vaccination respectively (ANOVA; P=0.0004), 

































































































Figure 5.7 Effect of autologous serum on functional aspects of cultured EPC: EC-CFU 
were generated in the presence of 5% serum obtained 6 hours post intramuscular injection or no 
serum. Eighteen wells were seeded from six subjects. Consistent with the initial dose ranging study 
serum caused a mild reduction in EC-CFU quantity. Migration towards VEGF-A and adhesion to 
fibronectin were similar under all three conditions with no significant differences between the two 
types of sera. Proliferative capacity of EC-CFU was significantly reduced by the addition of serum 
however it was there was no difference between serum obtained following vaccination or saline 
placebo. Data are expressed median (IQR) per well (colony generation), per subject (adhesion and 
migration) and per colony. 
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5.5 DISCUSSION 
 Putative haematopoietic EPC expressing CD34, EC-CFU and late outgrowth 
colonies are mobilised in response to vascular injury such as that occurring in the 
context of percutaneous coronary intervention or an acute coronary syndrome 
[Huang et al., 2007; Massa et al., 2005; Mills et al., 2009; Shintani et al., 2001; 
Wojakowski et al., 2004]. These clinical events also cause a systemic inflammatory 
response, however it remains unknown whether inflammation occurring in this 
context is a physiological event that may potentiate EPC mobilisation, or an 
inhibitory pathological process detrimental to vascular repair. In this study, I have 
examined the behaviour of a wide variety of putative vascular progenitors in response 
to an inflammatory stimulus using a model of acute systemic inflammation in the 
absence of a discrete vascular injury. The study demonstrates a biphasic response to 
acute systemic inflammation, with early and late mobilisation of CD14+ and CD34+ 
cells respectively. However, specific vascular progenitor subpopulations including late 
outgrowth colony precursors, CD45-CD34+ progenitor cells, and even leukocyte 
derived EC-CFU were unaffected by systemic inflammation.  
 
 Whilst EC-CFU are not mature endothelial cells, they do have an established 
association with cardiovascular disease and it is likely that EC-CFU have a 
vasculoprotective role through the secretion of a variety of angiogenic factors 
[Rehman et al., 2003]. EC-CFU are mobilised in response to discrete vascular injury 
such as that occurring during percutaneous coronary intervention in association with 
an inflammatory response [Mills et al., 2009]. However, neither EC-CFU or putative 
EPC were affected by the systemic inflammatory environment generated by 
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Salmonella Typhus vaccination, indicating that EPC and EC-CFU mobilisation are 
phenomena relatively specific to vascular injury, and that inflammation per se does 
not directly mobilise these populations. 
 
 It should be recognised however that acute systemic inflammation induced by 
Salmonella Typhus vaccination does have deleterious effects on endothelial function. 
The model employed here has been shown to impair endothelium-dependent 
vasodilatation [Hingorani et al., 2000], and furthermore that anti-inflammatory 
treatment ameliorates these adverse effects [Kharbanda et al., 2002; Vlachopoulos et 
al., 2005]. It would therefore appear that whilst the transient inflammatory response 
to Salmonella Typhus vaccination is sufficient to cause endothelial dysfunction, it is not 
sufficient to cause significant vascular denudation and stimulation of vascular 
progenitor cell mobilisation.  
 
 The interactions between EPC mobilisation and systemic inflammation are 
obscure. Both EC-CFU and late outgrowth EPC secrete pro-inflammatory cytokines 
such as tissue factor and monocyte chemo-attractant protein–1, a property 
potentiated by stimulation by other inflammatory mediators such tumour necrosis 
factor – alpha. This might suggest that EPC have a possible pro-inflammatory role 
[Zhang et al., 2009], and indeed many inflammatory states are characterised by 
neovascularisation and increased capillary density. However several studies support a 
direct inhibitory effect of inflammation on EPC. Experimental in-vitro studies suggest 
that CRP down-regulates the production of angiogenic chemokines by EC-CFU and 
impairs EC-CFU migration toward VEGF [Suh et al., 2004]. Mayr et al recently 
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reported a two-thirds reduction in the proportion of circulating EPC 
(CD34+CD133+VEGFR-2+) and EC-CFU 4-6 hours following intravenous 
lipopolysaccharide (LPS) infusion [Mayr et al., 2007]. The pro-inflammatory effects 
of LPS infusion results in a marked monocytopenia and lymphocytopenia, where as 
the inflammatory response to Salmonella Typhus vaccination in the present study 
involved a monocytosis and had little effect on circulating lymphocytes. Given that 
EC-CFU are derived from monocytic [Rehman et al., 2003] and lymphocytic 
subpopulations [Hur et al., 2007], it is quite possible that the reduction in EC-CFU in 
Mayr’s study was determined principally by a profound mononuclear cell depletion. 
Mayr et al., also reported a reduction in CD34+CD133+VEGFR-2+ following LPS 
induced inflammation, which appears to contradict the findings of our present study. 
However, as CD34+CD133+VEGFR-2+ concentrations were reported relative to the 
total leukocyte count, which was markedly increased due to a neutrophilia [Jilma, 
1999] it is entirely possible that the absolute number of circulating progenitors was 
unchanged. Unfortunately, absolute numbers were not reported preventing definitive 
conclusions from this study and making it difficult to compare these findings directly 
with my own. 
 
 I interpret the mobilisation of CD34 and CD14 cells as a non-specific response 
to inflammatory mediators induced by Salmonella Typhus polysaccharide exposure. 
CD14+ is a receptor for endotoxin predominantly expressed on circulating 
monocytes [Wright et al., 1990]. The mobilisation of monocytes is part of an acute 
phase response and is common to a wide variety of inflammatory, infective and 
neoplastic conditions. CD34 functions as a regulator of cellular adhesion and 
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identifies a naïve population of cells widely regarded as having ‘stem cell’ capacity. 
Mobilisation of CD34+ cells is similarly non-specific and occurs in response to a 
variety of inflammatory stimuli. Concordant with the findings of the present study, a 
delayed mobilisation of CD34+ cells occurs in healthy volunteers treated with G-CSF 
[Sato et al., 1994], and in patients following acute myocardial infarction [Shintani et 
al., 2001]. 
 
 Numerous factors responsible for EPC mobilisation, homing and recruitment 
into new or injured vessels have been identified [Tousoulis et al., 2008]. Although 
current understanding of these processes remains incomplete, two cytokines, SDF-1 
and VEGF-A are thought to be of particular importance to EPC mediated re-
endothelialisation through stimulation of their cognate receptors: CXCR4 and 
VEGFR-2 respectively [Adams et al., 2004; Asahara et al., 1999; Grunewald et al., 
2006; Kalka et al., 2000a; Seeger et al., 2009; Yla-Herttuala et al., 2007]. In the 
present study, Salmonella Typhus vaccination caused a significant increase in VEGF-A, 
however this alone was insufficient to mobilise putative EPC or EC-CFU. SDF-1 is 
thought to act down stream of VEGF in order to enhance the incorporation of EPC 
into sites of neo-endothelialisation [Grunewald et al., 2006] and is increased in 
response to vascular injury [Schober et al., 2003]. That SDF-1 and the concentration 
of those circulating cells expressing its receptor, CXCR-4 were unchanged following 
vaccination, supports the hypothesis that the necessary pathways for EPC 




 Finally, the concentration of circulating CD34+ populations fell over the six 
hour period following placebo, confirming a previously reported circadian variation 
of EPC concentrations [Thomas et al., 2008b]. Interestingly this circadian variation 
of EPC was attenuated by acute systemic inflammation in our study, presumably 
through disruption of normal trafficking of cells to and from the bone marrow. 
 
5.6 CONCLUSIONS 
 Acute systemic inflammation caused by Salmonella Typhus vaccination stimulates 
early and late mobilisation of CD14+ and CD34+ populations respectively. However, 
despite significant secretion of VEGF, systemic inflammation per se does not cause 
mobilisation of vascular progenitors including a surrogate measure of late outgrowth 
colonies. This would indicate that humoral factors specific to vascular injury are 
necessary for EPC mobilisation. It is likely that endothelial denudation or tissue 
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6.1 SUMMARY 
 Endothelial progenitor cells (EPC) are considered potential therapeutic targets 
in the treatment of patients with cardiovascular disease. I evaluated the relationship 
between putative EPC, atheroma burden, and clinical outcome. EPC populations 
were determined by flow cytometry and culture of circulating mononuclear cells in 
201 patients undergoing coronary angiography for suspected angina or an acute 
coronary syndrome (ACS). Survival free from revascularisation, recurrent myocardial 
infarction, and death was determined at 3 years.  
 Circulating CD34+VEGFR-2+ and CD34+VEGFR-2+CD133+ cells were rare 
(<0.009% of mononuclear cells), were not increased in patients with an ACS, and did 
not relate to atheroma burden or clinical outcome (P>0.1 for all). In contrast 
CD34+CD45- cells were increased in patients with coronary artery disease compared to 
those with normal coronary arteries (P=0.008) and correlated positively with atheroma 
burden (r=0.44, P<0.001). Increased concentrations of circulating CD34+CD45- 
cells were associated with a shorter cumulative event-free survival (P<0.02). Pro-
angiogenic monocytes (CD14+VEGFR-2+Tie-2+) and endothelial cell-colony 
forming units (EC-CFU) were increased in patients with an ACS (P<0.01 for both), 
however concentrations only reflected myocardial necrosis, and not the extent of 
coronary disease or clinical outcome.  
 Neither traditional EPC or EC-CFU were related to the extent of coronary 
artery disease or clinical outcome. However, CD34+CD45- cells were increased in 
patients with coronary atheroma and predicted future cardiovascular events with 
concentrations reflecting the extent of vascular injury.
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6.2 INTRODUCTION 
Cell therapy offers the potential to accelerate neo-vascularisation and 
enhance vascular repair through the differentiation and proliferation of progenitors 
into functionally mature phenotypes. However, clinical trials testing the efficacy of 
intra-coronary or intra-myocardial delivery of progenitor cells or the implantation of 
stents designed to capture circulating progenitors have failed to deliver consistent 
clinical benefits. An incomplete understanding of the progenitor cell populations 
involved in vascular repair continues to limit progress in this area. 
  
As described above, EPC have traditionally been defined on the basis of the 
co-expression of VEGFR-2 and the stem cell marker, CD34 [Cheng et al., 1996; 
Shalaby et al., 1995], and on occasion the co-expression of CD133 has also been used 
as evidence of cellular naivety [Peichev et al., 2000; Yang et al., 2004]. An inverse 
relationship between circulating CD34+VEGFR-2+ cells and cardiovascular 
outcome has been described [Schmidt-Lucke et al., 2005; Vasa et al., 2001b; Werner 
et al., 2005], and CD34+ [Shintani et al., 2001], CD34+VEGFR-2+ and 
CD133+VEGFR-2+ [Friedrich et al., 2006; Gill et al., 2001] populations are mobilised 
following angiogenic stress. However, whilst these populations accelerate re-
endothelialisation and attenuate neo-intimal hyperplasia in experimental models of 
vascular injury [Takamiya et al., 2006; Walter et al., 2002; Werner et al., 2002], it 
should be recognised that cell preparations enriched for double positive 
CD34+VEGFR-2+, or triple positive CD34+VEGFR-2+CD133+ cells have never 
been shown to differentiate into endothelial cells. Recent studies have identified non-
haematopoietic CD34+ subpopulations, negative for the pan-leukocyte marker CD45 
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(CD34+CD45-), that are capable of forming late-outgrowth endothelial colonies. 
These cell types have robust proliferative potential and are morphologically 
indistinguishable from mature endothelial cells. The CD34+CD45- population 
therefore is thought most likely to represent a true endothelial progenitor [Case et al., 
2007; Timmermans et al., 2007; Yoder et al., 2007]. 
 
Monocytes, identified by the surface expression of CD14, augment 
differentiation and proliferation of naïve progenitor cells, secrete pro-angiogenic 
factors [Rehman et al., 2003], and can also adopt endothelial characteristics in vitro 
[Fernandez Pujol et al., 2000]. In particular, angiogenic monocytes expressing the 
‘endothelial’ surface receptors VEGFR-2 and Tie-2 accelerate re-endothelialisation 
with demonstrable improvements in endothelial function under experimental 
conditions of vascular injury [Elsheikh et al., 2005; Nowak et al., 2004], and facilitate 
neo-angiogenesis in the context of neoplasia [Venneri et al., 2007]. Combined with a 
relative abundance in the peripheral circulation, such properties have made CD14+ 
subpopulations attractive therapeutic targets in the field of cardiovascular medicine. 
Partly composed of monocytic fractions, the traditional early outgrowth EPC colony 
described by Hill et al [Hill et al., 2003], although now recognised to be unable to 
form mature endothelial cells, is still considered to be relevant to cardiovascular 
repair via paracrine pro-angiogenic activity [Rehman et al., 2003]. 
 
In order for cell therapy to become a reality, our understanding of the role of 
putative progenitor cells must be further developed. I therefore sought to clarify the 
relevance of circulating CD34+ and CD14+ sub-populations by examining their 
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behaviour in response to an acute coronary syndrome, and their relationship to the 




The study was performed with the approval of the local research ethics 
committee in accordance with the Declaration of Helsinki, and the written informed 
consent of all volunteers. Patients were recruited following referral for coronary 
angiography for the investigation of suspected stable angina or following an acute 
coronary syndrome (ACS), defined as an increase in the plasma troponin 
concentration or evidence of myocardial ischemia (>1 mm ST deviation) on a 12-
lead electrocardiogram in the context of anginal chest pain. Patients with significant 
co-morbid illness, hematological or internal malignancy, hepatic or renal failure or 
concurrent infection were excluded from the study. Clinical characteristics, 
cardiovascular risk factors, and medication during admission were documented.  
 
6.3.2 Coronary angiography  
All patients underwent diagnostic coronary angiography performed via the 
femoral or radial artery with 5-6F arterial catheters using standard angiographic 
projections. Patients with suspected angina were classified as having coronary artery 
disease based on the presence of at least one ≥ 50% stenosis of a major epicardial 
arterial segment. Coronary artery disease severity was graded using the Gensini 
scoring system [Gensini, 1983, Ringqvist et al., 1983]. Patients underwent 





6.3.3 Blood sampling and assays 
Prior to coronary angiography, peripheral venous blood was collected and 
anti-coagulated with EDTA (Sarstedt-Monovette, Germany) for flow cytometry and 
isolation of peripheral blood mononuclear cells. Whole blood was analysed for the 
differential leukocyte count using an autoanalyser (Sysmex, UK). Plasma troponin 
concentrations were measured in the regional clinical reference laboratory using the 
Abbott Architect STAT troponin I assay (Abbott Laboratories, Abbott Park, IL). 
 
6.3.4 Flow cytometric identification of EPC 
 Endothelial progenitor cells were characterised phenotypically using flow 
cytometry as described above in the methods section. Briefly, cells were directly 
stained and analysed for phenotypic expression of surface proteins using pre-
conjugated anti-human monoclonal antibodies. Unstained samples were used to 
provide negative controls and to establish positive stain boundaries. Flow-
cytometric analysis was performed as described above. Approximately 500,000 
events were acquired in the leukocyte gate for each sample. The absolute 
concentration of cells per mL of blood was calculated by equating the total number 
of events in the leukocyte gate to the total leukocyte count from the full blood 
count. 
 
6.3.5 Endothelial cell - colony forming units 
 Endothelial cell-colony forming units (EC-CFU) [Hill et al., 2003] were 
generated as described above (Section 2.6.1) and counted in a minimum of four wells 
on day 5. 
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6.3.6 Clinical outcomes 
Clinical outcomes were obtained through review of medical records and using 
the TrakCare software application (InterSystems Corporation, Cambridge, MA, 
USA); an electronic patient record system used by the Acute Hospitals Division of 
Lothian National Health Service (NHS) Health Board, United Kingdom. Myocardial 
infarction was defined as admission with chest pain or ST-segment deviation of ≥0.5 
mm with evidence of myocardial necrosis using plasma troponin concentrations of 
≥0.2 ng/mL as the diagnostic threshold [Mills et al., 2011]. Revascularisation 
included all percutaneous and surgical coronary artery procedures. Hospitalisation 
for cardiovascular causes included any unplanned hospitalisation for acute coronary 
syndrome, heart failure, stroke or uncontrolled arrhythmia. Major adverse clinical 
events were a composite of cardiovascular death, recurrent myocardial infarction, 
coronary revascularisation or cardiovascular hospitalisation. 
 
6.3.7 Data analysis and statistics 
At a significance level of 5% and based on power calculations derived from 
previous studies [Mills et al., 2009; Padfield et al., 2010b], we estimated that a sample 
size of n=90 would give 80% power of detecting a putative clinically meaningful 15% 
difference in phenotypic EPC (CD34+VEGFR-2+) between patients with stable 
angina and ACS. A sample size of n=90 per group will give 95% power, at a 5% 
significance level, to detect meaningful correlations (r2>0.12) between measures of 
EPC number and clinical variables including Gensini score. Flow cytometric 
analyses, EC-CFU enumeration, and Gensini scoring were performed by an observer 
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blinded to the patient’s clinical profiles. Statistical analyses were performed with 
SPSS version 17 (SPSS Inc, Chicago, USA). Continuous variables are reported as 
mean ± standard error or median (inter-quartile range) where appropriate. Student’s 
t-test, Mann-Whitney tests and Pearson’s Chi-Square tests were used for comparisons 
between groups where appropriate. Spearman’s test was used to test for correlation 
analysis between variables. For partial correlation analyses controlling for covariates, 
data were normalised where appropriate. Cell populations were categorised into 
tertiles after natural logarithmic transformation in order to evaluate associations 
between circulating progenitors and clinical endpoints. Multivariate Cox-regression 
analysis was performed to determine associations between progenitor cells and event-
free survival with adjustment for the diagnosis of ACS on enrollment and 
cardiovascular risk factors. Hazard ratios represent the predicted change in the 
hazard between the lowest and the highest tertiles. Statistical significance was taken 
at a two-sided P value <0.05. 
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6.4 RESULTS 
6.4.1 Study population 
I enrolled 201 patients undergoing coronary angiography for the investigation 
of suspected stable angina (n=90) or ACS (n=111) to the study (Table 6.1). 
Table 6.1: Demographic, clinical and angiographic characteristics  









Age, years 61 (11) 60 (11) 63 (11) 0.10 
Male gender, (%) 168 (83.6) 96 (86.5) 72 (80.0) 0.22 
Body mass index, kg/m2 28.7 (0.4) 28.6 (0.6) 28.9 (0.6) 0.69 
Clinical characteristics 
Diabetic, (%) 30 (14.9) 16 (14.4) 14 (15.6) 0.82 
Ever smoked, (%) 133 (66.2) 77 (69.4) 56 (62.2) 0.29 
Hypertension, (%) 105 (52.2) 46 (41.4) 59 (65.6) 0.001 
Family history of CHD, (%) 84 (41.8) 43 (38.7) 40 (44.4) 0.41 
Hyperlipidaemia, (%) 151 (75.1) 73 (65.8) 78 (86.7) 0.001 
Peripheral vascular disease, (%) 15 (7.5) 6 (5.4) 9 (10.0) 0.22 
Prior myocardial infarction, (%) 39 (19.4) 21 (18.9) 18 (20.0) 0.85 
Cerebrovascular disease, (%) 10 (5.0) 5 (4.5) 5 (5.6) 0.73 
LVSD, (%) 21 (10.4) 11 (9.9) 10 (11.1) 0.78 
Prior PCI, (%) 45 (22.4) 21 (18.9) 24 (27.0) 0.18 
Prior CABG, (%) 14 (7.0) 6 (5.5) 8 (8.9) 0.34 
Biochemistry 
Troponin I, ng/mL - 0.42 (0.2-3.3) <0.2 0.001 
Creatinine, mg/dL 1.04 (0.02) 1.05 (0.02) 1.04 (0.02) 0.53 
Cholesterol, mg/dL 174 (4) 177 (4) 167 (4) 0.10 
HbA1c, (%) 5.8 (5.5-6) 5.7 (5.4-6) 5.9 (5.6-6.1) 0.005 
Angiographic findings     
Coronary segment score 6.6 (0.3) 6.8 (0.3) 6.2 (0.4) 0.21 
Gensini score, units 20 (8.5-42) 21 (11-48) 17 (5-35) 0.052 
Continuous variables are expressed as the mean (±standard error) or median (interquartile range) 
with statistical comparisons performed using Students t-test or Mann-Whitney where appropriate; 
Categorical variables are expressed as the absolute number of cases  (% of group) with statistical 
comparisons performed using a Chi-square; ACS = acute coronary syndrome; CABG = coronary 
artery bypass grafting; LVSD = left ventricular systolic dysfunction. 
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Patients were predominantly male (84%) with a mean age of 61±11 years. Both 
groups were well matched for age, gender, cigarette smoking, diabetes mellitus, 
previous revascularisation and renal function (P>0.1 for all). Therapy for 
cardiovascular risk factors and for the treatment of acute coronary syndrome differed 
slightly between groups (Table 6.2). The Gensini score was greater in patients with 
an ACS than those with suspected stable angina (21 (11-48) versus 17 (5-35); 
P=0.052). 
 
Table 6.2. Medical therapy of the study population 
Medication ACS (n=111) Stable angina (n=90) P value 
Aspirin 107 (97) 86 (96) 0.51 
Clopidogrel 100 (91) 54 (60) 0.0001 
LMWH 78 (71) 3 (3) 0.0001 
Warfarin 2 (2) 1 (1) 0.7 
Beta-blocker 81 (74) 71 (79) 0.39 
ACE inhibitor 64 (58) 38 (42) 0.03 
ARB 7 (6) 6 (7) 0.92 
Statin 103 (94) 84 (93) 0.93 
Nicorandil 9 (8) 13 (14) 0.16 
Long acting nitrate 20 (18) 21 (23) 0.37 
Ca-channel antagonist 20 (18) 30 (33) 0.01 
Diuretic 12 (11) 25 (28) 0.002 
Insulin 0 (0) 1 (1) 0.27 
Metformin 6 (5) 5 (6) 0.96 
Sulphonylurea 7 (6) 3 (3) 0.57 
PPI 25 (23) 25 (28) 0.39 
Data are expressed as the absolute number of cases (%) with statistical comparisons performed 
using a Chi-squared test. LMWH = low-molecular weight heparin; ACE = angiotensin 
converting enzyme; ARB = angiotensin receptor blocker. PPI = proton pump inhibitor. 
Statistical significance is taken at a P value of <0.05. 
 
Patients undergoing elective angiography were further classified as having coronary 
heart disease (n=70) based on the presence of at least 1 ≥ 50% stenosis of a major 
epicardial arterial segment. Patients with an ACS were further classified as having 
unstable angina (n=39) or acute myocardial infarction (n=72) based on the plasma 
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troponin concentration. The median plasma troponin concentration in patients with 
ACS was 0.42 (0.20-3.3) µg/ 
 
6.4.2 Progenitor cell populations 
Progenitor populations were determined on the day of admission in elective 
patients undergoing angiography, and 3 (1-5) days following hospital admission in 
patients with ACS (Table 6.3).  
 
CD34+ progenitor cells 
CD34+ cells were readily detectable in the peripheral circulation and were 
increased in patients following an ACS compared to those with suspected stable 
angina (3.44 (2.54-4.85) versus 2.84 (2.15-4.18) x106 cells/L; P=0.04). The majority of 
circulating CD34+ cells were CD45+, and the proportion of CD45+ cells did not 
differ between groups. The less abundant CD34+CD45- population was increased in 
patients with ACS compared to patients with stable angina (1.05 (0.70-1.64) versus 
0.90 (0.55-1.30) x106 cells/L; P=0.02) (Table 6.3). The concentration of CD34+CD45- 
cells was increased in patients with both stable and unstable coronary disease compared 
to patients with normal coronary arteries (ANOVA, P=0.008). The presence of 
myocyte necrosis did not influence CD45-CD34+ concentrations (P=0.71; Figure 
6.1). When patients with an ACS were further categorised according to the time from 
the onset of symptoms to enrolment in the study, the CD34+CD45- concentration 
remained constant. (P=0.72; Figure 6.2). Regardless of CD45 expression, 
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CD34+VEGFR-2+ and CD34+VEGFR-2+CD133+ cells were rare and frequently 
undetectable in both 
Table 6.3. Selected putative progenitor population frequencies 
 ACS Stable angina P value 
CD45± 
CD34+ 3.44 (2.54-4.85) 2.84 (2.15-4.18) 0.04 
CD34+VEGFR-2+ 0.13 (0.07-0.27) 0.10 (0.06-0.18) 0.06 
CD34+VEGFR-2+CD133+ 0.05 (0.02-0.12) 0.05 (0.03-0.09) 0.33 
CD34+CD133+ 1.26 (0.85-1.79) 1.08 (0.69-1.81) 0.14 
CD133+ 1.81 (1.34-2.68) 1.70 (1.19-2.36) 0.17 
CD133+VEGFR-2+ 0.15 (0.08-0.27) 0.12 (0.07-0.22) 0.15 
CD45+ 
CD34+ 2.18 (1.5-2.96) 1.9 (1.34-2.71) 0.16 
CD34+VEGFR-2+ 0.09 (0.04-0.2) 0.07 (0.04-0.14) 0.11 
CD34+VEGFR-2+CD133+ 0.05 (0.02-0.1) 0.04 (0.02-0.08) 0.37 
CD34+CD133+ 1.17 (0.73-1.68) 0.98 (0.65-1.58) 0.25 
CD133+ 1.74 (1.22-2.58) 1.59 (1.05-2.19) 0.19 
CD133+VEGFR-2+ 0.13 (0.07-0.25) 0.11 (0.06-0.21) 0.18 
CD45- 
CD34+ 1.05 (0.7-1.64) 0.9 (0.55-1.3) * 0.02 
CD34+VEGFR-2+ 0.03 (0-0.06) 0.02 (0-0.05) 0.29 
CD34+VEGFR-2+CD133+ 0 (0-0) 0 (0-0) 0.74 
CD34+CD133+ 0.06 (0.01-0.12) 0.06 (0.01-0.13) 0.89 
CD133+ 0.08 (0.03-0.14) 0.07 (0.03-0.15) 0.69 
CD133+VEGFR-2+ 0 (0-0.02) 0 (0-0.02) 0.61 
CD14+ 
CD14+ 474.4 (384.1-591) 457 (356-547.2) 0.29 
CD14+VEGFR-2+ 74.8 (47.1-136.9) 53.9 (30.6-103.1) * 0.02 
CD14+Tie 2+VEGFR-2+ 9 (3.9-20.5) 4.5 (2.1-8.8) ** 0.003 
EC-CFU 11.5 (3.5-27.0) 6.3 (2.0-16.5) ** 0.005 
Values are medians and interquartile range. CD34+ and CD14+ populations are cell 
concentration x106/L. EC-CFU are expressed as the number of colonies formed per 800,000 
mononuclear cells plated. Statistical comparisons are made using a Mann-Whitney test with 
significance at the 0.05* and 0.01** level (2-tailed). VEGFR-2 = vascular endothelial growth 
factor receptor – 2 
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groups and were not increased in patients with an ACS compared to those with 
undergoing elective angiography (0.13 (0.07-0.27) versus 0.10 (0.06-0.18) x106 cells/L, 
P=0.06, and 0.05 (0.02-0.12) versus 0.05 (0.03-0.09) x106 cells/L, P=0.33 respectively; 
Table 6.2, Figure 6.1). 
 
CD14+ pro-angiogenic monocytes 
CD14+ subpopulations were determined in a subgroup of 119 patients with a 
similar clinical profile to the main cohort (table 6.4): 50 patients with suspected stable 
angina and 69 patients with ACS. The concentration of circulating CD14+ cells was 
not different in patients with ACS compared to elective group (474 (384-591) versus 
457 (356-547) x106 cells/L; P=0.29). However there was an increase in 
CD14+VEGFR-2+ (74.8 (47.1-136.9) versus 53.9 (30.6-103.1) x106 cells/L; P=0.02) 
and CD14+VEGFR-2+Tie-2+ cells (9.0 (3.9-20.5) versus 4.5 (2.1-8.8) x106 cells/L; 
P=0.003) in patients with an ACS (Table 6.3). Concentrations of circulating 
angiogenic monocytes in patients with ACS were higher in patients with myocardial 
infarction compared to patients with stable angina or normal coronary arteries 
(ANOVA, P=0.015; Figure 6.1). The CD14+VEGFR-2+Tie-2+ concentration was 
highest in patients recruited on the same day as the onset of symptoms, falling 
progressively to concentrations comparable to patients with stable angina after ~ five 
days (P=0.025; Figure 6.2).  
 
EC-CFU colonies 
EC-CFU colonies expressed a variety of endothelial and haematopoietic 
characteristics as described above and were increased in patients with ACS 
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compared to patients with suspected stable angina (12 (4-27) versus 6 (2-17); P=0.005; 
Table 6.3). Differences were determined by higher concentrations in those patients 
with myocardial infarction compared to patients with stable angina or normal coronary 
arteries (ANOVA, P=0.018; Figure 6.2). 
 
6.4.3 Clinical correlates 
In patients undergoing elective angiography for suspected stable angina, there 
was a positive correlation between CD34+CD45- cells and the Gensini score 
(R=0.44; P<0.0001; Table 6.5). In contrast, CD45+ cells expressing VEGFR-2+, 
CD133+ and VEGFR-2+CD133+ did not correlate with coronary artery disease 
severity (P>0.1 for all). The correlation between CD34+CD45- cells and extent of 
coronary atheroma persisted after controlling for cardiovascular risk factors and the 
use of cardiac medication (r=0.35; P=0.04). Similarly, when patients were stratified 
into quartiles according to Gensini score, CD34+CD45- concentrations increased in 
a step-wise fashion with each increment of severity of coronary artery disease 
(Median CD34+CD45- concentrations were 0.75 (0.45-1.13), 0.91 (0.58-1.52), 1.01 
(0.71-1.53) and 1.34 (0.76-1.59) x106 cells/L, given Gensini scores of <9, 9-20, 21-42 
and >43 respectively; ANOVA = 0.013; Figure 6.3). Circulating CD14+ cells did not 
correlate with coronary artery disease severity (r=0.221; P=0.08). CD14+VEGFR-2+ 
cells correlated weakly with CAD severity (r=0.29; P=0.03), but not after adjusting 
for cardiovascular risk factors (r=0.15; P=0.39). 
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6.4.4 Clinical events  
Patients were followed up for approximately three years: median 1,068 (970 – 
1145) days with no loss to follow up. During this period 123 patients underwent 
coronary revascularisation (64%), with 28 patients undergoing coronary artery 
bypass grafting (15%) and 95 patients percutaneous coronary intervention (49%). In 
57 patients (30%) revascularisation was performed ad-hoc following the initial 
diagnostic angiogram. Six patients died (3%), five from cardiovascular causes and 
one from lung cancer. Fifty-seven patients were hospitalised for a cardiovascular 
event (30%), 15 patients had a recurrent myocardial infarction (7%), and a first 
major adverse cardiovascular event occurred in 74 patients (35%) during the follow 
up period. 
The concentration of CD34+CD45- cells was the only population that 
predicted clinical events. There were no differences in event free survival according 
to concentrations of circulating CD45+CD34+, CD34+VEGFR-2+, CD34+VEGFR-
2+133+, CD14+VEGFR-2+ or CD14+VEGFR-2+Tie-2+ cells (P > 0.3 for all). The 
CD34+CD45- cell concentration was significantly higher in patients with recurrent 
myocardial infarction (1.40 (0.88-1.64) versus 0.96 (0.62-1.44) x106 cells/L; P=0.023), 
undergoing coronary revascularisation (1.05 (0.75-1.53) versus 0.77 (0.47-1.27) x106 
cells/L; P=0.003) or with a first major adverse coronary event (1.04 (0.7-1.53) versus 
0.87 (0.45-1.27) x106 cells/L; P=0.010) during the follow up period. There were no 
differences in CD34+CD45- cell concentration with respect to death or 
hospitalisation (P>0.05 for all).  
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Patients were stratified into tertiles according to the concentration of 
CD34+CD45- cells (Table 6.6). Baseline characteristics of the patients in each tertile 
were similar with the exception of higher Gensini score in those patients with the 
highest CD34+CD45- cell concentrations (P=0.001). Event rates were lower in 
patients in the lowest tertile compared to the highest tertile: for myocardial infarction 
hazard ratio (HR) 0.20 (95% confidence intervals (CI) 0.06 to 0.67, P=0.009); for 
revascularisation HR 0.47 (95% CI 0.29 to 0.877, P=0.003); and for major adverse 
cardiovascular events HR 0.50 (95% CI 0.27 to 0.92, P=0.026). In patients with 
higher circulating CD34+CD45- cell concentrations, the cumulative event-free 
survival was lower for coronary revascularisation (P=0.01), recurrent myocardial 
infarction (P=0.02), or any major adverse cardiovascular event (P=0.02). In a cox-
regression analysis correcting for covariates, these associations remained significant 
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Table 6.4. Demographic, clinical and angiographic characteristics of 
CD14 group 
Characteristic ACS (n=69) Stable angina (N=50) P value 
Age, years 56 (1) 56 (1) 0.81 
Male gender, (%) 59 (86) 34 (68) 0.23 
Body mass index, kg/m2 28 (1) 29 (1) 0.33 
Cardiovascular risk factors and medical history 
Diabetic, (%) 10 (14) 8 (16) 0.82 
Never smoked, (%) 46 (67) 30 (60) 0.46 
Hypertension, (%) 27 (39) 33 (66) 0.004 
Family history of CHD, (%) 24 (35) 24 (48) 0.15 
Hyperlipidaemia, (%) 45 (65) 42 (84) 0.23 
Peripheral vascular disease, (%) 3 (4) 5 (10) 0.22 
Prior myocardial infarction, (%) 14 (20) 7 (14) 0.38 
Cerebrovascular disease, (%) 3 (4) 2 (8) 0.93 
Left ventricular dysfunction, (%) 6 (9) 3 (6) 0.58 
Prior PCI, (%) 13 (19) 12 (24) 0.46 
Prior CABG, (%) 4 (6) 3 (6) 0.98 
Biochemical and angiographic parameters  
Troponin I concentration, ng/mL 0.36 (0.2 - 2.2) <0.2 <0.0001 
Creatinine concentration, mg/dL 1.04 (0.03) 1.01 (0.04) 0.36 
Cholesterol, mg/dL 182 (5) 173 (7) 0.36 
HbA1c, (%) 5.7 (5.4 - 6) 6 (5.7 - 6.2) 0.01 
No. of diseased coronary segments 6.8 (0.4) 5.1 (0.5) 0.01 
Gensini Score, units 23 (13.5 - 45) 11.5 (1 - 24.5 0.0002 
Medical therapy 
Aspirin 67 (97) 47 (94) 0.41 
Clopidogrel 62 (89) 30 (60) <0.001 
LMWH 47 (68) 1 (2) <0.001 
Warfarin 1 (1) 0 (0) 0.39 
Beta-blocker 51(74) 39 (78) 0.61 
ACE inhibitor 42 (61) 18 (36) 0.01 
ARB 2 (3) 5 (10) 0.1 
Statin 66 (96) 46 (92) 0.4 
Nicorandil 7 (10) 9 (0.18) 0.22 
Long acting nitrate 14 (20) 13 (26) 0.46 
Ca-channel antagonist 11 (16) 19 (38) 0.01 
Diuretic 8 (12) 12 (24) 0.07 
Insulin 0 (0) 1 (2) 0.24 
Metformin 1 (1) 2 (4) 0.38 
Sulphonylurea 3 (4) 1 (2) 0.76 
Proton pump inhibitor 16 (23) 18 (36) 0.13 
Categorical data are expressed as the absolute number of cases (%) with statistical comparisons 
performed using a Chi-squared test. Continuous variables expressed as the mean (±standard error) 
or median (interquartile range) with comparisons performed using Students t-test or Mann-
Whitney where appropriate. Statistical significance is taken at a two sided P value of <0.05. 
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Table 6.5. Bi-variate and partial correlation analysis between 
CD34+CD45- and coronary atheroma burden in patients undergoing 
elective angiography. 
 Correlation R P value Adjusted P value 
CD45+ 
CD34+ 0.09 0.40 - 
CD34+VEGFR-2+ 0.16 0.14 - 
CD34+VEGFR-2+CD133+ 0.08 0.48 - 
CD34+CD133+ 0.06 0.57 - 
CD133+ 0.06 0.60 - 
CD133+VEGFR-2+ 0.05 0.65 - 
CD45- 
CD34+ 0.44** 0.0002 0.04 
CD34+VEGFR-2+ 0.08 0.45 - 
CD34+VEGFR-2+CD133+ 0.06 0.55 - 
CD34+CD133+ 0.12 0.26 - 
CD133+ 0.12 0.28 - 
CD133+VEGFR-2+ 0.08 0.44 - 
CD14+ 
CD14+ 0.22 0.09 - 
CD14+VEGFR-2+ 0.29* 0.03 0.39 
CD14+VEGFR-2+Tie-2+ 0.23 0.10 - 
EC-CFU 0.07 0.53 - 
Partial correlations made between normalised putative EPC concentration and the Gensini score 
corrected for age, gender, BMI, diabetes and smoking status, creatinine, total cholesterol and 
HbA1c. Correlations are significant at the <0.05* and <0.01** level (2-tailed). VEGFR-2 = 






Table 6.6. Demographic, clinical and angiographic characteristics of the 
study population stratified by CD34+CD45- concentration 








Age, years 61±11 62±10 61±11 62±11 0.89 
Male gender, n (%) 162 (84) 55 (85) 51 (80) 56 (88) 0.48 
Body mass index, kg/m2 29±6 29±6 29±6 28±6 0.52 
Cardiovascular risk factors and medical history 
Diabetic, n (%)  27 (14) 10 (15) 8 (13) 9 (14) 0.89 
Never smoked, n (%) 67 (35) 21 (32) 27 (42) 26 (41) 0.37 
Hypertension, n (%) 100 (52) 36 (55) 30 (47) 30 (47) 0.61 
Family history of CHD, n (%) 80 (42) 28 (43) 29 (45) 23 (36) 0.53 
Hyperlipidaemia, n (%) 145 (75) 52 (80) 44 (69) 49 (77) 0.32 
PVD, n (%) 15 (8) 5 (8) 0 (0) 10 (16) 0.004 
Prior MI (%) 37 (19) 13 (20) 9 (14) 15 (23) 0.40 
AMI, n (%) 107 (55) 30 (46) 36 (56) 41 (64) 0.12 
CVD, n (%) 19 (5) 3 (4.6) 1 (2) 5 (8) 0.25 
LVSD, n (%) 21 (11) 7 (11) 5 (8) 9 (14) 0.53 
Prior PCI, n (%) 43 (22) 12 (19) 15 (24) 16 (25) 0.64 
Prior CABG, n (%) 14 (7) 7 (11) 1 (2) 6 (10) 0.09 
Biochemical and angiographic parameters 
Troponin I, ng/mL 2.1±6.8 0.2 (0.2-0.5) 0.2(0.2-0.4) 0.2(0.2-1.1) 0.45 
Creatinine, mg/dL  1.67±0.36 1.60±0.28 1.61±0.34 1.75±0.37 0.04 
Cholesterol, mg/dL 174±43 170±43 170±43 174±4.3 0.95 
HbA1c, % 6.0±0.9 6.1±1.1 5.9±1.0 5.9±0.6 0.38 
No. of diseased coronary 
segments 
6.6±0.4 6.4±0.5 5.9±0.4 7.4±0.4 0.03 
Gensini Score, units 20 (8-43) 11 (4 – 27) 19 (12-32) 30 (13-73) 0.001 
Medical therapy 
Aspirin, n (%) 186 (96) 64 (99) 64 (100) 60 (94) 0.35 
Clopidogrel, n (%) 150 (78) 44 (68) 56 (88) 50 (78) 0.03 
LMWH, n (%) 79 (41) 22 (34) 30 (47) 27 (42) 0.31 
Warfarin, n (%) 3 (2) 1 (2) 2 (3) 1 (2) 1.0 
Beta-blocker, n (%) 148 (77) 54 (83) 47 (73) 47 (73) 0.33 
ACE inhibitor, n (%) 98 (51) 33 (51) 31 (49) 34 (53) 0.87 
ARB, n (%) 13 (7) 8 (12) 2 (3) 3 (5) 0.09 
Statin, n (%) 172 (89) 61 (94) 58 (91) 61 (95) 0.56 
Nicorandil, n (%) 21 (11) 4 (6) 6 (9) 12 (19) 0.05 
Long acting nitrate, n (%) 38 (20) 11 (17) 10 (16) 17 (27) 0.24 
Ca-channel blocker, n (%) 47 (24) 16 (25) 13 (20) 18 (28) 0.59 
Diuretic, n (%) 35 (18) 13 (20) 7 (11) 15 (23) 0.17 
Insulin, n (%) 1 (1) 1 (2) 0 (0) 0 (0) 0.37 
Metformin, n (%) 11 (6) 4 (6) 3 (5) 4 (6) 0.91 
Proton pump inhibitor, n (%) 48 (25) 19 (29) 15 (23) 14 (22) 0.60 
Patients are grouped into tertiles according to the CD34+CD45- concentration. Continuous variables are 
expressed as the mean (standard error) or median (interquartile range) with statistical comparisons between groups 
performed using one-way analysis of variance. Categorical variables are expressed as the absolute number of cases 








Figure 6.3. CD34+CD45- concentration according to Gensini score 
Patients were stratified into quartiles according to Gensini score. Median CD34+CD45- 
concentrations fell in a step-wise fashion with each decrement in the severity of coronary 
artery disease (ANOVA P=0.013). 
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6.5 DISCUSSION 
In 201 patients with coronary artery disease, I have evaluated a 
comprehensive range of cellular markers that have been used to identify circulating 
putative EPC. Traditional EPC populations determined by phenotype (CD34+ 
VEGFR-2+) or cell culture (EC-CFU) are not related to the extent of coronary artery 
disease or clinical outcome, but do appear to be increased in patients who have 
sustained a myocardial infarction. In contrast, it is the CD34+CD45- cells that are 
increased in patients with coronary atheroma and predict future cardiovascular 
events, suggesting that they represent a measure of on going chronic vascular injury 
and repair. 
 
Previous studies have demonstrated that CD34+ cells are mobilised following 
acute myocardial infarction with the peak in concentration varying from 24 hours to 
a week following the onset of symptoms [Brehm et al., 2009; Massa et al., 2005; 
Shintani et al., 2001; Spevack et al., 2006; Turan et al., 2007; Wojakowski et al., 2004]. 
Similarly, I have observed a higher CD34+ count in patients with an acute coronary 
syndrome, determined wholly by an elevated CD34+CD45- concentration in the 
ACS group. However, in elective patients, where circulating concentrations did not 
reflect the dynamic response to acute vascular injury or myocardial ischemia, I 
detected a significant positive correlation between the CD34+CD45- concentration 
and the severity of coronary atheroma. The difference in the CD34+CD45- count 
between the stable and unstable patients was in fact driven by the proportion of 
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patients in the elective group with normal coronary arteries who had significantly 
lower circulating CD34+CD45- concentrations. Indeed, amongst patients with 
angiographically proven coronary artery disease, the CD34+CD45- concentration 
was similar regardless of whether the patient presented with stable or unstable 
disease. Furthermore there was no evidence of a dynamic response in the 
CD34+CD45- concentration when patients with an ACS were examined with respect 
to the time from the onset of symptoms. The circulating CD34+CD45- concentration 
therefore provided a measure of vascular injury and atheroma burden but not acute 
angiogenic stress. 
 
These observations are consistent with those of Guven et al, who described a 
positive correlation between coronary artery disease severity and late outgrowth 
colonies [Guven et al., 2006]. The source of CD34+CD45- cells has not been well 
established and whether or not their presence in the circulation represents a 
reparatory response remains unclear. Mature endothelial cells may also express 
CD34 [Fina et al., 1990], and are also CD45-. CD34+CD45- cells may therefore be 
circulating endothelial cells, and simply represent vascular detritus rather than bone 
marrow derived progenitor cells. One might predict that if CD34+CD45- cells 
possess regenerative capacity, that increased concentrations of CD34+CD45- cells 
would protect against adverse coronary events. I observed the opposite effect, 
however it is quite plausible that the reparatory capacity of CD34+CD45- cells 
mobilised in response to vascular injury was insufficient to overcome the multitude of 
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noxious stimuli to which the endothelium is constantly exposed. The function of 
CD34+CD45- cells is therefore not adequately described here, although their 
presence in the circulation does serve as a biomarker of atheroma burden and 
predicts the occurrence of adverse coronary events, namely recurrent myocardial 
infarction and the need for coronary revascularisation.  
 
CD34+ populations expressing CD133 or VEGFR-2 were neither affected by 
the presence of acute cardiovascular stress nor related to the extent or severity of 
coronary artery disease. Mobilisation of CD133+ cells following extensive tissue 
injury such as coronary artery bypass grafting or burns is recognised [Gill et al., 
2001], and Friedrich et al describe a CD133+CD34-VEGFR-2+ population thought 
to be a precursor of CD34+ cells that is up-regulated in unstable atheromatous 
plaques [Friedrich et al., 2006]. Quirici et al, report pluripotency of CD133+ cells with 
an ability to form endothelial-like cells with rapid population doubling-times in 
culture [Quirici et al., 2001]. However, Timmermans et al, found that CD133+ are 
devoid of endothelial potential, and that this property lies exclusively in circulating 
CD34+CD45-CD133- cells [Timmermans et al., 2007]. Although CD34+VEGFR-2+ 
and CD34+VEGFR-2+CD133+ cells have been used previously in clinical studies, I 
found that both were exceedingly rare and were frequently undetectable. These 
populations are difficult to quantify accurately, even in carefully conducted, large 
clinical studies such as this one. I therefore hesitate to draw definitive conclusions 
regarding the absence of VEGFR-2 or CD133 expression on CD34+ sub-populations 
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but do not believe that they are likely to play a significant role in the acute response 
to vascular injury or myocardial infarction. 
 
Consistent with the presence of acute cardiovascular stress, there was an 
increase in EC-CFU concentrations in those patients presenting with an acute 
coronary event as compared to those undergoing elective angiography. Although the 
significance of these early outgrowth populations remains unclear, it is likely that EC-
CFU potentiate re-endothelialisation and neo-vascularisation via the secretion of 
angiogenic cytokines and enhanced proliferation and migration of endothelial cells 
and EPC [Rehman et al., 2003; Sieveking et al., 2008]. Consistent with this 
hypothesis, I report an association between angiogenic monocytes co-expressing 
VEGFR-2 and Tie-2 and acute myocardial infarction. Furthermore in patients with 
an ACS I observed a time dependent decay in the angiogenic monocyte 
subpopulation concentration indicating that these cells are mobilised acutely in 
response to cardiovascular stress. An increase in circulating VEGFR-2 expressing 
monocytes following myocardial infarction has been reported previously in a very 
small clinical study, and intra-myocardial injection of this population has improved 
ventricular function in a murine model of infarction [Bruno et al., 2006]. Contrary to 
our findings, Hu et al found no difference in CD14+VEGFR-2+ cells between 
patients with stable or unstable coronary artery disease and healthy controls. 
However, this study included only 25 patients, two weeks following the initial 
presentation with an acute coronary syndrome, and troponin concentrations were 
not reported. Comparison with our study is therefore limited [Hu et al., 2008]. I did 
not detect a robust correlation between coronary artery disease severity and 
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CD14+VEGFR-2+Tie-2+ concentration. I believe that unlike CD34+CD45- cells, 
angiogenic monocytes are mobilised acutely in response to cardiovascular stress and 
are possibly a more sensitive measure of myocardial injury than vascular or 
endothelial injury.  
 
6.6 CONCLUSIONS 
Traditional EPC expressing CD34+VEGFR-2+ and CD133+ are impractical to 
measure and are unlikely to mediate cardiovascular regeneration. CD34+CD45- cells 
are not mobilised acutely following an ACS, but an increased concentration indicates 
a greater severity of coronary atheroma burden, and predicts the occurrence of 
adverse coronary events. The CD34+CD45- concentration likely reflects underlying 
cardiovascular injury, but additional studies are required in order to determine 
whether these populations have a reparatory function or are tissue resident cells 
liberated from injured tissue. Pro-angiogenic monocytes (CD14+VEGFR-2+Tie-2+) 
and endothelial cell-colony forming units (EC-CFU) are increased in patients with an 
ACS, however concentrations reflect acute myocardial necrosis and do not predict 
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 7.1 SUMMARY 
 CD34+CD45- cells are increased in patients with coronary artery disease. I 
wished to determined the behaviour of CD34+CD45- cells in response to discrete 
vascular injury during percutaneous coronary intervention (PCI).  
 Using flow cytometry I quantified circulating CD34+CD45- cells, in addition to 
traditional CD34+VEGFR-2+ EPC, angiogenic monocytes (CD14+VEGFR-2+Tie-
2+) and intercellular adhesion molecule expression (CXCR-4 and CD18) in patients 
before and during the first week following diagnostic angiography (n=13) or PCI 
(n=23). Vascular endothelial growth factor-A (VEGF-A) and C-reactive protein 
(CRP) were quantified by ELISA. PCI, but not angiography alone, increased 
circulating neutrophil and CRP concentrations, peaking at 24 and 48 hours 
respectively (P<0.002 for both). Serum VEFG-A concentration was unaffected by 
either procedure (P>0.2 for both). CD34+CD45- cell concentrations were unchanged 
following angiography alone (P>0.4), but were transiently increased six hours 
following PCI [median (IQR): 0.93 (0.43-1.49) versus 1.51 (0.96-2.15) x106 cells/L; 
P=0.01], returning to normal by 24 hours. Adhesion molecule expression on CD34+ 
cells, and traditional EPC, angiogenic monocyte and VEFG-A concentrations were 
unchanged (P>0.1 for all). PCI therefore causes a transient release of CD34+CD45- 
cells into the peripheral circulation, without affecting factors associated with CD34+ 
mobilisation from the bone marrow. CD34+CD45- cells are likely released directly 
from the vessel wall. Traditional putative EPC and angiogenic monocytes are 
unlikely to be important in the acute response to vascular injury.
 186 
7.2 INTRODUCTION 
Percutaneous coronary intervention (PCI) involves the deployment of rigid 
stent struts at high-pressures that strip the treated vessel of its endothelium and cause 
laceration of the underlying intima. Vascular injury caused by PCI initiates platelet 
aggregation and thrombus formation [Mak et al., 1996], and triggers an 
inflammatory cascade that drives vascular smooth muscle proliferation and neo-
intimal hyperplasia [Farb et al., 1999]. The loss of endogenous thrombolytic function 
and anti-inflammatory signalling normally provided by the endothelium potentiates a 
maladaptive response to vascular injury that can lead to in-stent restenosis or 
thrombosis. Re-endothelialisation of the denuded arterial segment is therefore a 
crucial component of vascular healing, necessary to protect against adverse 
consequences following PCI.  
 
EPC are mobilised in response to cardiovascular injury such as myocardial 
infarction [Shintani et al., 2001; Wojakowski et al., 2004], improve organ perfusion 
and function in animal models of ischaemia [Friedrich et al., 2006; Gill et al., 2001; 
Kong et al., 2004a; Takamiya et al., 2006; Walter et al., 2002; Werner et al., 2003; 
Werner et al., 2002; Yoshioka et al., 2006], and are negatively associated with adverse 
cardiovascular outcomes [Schmidt-Lucke et al., 2005; Vasa et al., 2001b; Werner et 
al., 2005]. Circulating EPC concentrations are regulated by angiogenic growth 
factors such as vascular endothelial growth factor and stromal derived factor-1 acting 
through their cognate receptors, VEGFR-2 and CXCR-4 [Asahara et al., 1999; 
Dimmeler et al., 2001; Llevadot et al., 2001; Seeger et al., 2009; Yla-Herttuala et al., 
2007]. Peripheral homing and incorporation of EPC are dependent on the 
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expression of surface adhesion molecules, including beta-integrins such as CD18 
[Chavakis et al., 2005]. Given their putative vasculoprotective role it is plausible that 
EPC might be mobilised in order to facilitate vascular repair following injury. 
However, several investigators have shown previously that acute mobilisation of 
traditional phenotypic CD34+VEGFR-2+ EPC in response to a discrete vascular 
injury during PCI does not occur [Mills et al., 2009]. Mobilisation of CD34+VEGFR-
2+ cells following PCI may however be delayed, as measurements have not been 
performed beyond 24 hours [Mills et al., 2009; Thomas et al., 2008a]. 
 
In the last chapter I described that traditional EPC were unaffected by the 
presence of an acute coronary syndrome (ACS) and were unrelated to the severity of 
coronary atheroma in a cohort of over 200 patients undergoing coronary 
angiography [Padfield et al., 2013]. This would indicate that traditional EPC are not 
clinically relevant to atherosclerosis or acute atherothrombotic events. Indeed EPC 
defined in the traditional fashion identify populations capable of forming 
haematopoietic rather than endothelial colonies in culture, that lack significant 
proliferative potential or the capacity to incorporate into perfusing vessels in-vivo 
[Yoder et al., 2007]. In contrast, non-haematopoietic CD34+CD45- cells form 
endothelial colonies with robust proliferative potential and can incorporate into 
perfusing vessels [Case et al., 2007; Timmermans et al., 2007; Yoder et al., 2007]. 
Although not mobilised acutely by an ACS, I found that non-haematopoietic, 
CD34+CD45- concentrations, are directly associated with atheroma burden and 
predict the occurrence of adverse coronary events. Circulating CD34+CD45- cells 
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therefore serve as a measure of vascular injury, but their origin and 
pathophysiological significance are unknown. In particular it is unclear whether or 
not they are bone marrow derived cells with regenerative capacity or are released 
directly from the vessel wall itself. 
 
Monocytes accumulate at sites of new vessel formation and augment the 
differentiation and proliferation of endothelial cells via the secretion of pro-
angiogenic factors [Fernandez Pujol et al., 2000; Rehman et al., 2003; Schmeisser et 
al., 2001; Urbich et al., 2003; Zhao et al., 2003]. Vascular injury associated with PCI 
mobilises monocyte derived angiogenic colony forming units (EC-CFU) within 24 
hours, indicating that this population participates in the acute cellular response to 
vascular injury [Mills et al., 2009]. The specific sub-populations responsible for EC-
CFU generation are unknown, however monocytes expressing the endothelial 
epitopes vascular endothelial growth factor receptor–2 (VEGFR-2) and Tie-2 
accelerate re-endothelialisation and improve left ventricular function following 
experimental cardiovascular injury [Bruno et al., 2006; Elsheikh et al., 2005; Nowak et 
al., 2004], and as described in chapter five, are mobilised following an acute coronary 
syndrome. Their behaviour in response to discrete vascular injury however is also 
unknown. 
 
I hypothesised that re-endothelialisation following PCI may be accelerated by 
circulating angiogenic monocytes and EPC [Padfield et al., 2010a], and conducted 
this study in order to determine the behaviour of a variety of putative angiogenic cell 
populations in response to a discrete vascular injury caused by PCI.
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7.3 METHODS AND MATERIALS 
7.3.1 Study population 
The study was performed with the approval of the local research ethics 
committee in accordance with the Declaration of Helsinki, and the written informed 
consent of all volunteers. Patients undergoing elective coronary angiography at 
Edinburgh Royal Infirmary (ERI), Edinburgh, United Kingdom, for the 
investigation of suspected angina (Canadian Cardiovascular Society grade 2) or as 
part of an evaluation prior to surgery for valvular heart disease were identified 
prospectively and invited to take part in the study. Patients with a recent acute 
coronary syndrome (<3 months), significant co-morbid illness, haematological or 
internal malignancy, hepatic or renal failure or concurrent infection were excluded 
from the study. Clinical characteristics and medical therapy during admission were 
documented.  
 
7.3.2 Coronary angiography  
Coronary angiography was performed via the femoral or radial artery using 
5-6F arterial catheters and standard angiographic projections. Stenoses affecting a 
major epicardial artery of ≥50% were defined as significant, and the overall 
atheroma burden was graded using the Gensini scoring system [Gensini, 1983, 
Ringqvist et al., 1983]. Patients underwent percutaneous coronary intervention at the 
discretion of the operator following pre-treatment with oral Clopidogrel 300 mg and 
5000 IU of intravenous unfractionated heparin. Intracoronary stents were implanted 




7.3.3 Blood sampling and assays 
Prior to coronary angiography peripheral venous blood anti-coagulated with 
ethylene diamine tetra-acetic acid (EDTA) (Sarstedt-Monovette, Germany) was 
collected for flow cytometry in all subjects. Whole blood was analysed for the 
differential leukocyte count using an autoanalyzer (Sysmex, UK). Plasma troponin 
concentrations were measured using the ARCHITECT STAT troponin I assay 
(Abbott Laboratories, Abbott Park, IL). An ELISA was used to quantify serum 
VEGF-A concentration (Invitrogen, UK) ([Padfield et al., 2010b] and serum high 
sensitivity-CRP was quantified using an immunonephlometric method (Dade-
Behring Marburg, Germany) [Mills et al., 2008] as described above. 
 
7.3.4 Flow cytometric identification of EPC 
Endothelial progenitor cells and angiogenic monocytes were phenotyped as 
described in previous chapters. 
 
7.3.5 Data analysis and statistics 
Continuous variables are reported as the mean ± SEM or median and IQR where 
appropriate. Statistical analyses were performed with SPSS version 17 (SPSS Inc, 
Chicago, USA). The D’Agostino and Pearson test was used to test for normality of 
distribution. Analyses were performed using parametric or non-parametric analysis 
of variance (ANOVA) where appropriate. Two-tailed Student’s t-test, Mann-Whitney 
tests and Pearson’s Chi-Square tests for between and within group comparisons 
where appropriate. Statistical significance was taken at a two-sided P value of 0.05.
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7.4 RESULTS 
7.4.1 Subjects and procedures 
Thirteen patients underwent diagnostic coronary angiography alone and 23 
underwent PCI using intracoronary stents. Patients were well matched in terms of 
age and sex and with respect to their cardiovascular risk profile and baseline 
medications (Table 7.1).  
 
Table 7.1: Demographic, clinical characteristics and medical therapy 
of the study population 
 
Angiography (n=13) PCI (n=23) P value 
Demographics 
Age, years 63 ± 2.7 61 ± 2.3 0.51 
Male gender, no. (%) 10 (77) 19 (83) 0.68 
Body mass index, kg/m2 27.5 ± 1.8 28.9 ± 0.9 0.51 
Clinical characteristics 
Smoking status, n (%)    
   Current smoker  4 (31) 2 (9) 0.11 
   Ex smoker 6 (46) 11 (48) 0.71 
   Non smoker 3 (23) 10 (44) 0.22 
Hypertensive, n (%) 6 (46) 19 (83) 0.02 
Diabetic, n (%) 2 (15) 3 (13) 0.85 
Hyperlipidaemia, n (%) 8 (62) 17 (74) 0.32 
Family history of IHD, n (%) 5 (39) 16 (70) 0.07 
Previous MI, n (%) 5 (39) 13 (57) 0.30 
CABG, n (%) 1 (8) 2 (9) 0.92 
PCI, n (%) 2 (15) 10 (44) 0.09 
PVD, n (%) 2 (15) 3 (13) 0.85 
LVSD, n (%) 3 (23) 6 (26) 0.84 
Stroke, n (%) 1 (8) 1 (4) 0.67 
Creatinine mg/dL 103 ± 4 98 ± 3 0.34 
Cholesterol mg/dL 4.3 ± 0.3 4.4 ± 0.2 0.95 
Medical therapy 
Aspirin, n (%) 9 (77) 23 (100) 0.05 
Clopidogrel, n (%) 4 (31) 18 (78) 0.01 
Beta-blocker, n (%) 7 (54) 17 (74) 0.22 
Statin, n (%) 10 (77) 22 (96) 0.09 
ACE inhibitor, n (%) 4 (31) 14 (61) 0.08 
ARB, n (%) 1 (8) 1 (4) 0.67 
Continuous variables are expressed as the mean ± standard error or median (interquartile range) 
with statistical comparisons between patients with ACS and suspected stable angina performed using 
Students t-test or Mann-Whitney where appropriate. Categorical variables are expressed as the 
absolute number of cases and the group proportion (%) with statistical comparisons performed using 
a Chi-squared test. ACE = angiotensin converting enzyme; ARB = angiotensin receptor blocker; 
CABG = coronary artery bypass; IHD = ischaemic heart disease; LMWH = low-molecular weight 
heparin; LVSD = left ventricular systolic dysfunction; MI = myocardial infarction; PCI = 
percutaneous coronary intervention; PVD = peripheral vascular disease. 
 192 
 
Table 7.2: Procedural characteristics of the study population 
 Angiography (n=13) PCI (n=23) P value 
Radial access, n (%) 9 (69) 18 (78) 0.55 
Coronary disease severity    
Normal/Minor, n (%) 2 (15) 1 (5) 0.27 
1 vessel, n (%) 2 (15) 10 (46) 0.09 
2 vessel, n (%) 2 (15) 6 (27) 0.46 
3 vessel, n (%) 7 (54) 5 (23) 0.05 
3 vessel or LMS, n (%) 9 (69) 5 (23) 0.01 
Gensini score, units 34 (26 - 79) 26 (16 - 80) 0.70 
Target vessel, n (%)    
LAD - 11 (48) - 
LCx - 10 (44) - 
RCA - 5 (22) - 
SVG - 2 (9) - 
Multi-vessel - 7 (30) - 
Balloon inflation time, s - 44 (30 - 54) - 
Number of stents - 1 (1-2) - 
Drug eluting stents - 13 (57) - 
Stent length, mm - 25.3 ± 3.2 - 
Stent diameter, mm - 3.1 ± 0.1 - 
Pre-dilatation, n (%) - 18 (78) - 
Post-dilatation, n (%) - 4 (17) - 
Case time, minutes 16 ± 1.6 36 ± 2.2 <0.001 
Continuous variables are expressed as the mean ± standard error or median and 
interquartile range with statistical comparisons between patients with ACS and suspected 
stable angina performed using Students t-test or Mann-Whitney where appropriate. 
Categorical variables are expressed as the absolute number of cases and the group 
proportion(%) with statistical comparisons performed using a Chi-squared test. Statistical 
comparisons were performed using Student’s t-test, Mann-Whitney test or Chi-squared 
analysis where appropriate. LAD = left anterior descending; LCx = left circumflex; PCI 
= percutaneous coronary intervention; RCA; right coronary artery; SVG = saphenous 
vein graft. 
  
Patients undergoing diagnostic coronary angiography alone were more likely 
to have left main stem or triple vessel disease (P=0.001), although Gensini scores 
were similar (26 (16-80) versus 34 (26-79) units; P>0.70). Patients undergoing PCI 
required a longer total procedure time compared to diagnostic angiography alone (36 
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± 2.2 versus 16 ± 1.6 minutes; P<0.001). Patients received a median of 1 (1-2) stent 
with a median total balloon inflation time of 44 (30-54) seconds. Drug eluting stents 
were used in 57% of patients (Table 7.2). No significant complications arose during 
the course of the study and all patients were discharged within 24 hours of the 
procedure. 
 
7.4.2 Measures of inflammation and myocyte necrosis 
All parameters were similar in both groups at baseline (P>0.05 for all; Table 
7.3). The median troponin concentration at 24 hours was undetectable in both 
groups (P=0.13). Following PCI, the leukocyte count was increased (P=0.04 for 
ANOVA of repeated measures), peaking at 24 hours (7.21±0.28 versus 6.24±0.20 
x106 cells/L; P=0.002). Serum CRP also increased following PCI (P=0.002 for 
ANOVA of repeated measures), peaking at 48 hours (3.95 (1.26-8.26) versus 1.02 
(0.64-2.33) mg/L; P=0.001). Serum VEGF-A concentrations were unchanged 
following PCI (P=0.16 for ANOVA of repeated measures). Diagnostic coronary 
angiography alone had no effect on the total leukocyte count, CRP, or serum VEGF-
A concentration throughout the study period (P>0.5 for ANOVA of repeated 
measures for all). 
 
7.4.3  Progenitor cell populations 
All cell concentrations were similar in both groups at baseline (P>0.05 for all; 
Table 7.4). Following PCI circulating CD34+CD45- cell concentrations were 
increased (P=0.04, for ANOVA of repeated measures), peaking at 6 hours (1.51 
(0.96-2.15) versus 0.93 (0.43-1.49) x106 cells/L; P=0.01), returning to baseline 
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concentrations at 24 hours (Table 7.4 and figure 7.1). The CD34+CD45- 
concentration was unaffected by diagnostic coronary angiography alone (P=0.97 for 
ANOVA of repeated measures; Table 7.4 and figure 7.1). Traditional EPC 
phenotypes expressing CD34+VEGFR-2+ and those expressing CD34+VEGFR-
2+CD133+ and CD34+CD45+ were unaffected in both groups (P>0.5 for all; Table 
7.4). CXCR-4 and CD18 expression on CD34+ cells was 47 ± 7% and 36 ± 5% 
respectively at baseline and were unchanged throughout the study period in both 
groups (P>0.2 for all; data not shown). The total CD14 count was not affected by 
either procedure (P>0.5 for both). Angiogenic monocytes expressing Tie-2 and 
VEGFR-2 comprised 0.72% (0.28-2.65) of circulating CD14+ cells and were 
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I have examined the behaviour of a variety of circulating angiogenic cells in 
response to a discrete vascular injury caused by PCI. I observed a rapid, but transient 
increase in circulating CD34+CD45- cells into the peripheral circulation at six hours 
following PCI, with circulating concentrations returning to baseline at 24 hours. The 
increase in CD34+CD45- cells preceded the systemic inflammatory response to 
vascular injury, which peaked at 48 hours. Whilst the number of CD34+CD45- cells 
increased, there was no change in the expression of surface adhesion molecules on 
CD34+ cells or in VEGF-A concentrations. Taken together, these observations 
suggest that the increase in CD34+CD45- cells following PCI is not mediated by a 
circulating cytokine or growth factor acting on the bone marrow, but rather results 
from mechanical injury and the release of CD34+CD45- cells from the coronary 
artery directly. Traditional phenotypic EPC populations (CD34+VEGFR-2+ and 
CD34+VEGFR-2+CD133+) and, haematopoietic CD45+ subpopulations including 
angiogenic monocytes were unaffected by discrete vascular injury up to one week 
following PCI, suggesting these populations are not mobilised in the acute response 
to vascular injury and are unlikely to play a direct role in vascular repair. 
 
Two small clinical studies have demonstrated a fall in CD34+VEGFR-2+ cells 
within the first few hours of coronary angioplasty [Lee et al., 2009; Thomas et al., 
2008a]. Neither of these studies used a control group, and interpretation is therefore 
limited, but it is likely that this ‘dip’ in CD34+ concentration is explained by the 
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diurnal variation that I described in chapter five [Padfield et al., 2010b; Thomas et al., 
2008b]. Previous studies have not specifically examined the behaviour of 
CD34+CD45- cells following PCI. Pelliccia et al, found that higher concentrations of 
CD34+VEGFR-2+CD45- and CD133+VEGFR-2+CD45- cells prior to 
revascularisation identified patients more likely to develop restenosis [Pelliccia et al., 
2010]. I described previously that a direct relationship exists between coronary 
atheroma burden and CD34+CD45- cells [Padfield et al., 2013], and both 
CD34+CD45- cell derived late outgrowth colonies [Guven et al., 2006]. 
CD34+CD45- cell derived late outgrowth colonies [Guven et al., 2006] are associated 
with atheroma burden in the coronary arteries. Therefore, it seems likely that 
CD34+CD45- cells are a measure of vascular injury, however whether or not they 
are derived from the bone marrow or possess reparatory function remains unclear.  
Mature endothelial cells also express CD34 [Fina et al., 1990] and are CD45-, and 
circulating CD34+CD45- cells may therefore simply reflect shedding of vascular 
detritus to the peripheral circulation as a consequence of cell turnover in 
atherosclerotic arteries. The early and transient appearance of CD34+CD45- cells in 
the circulation following vascular perturbation observed in the current study is 
consistent with this hypothesis. Furthermore, despite mobilisation of CD34+CD45- 
cells, neither plasma VEGF concentration nor the expression of the surface receptors, 
CXCR-4 or CD18 on circulating CD34+ cells were affected by PCI. Stem cell 
mobilisation occurs via activation of the phosphatidylinositol 3-
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kinase/Akt/endothelial nitric oxide synthase pathway (PI3K/Akt/eNOS). 
PI3K/Akt/eNOS is responsible for the regulation of cellular mobilisation, 
proliferation and migration, and apoptosis in a variety of biological systems, 
including the cardiovascular system [Shiojima et al., 2002]. Activation of 
PI3K/Akt/eNOS occurs via angiogenic factors such as VEGF through stimulation of 
nitric oxide synthesis by bone marrow stromal cells [Dimmeler et al., 2001; Llevadot 
et al., 2001]. Increased nitric oxide bioavailability leads to cleavage of intracellular 
adhesions between stem cells and stromal cells of the bone marrow [Heissig et al., 
2002], allowing them to mobilise to the peripheral circulation in response to a 
stromal cell-derived factor-1 gradient generated by bone marrow stromal cells acting 
through the CXCR-4 receptor [Asahara et al., 1999; Seeger et al., 2009; Yla-
Herttuala et al., 2007]. Cell surface adhesion molecules such as CD18 mediate EPC 
homing and cells adhesion and are required for incorporation of EPC into the 
vasculature [Chavakis et al., 2005]. Although I did not performed a comprehensive 
evaluation of the factors involved in the mobilisation of stem cells from the bone 
marrow, the absence of any change in VEGF concentration or CD18 and CXCR-4 
expression further supports the hypothesis that CD34+CD45- cells were not 
mobilised from the bone marrow, but released directly from the injured coronary 
artery.  
 
Although I did not observe an increase in circulating CD34+CD45+ cells 
following PCI in the present study, this phenomenon has been described. However 
previous studies have also included patients with significant myocardial necrosis 
[Bonello et al., 2006; Inoue et al., 2007; Schober et al., 2005]. Peak mobilisation varied 
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from 24 hours to a week, and was proportional to the degree of systemic 
inflammation with CD34+CD45+ concentrations predicting future development of 
in-stent restenosis. Whether CD34+CD45+ cells contribute directly to the 
development of restenosis is unknown, although it is interesting to note that the use of 
drug eluting stents was associated with less inflammation and CD34+CD45+ 
mobilization. This suggests drug-eluting stents may in part suppress restenosis by 
attenuating inflammatory signalling to the bone marrow by suppressing local 
vascular inflammation. CD34+CD45+ cells may therefore contribute to the 
development of in-stent restenosis, although the mechanism is unclear. CD34+ cells 
have the capacity to adopt smooth muscle cell characteristics in-vitro and may 
therefore potentiate the development of in-stent restenosis by acting as circulating 
smooth muscle progenitor cells (SMPC) [Sata et al., 2002]. Putative SMPC have been 
reported to express both CD34 and VEGFR-2 [Simper et al., 2002], and both CD34 
and CD133 are expressed at higher concentrations in the neo-intima of restenotic 
lesions compared to de novo lesions [Skowasch et al., 2003]. Inoue, et al, 
demonstrated that circulating mononuclear cells of patients with in-stent restenosis 
exhibit a propensity to develop a smooth muscle phenotype over that of an 
endothelial phenotype compared to those without [Inoue et al., 2007]. Therefore 
plasticity of circulating CD34+ cells may lead to acceleration of neo-intimal 
hyperplasia if a pro-inflammatory microenvironment in a particular patient dictates 
such a response.  
 
 Monocytes will express a variety of endothelial characteristics in-vitro under 
appropriate angiogenic stimulation [Fernandez Pujol et al., 2000; Rehman et al., 
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2003; Schmeisser et al., 2001; Urbich et al., 2003; Zhao et al., 2003]. Monocyte 
chemo-attractant protein-1 (MCP-1) is released by endothelial cells in response to 
shear stress and tissue ischemia [Ito et al., 1997], causing monocytes to accumulate at 
sites of new vessel formation, adhere to injured endothelium, and accelerate re-
endothelialisation and improve endothelial vasomotor function [Elsheikh et al., 2005; 
Nowak et al., 2004]. However, the remarkable plasticity of monocytes may result in a 
diverse response to vascular injury depending on the local microenvironment. For 
instance there is a strong correlation between circulating monocyte concentration 
and the development of in-stent restenosis [Fukuda et al., 2009], and MCP-1 is 
significantly elevated, in both the plasma [Cipollone et al., 2001; Hokimoto et al., 
2000] and in the coronary atherectomy specimens of patients who develop in-stent 
restenosis following PCI [Hokimoto et al., 2002]. Furthermore, treatment with anti-
MCP-1 monoclonal antibodies following balloon angioplasty in rats inhibits neo-
intimal hyperplasia [Furukawa et al., 1999]. The role of monocytes following vascular 
injury is therefore diverse and again probably depends on the local 
microenvironment. PCI mobilises monocyte derived angiogenic colony forming units 
(EC-CFU) within 24 hours although whether specific sub-populations participate in 
the acute cellular response to vascular injury is unknown [Mills et al., 2009]. In 
chapter five I observed that monocytes expressing Tie-2 and VEGFR-2 are mobilised 
acutely following an ACS, however this appeared to be as a consequence of myocyte 
necrosis, rather than the presence of atheroma burden or the presence of an ACS per 
se. In this study, CD14+Tie-2+VEGFR-2+ were not mobilised acutely by PCI, 
suggesting that mobilisation of this monocytic subpopulation occurs in response to 
more extensive myocardial injury rather than discrete vascular injury 
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7.6 CONCLUSIONS 
 Discrete vascular injury associated with PCI causes a rapid, but transient 
release of CD34+CD45- cells into the peripheral circulation, in the absence of a 
concurrent increase in CD34+ adhesion molecule expression or VEGF-A secretion. I 
conclude that CD34+CD45- cells are released directly from the vessel wall through 
mechanical injury to the coronary artery. Traditional EPC and VEGFR-2+Tie-2+ 
monocytes are unaffected by PCI, and are unlikely to be important in the acute 







CONCLUSIONS AND FUTURE DIRECTIONS 
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8.1 SUMMARY OF THESIS FINDINGS 
 The endothelium is critical in maintaining normal vascular homeostasis 
through the regulation of vascular tone and endogenous fibrinolysis, and the 
inhibition of vascular inflammation and neo-intimal proliferation. Disruption of 
endothelial function as a result of denuding vascular injury caused by PCI is of major 
significance in the development of procedure related complications, namely in-stent 
restenosis and thrombosis. Devising a means of accelerating re-endothelialisation 
following PCI is therefore desirable. The discovery of bone marrow derived EPC 
within the adult circulation has offered the potential to realise this aspiration. 
Compelling evidence exists that EPC exist, however their identity and significance 
remain undetermined and cell therapy for cardiovascular disorders remains out of 
reach. In order to develop effective strategies to enhance vascular repair following 
PCI, we need a better understanding of the role of EPC following vascular injury. 
 These studies were conducted in order to clarify the relationship between 
putative EPC and vascular injury. I have examined the behaviour of specific 
populations previously implicated in vascular repair, namely CD34+ cells expressing 
VEGFR-2 and CD133+, and monocytic fractions expressing Tie-2 and VEGFR-2 
and in addition to the inaptly named, endothelial cell - colony forming unit assay. 
Given their presumed vasculoprotective role, I hypothesised that these cell 
populations would be mobilised in response to discrete vascular injury but would be 
diminished in the patients with significant atherosclerosis as a result of chronic 
vascular injury. I further hypothesised that EPC would be mobilised as part of an 
inflammatory response but that excessive systemic inflammation may be deleterious 
to EPC function. 
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8.1.1. Dissociation of phenotypic and functional endothelial 
progenitor cells in patients undergoing percutaneous coronary 
intervention. 
Circulating concentrations of CD34+VEGFR2+ cells and their presumed 
progeny, EC-CFU were determined in patients before, and 24 hours following PCI 
or diagnostic coronary angiography alone. Vascular injury associated with PCI 
caused significant systemic inflammation, commensurate with a three-fold increase in 
EC-CFU. CD34+VEGFR-2+ EPC were unaffected and furthermore circulating 
concentrations of EC-CFU and CD34+VEGFR-2+ cells did not correlate with each 
other. EC-CFU and CD34+VEGFR-2+ cells are therefore distinct populations, 
mobilised via dissociated mechanisms. These findings indicate that EC-CFU are in 
some way involved in the acute response to vascular injury, unlike CD34+VEGFR-
2+ cells which are unchanged acutely in response to PCI.  
 
8.1.2. EC-CFU - characterisation and mechanisms of generation. 
 Phenotypic analysis demonstrated that while EC-CFU display some endothelial 
antigens, they predominantly express haematopoietic surface antigens, widely 
expressing the pan leukocyte marker CD45 and most intensely the macrophage 
markers CD68 and CD105 in addition to the lymphocyte antigens CD4 and CD8. 
Direct visualisation of developing EC-CFU confirmed that they are a powerful 
stimulus for the migration of monocytes and both T and B-lymphocytes. In addition, 
EC-CFU contain proliferating cells which are instrumental to colony formation. 
Therefore EC-CFU do not appear to represent circulating progenitors, and although 
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confirmatory in-vivo studies are required, it is more likely that EC-CFU serve as an in-
vitro measure of the cellular response to vascular injury, whereby activated leukocytes 
form a nidus of cellular proliferation and induce cell migration to the site of vascular 
injury and differentiation of monocytes into macrophages. 
 
8.1.3. Circulating EPC are not affected by acute systemic inflammation 
 Mobilisation of EC-CFU occurs in the context of systemic inflammation. In 
order to determine whether this is a specific response to vascular injury, Salmonella 
typhus vaccination was used to generate acute systemic inflammation in healthy 
volunteers in the absence of discrete cardiovascular injury. Interestingly despite 
significant systemic inflammation, neither EC-CFU or EPC changed during the 
course of the study, suggesting that factors specific to vascular injury are responsible 
for the mobilisation of EC-CFU following PCI. 
 
8.1.4. EPC, atheroma burden and clinical outcome in patients with 
coronary artery disease 
 Dysfunction of endogenous endothelial repair mechanisms would be expected 
to potentiate atherosclerosis. I therefore evaluated the relationship between putative 
EPC populations, coronary atheroma burden, and clinical outcomes in 201 patients 
undergoing coronary angiography for suspected angina or following an acute 
coronary syndrome (ACS). This larger clinical study highlighted the rarity of 
circulating CD34+VEGFR-2+ and CD34+VEGFR-2+CD133+ cells, and 
importantly demonstrated that these populations were neither increased in patients 
with an ACS nor related to atheroma burden or survival free from revascularisation, 
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recurrent myocardial infarction, or death. Circulating concentrations of the recently 
identified putative CD34+CD45- EPC population were increased in patients with 
coronary artery disease, and correlated positively with atheroma burden. Increased 
concentrations of circulating CD34+CD45- cells were also associated with a shorter 
cumulative event-free survival. Pro-angiogenic monocytes (CD14+VEGFR-2+Tie-2+) 
and EC-CFU were increased in patients with an ACS, however concentrations only 
reflected myocardial necrosis, and did not predict the extent of coronary disease or 
clinical outcome. Unlike circulating angiogenic monocyte concentrations, there was 
no evidence of a dynamic response by CD34+CD45- cells following an ACS, 
suggesting that CD34+CD45- cells may be a measure of atheroma burden and 
vascular injury, rather than a reparatory response to vascular injury. 
 
8.1.5. Percutaneous coronary intervention causes a rapid but transient 
mobilisation of CD34+CD45- cells. 
 Although postulated to be involved in vascular repair, I found that circulating 
CD34+VEGFR-2+ concentrations were unrelated to coronary atheroma burden and 
were unaffected by vascular injury associated with ACS or PCI. CD34+CD45- cells 
were increased in patients presenting with ACS, however this phenomenon was in 
fact associated with a greater severity of coronary atheroma in these patients. I 
therefore returned to elective PCI as a model of discrete vascular injury in order to 
interrogate the significance of the association between atheroma burden and 
circulating CD34+CD45- cell concentration and to determine the presence of any 
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late mobilisation of CD34+VEGFR-2+ cells. Populations were measured before and 
during the first week following PCI compared to diagnostic coronary angiography 
alone. PCI caused a significant systemic inflammatory response and traditional 
phenotypic EPC were unaffected by PCI, and showed no evidence of delayed 
mobilisation. However, CD34+CD45- cell concentrations were transiently increased 
six hours following PCI, returning to normal by 24 hours. Interestingly this transient 
mobilisation occurred in the absence of any increase in CD34+ adhesion molecule 
expression or VEGF-A production, suggesting that CD34+CD45- cells are released 
directly from the vessel wall following mechanical injury. 
 
8.1.6 Summary 
 Vascular injury caused by PCI is associated with systemic inflammation 
commensurate with an increase in circulating EC-CFU. EC-CFU formation appears 
to represent a specific cellular response to vascular injury, whereby proliferating cells 
serve as a migratory stimulus for monocytes and lymphocytes. CD34+CD45- cells are 
mobilised within 6 hours following PCI and are increased in the circulation relative 
to the degree of atheroma burden and act as an indication of the extent of vascular 
injury as increased numbers of CD34+CD45- cells predict poor clinical outcome. 
Circulating CD34+CD45- concentrations are probably constituents of the vessel wall, 
and rather than having a reparatory function, likely reflect the extent of atheroma 
burden and vascular injury. ‘Traditional’ phenotypic CD34+VEGFR-2+ putative 
EPC are unrelated to the extent of vascular injury, are not mobilised following PCI 
or ACS and probably have little role in the acute response to vascular injury. 
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8.2 LIMITATIONS OF THE STUDIES 
 There are a number of limitations of the studies described above. Of particular 
note, and of relevance to all of the clinical studies, was the extreme rarity of the 
putative EPC populations I was studying. Such rare event analysis by flow cytometry 
is prone to large intra-observer variability. To reduce this problem, a large number of 
total FACS events were acquired (>500,000 per sample), although even with this 
number of events it was difficult to acquire a satisfactory number of positive events. 
This was particularly so for triple positive cell fractions which were rare with a large 
co-efficient of variation. This raises concern that my conclusions that traditional EPC 
are not mobilised in response to discrete vascular injury or related to coronary 
disease may be a result of a type 2 statistical error. It is however reassuring that other 
published series have similarly failed to show such a relationship.  
In the registry of patients undergoing angiography I recognise the limitations in 
drawing conclusions about clinical outcomes in a study of this size. The observation 
of an increased event rate in association with high circulating CD34+CD45- levels 
therefore requires confirmation from larger studies, however the finding is consistent 
with the association between CD34+CD45- cells and the severity of coronary disease 
I observed in these patients. Further to this I would note that Gensini scoring, whilst 
gauging severity of coronary disease, is an indirect measure of coronary atheroma 
burden, and may underestimate it. Nevertheless angiographic severity of coronary 
disease is well correlated with atheroma burden and for the purposes of the 
correlation analyses I conducted, Gensini scoring is a reasonable surrogate measure 
of atheroma. My finding that CD34+CD45- cells are associated with greater degrees 
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of vascular injury is of most interest as these cells are possible precursors of late 
outgrowth endothelial colonies or endothelial cell forming colonies (ECFC). It is 
unfortunate therefore that I was unable to measure ECFC directly, however 
production of ECFC from adult peripheral blood was most infrequent. More often 
than not I was unable to grow any colonies at all (even following enrichment for their 
putative precursor CD34+CD45-). I therefore did not develop this assay to a stage 
where it was applicable to the clinical studies I undertook.  
The mechanism by which circulating CD34+45- cells increased following PCI 
associated vascular injury was also not robustly determined. Although it is plausible 
these cells were mobilised from the coronary directly, this remains somewhat 
speculative and further studies are required to determine this definitively. 
Furthermore it would also have been useful if I had determined the presence of 
mature endothelial cell markers on these cells. 
In my characterisation of EC-CFU I did not measure directly which cells in the assay 
were proliferating. However, in parallel experiments (see appended manuscript; The 
constituents and mechanisms of generation of ‘EC-CFU’.) cells enriched for CD14 
generated multiple EC-CFU and showed significant Brd-U uptake indicating that 
CD14+ cells are likely responsible for proliferation however this needs further 
confirmation. 
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8.3 FUTURE DIRECTIONS 
 Several questions have been generated by these studies that are to be addressed 
in ongoing studies. Primarily we wish to determine whether certain cell types are 
associated with favourable vascular repair that may be harnessed in order to reduced 
ISR following PCI.  
 
8.3.1. The STARS trial 
Are peri-procedural EPC concentrations related to in-stent restenosis? 
Does anti-inflammatory treatment affect EPC mobilisation following 
PCI?  
In the absence of an intact endothelium persistent inflammation encourages 
smooth muscle hypertrophy and in-stent restenosis [Toutouzas et al., 2004]. Elevated 
pre-procedural serum CRP concentrations predict adverse outcomes after coronary 
stent implantation and are associated with a greater degree of angiographic 
restenosis. This would suggest that systemic inflammation inhibits vascular repair and 
is associated with an adverse proliferative response [Walter et al., 2001a]. Studies 
addressing the effect of corticosteroids on the development of ISR have brought 
mixed results, probably as a result of insufficient dosing of glucocorticoids in some of 
these studies [Lee et al., 1999; Pepine et al., 1990; Sahara et al., 2003; Versaci et al., 
2002]. 
 
 In collaboration with Dr Mark de Belder at James Cook University Hospital 
Middlesbrough (JCUH), we are participating in the STeroids Against Re-Stenosis 
(STARS) Trial, a 2x2 randomised controlled trial examining the effect of oral 
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Prednisolone and two different stent designs on the development of in-stent restenosis 
following PCI. The study population is undergoing protocol driven repeat coronary 
angiography and IVUS examination at six months following stent insertion, and 
therefore provides the ideal vehicle with which to assess the relationship between 
EPC and adverse vascular remodelling. We are using this cohort of patients to 
conduct a prospective study testing the hypothesis that increased circulating 
progenitors and mobilisation following angioplasty will encourage early 
endothelialisation and prevent persistent vascular inflammation and in-stent 
restenosis. This study also provides an opportunity to explore the effect of anti-
inflammatory treatment on EPC mobilisation and function.  
 
Experimental Design 
 Patients undergoing coronary angiography with a view to follow on PCI 
undergo baseline evaluation of clinical, biochemical and putative EPC concentration. 
Between 8 and 24 hours prior to angiography patients are randomised in a double-
blind fashion to receive oral prednisolone 40 mg or placebo in addition to empirical 
proton pump inhibition with Lansoprazole 30mg. Study medications are prepared at 
JCUH pharmacy and are identifiable only by a study reference code. Following the 
decision to treat any de novo lesion affecting a native coronary artery with a 
reference diameter of > 3mm with a BMS, patients are randomised by sealed 
envelope in a single blind fashion to receive either Zeta™ or Vision™ bare metal 
stents (Abbott Vascular; UK). Exclusion criteria are the intended use of drug eluting 
stent, primary PCI for AMI, re-stenotic lesions, vein graft lesions or any unprotected 
left main stem PCI. Prior to PCI target lesions are assessed fluoroscopically in two 
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orthogonal views following the administration of 200ug of intra-coronary GTN. Oral 
prednisolone 40mg daily, is continued for a total of 28-days, and aspirin 75mg and 
clopidogrel 75 mg daily, are given to all patients for at least three months following 
PCI. The prescription of other pharmacological agents is at the discretion of the 
attending physician. Patients are re-evaluated at six and 24 hours and again at one 
and four weeks in order to assess clinical status and perform serial assays of 
haematological and biochemical assays and EPC measures. At six months patients 
undergo repeat coronary angiography using the same orthogonal views and 
intravascular ultrasound (IVUS) examination of the stented segment. Patients treated 
with drug eluting stents (DES), or those not undergoing PCI receive no further study 
medication, but are invited to return at 24 hours to measure the response of putative 
EPC. The protocol for the STARS trial is summarised on page 63. 
 
The primary outcome measure will be in-stent neointimal hyperplasia at 6 months. 
Neointimal hyperplasia within the stented arterial segment will be quantified by 
IVUS and volume calculated using a well-validated edge-detection algorithm as 
described previously [von Birgelen et al., 1997]. Briefly, the coronary artery is 
cannulated with a guiding catheter, and a 3.2F 40-MHz IVUS imaging catheter 
(Atlantis SR Pro, Boston Scientific) advanced into the artery. IVUS examination is 
performed at 0.5 mm/s with a motorised pullback device (Boston Scientific). 
Computerised 3D reconstructions of the stented segments will be performed offline 
by a single blinded operator using the TomTec computer system (Echoscan, 
TomTec Imaging Systems) [Newby et al., 2001]. A secondary outcome measure will 
be angiographic restenosis, defined as a >50% reduction in target lesion minimum 
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lumen diameter (MLD) as determined by blinded off-line quantitative coronary 
angiographic (QCA) analysis immediately post-stent deployment and at 6 months 
(Figure 8.1).  
 
In order to test the hypothesis that reduced EPC numbers prior to and 
following PCI are associated with in-stent restenosis, we will quantify circulating 
putative EPC (CD34+CD45-, CD34+VEGFR-2+, CD34+VEGFR-2+CD133+) and 
EC-CFU concentrations at baseline and at six hours following the procedure at the 
interval associated with peak mobilisation of CD34+CD45- cells as determined in 
chapter seven. In addition, blood samples will be obtained at 24-hours, at one week 
and at one month following PCI. Baseline EPC concentrations and the response to 
PCI may then be related to the extent of neo-intimal hyperplasia. Plasma and serum 
will be prepared for storage and batch analysis for inflammatory cytokines and CRP. 
Data from the intervention and placebo arms of the STARS study will be assessed 
separately. 
 
 Expected Outcomes: We anticipate that a robust response by EC-CFU in 
response to vascular injury will be associated with enhanced vascular healing and a 
reduction in neo-intimal hyperplasia. However, consistent with previous studies, 
persistent vascular inflammation is likely to be associated with an increase in neo-
intimal hyperplasia. Therefore a sustained increase in EC-CFU may similarly be 




Figure 8.1 Evaluation of proximal circumflex lesion by QCA and IVUS: A: An LAO 
caudal view of the left coronary artery demonstrating lesions in the proximal left anterior 
descending artery and a restenotic lesion in the circumflex. B: The circumflex (Cx) has been 
analysed using edge detection software providing a reference vessel diameter and percentage 
stenosis. C: The relatively healthy proximal segment of Cx same lesion as assessed by IVUS. 
There is mild concentric plaque, mainly between 3 and 6 o’clock. D: In stent. There is marked, 
concentric neointimal hyperplasia shown here in green. E: a volume rendering depicting the 
volume of neo-intima calculated by summation of each segment.   
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reflect the degree of vascular injury, we anticipate a positive correlation between 
increased CD34+CD45- cells and in-stent neointimal hyperplasia at 6 months. 
However, if CD34+CD45- cells possess reparatory function we will observe a 
negative correlation. It is likely that traditional putative EPC bearing CD34 and 
VEGFR-2 will have little bearing on the development of ISR however this has yet to 
be prospectively assessed in a clinical trial.  
 
8.3.2. Where are CD34+CD45- cells mobilised from following PCI? 
 We wish to determine the regenerative capacity of CD34+CD45- cells and their 
effect on vascular healing. As we have identified CD34+CD45- cells as a potential 
therapeutic target in regenerative medicine, determining their source of origin is of 
interest. If of bone marrow origin, CD34+CD45- cells may be potentially harvested 
and are likely to have a high regenerative capacity, unlike cells merely sloughed from 
the vasculature. To determine the source of origin of CD34+CD45- cells and their 
regenerative capacity we propose parallel studies using transgenic mice subjected to 
vascular injury and a direct comparison of CD34+CD45- concentrations in the 
coronary arterial and venous blood before and following PCI in man.  
 
Animal model experimental design 
Transgenic mice expressing green fluorescent protein (GFP) will be bred at 
the MRC Centre for Regenerative Medicine, Edinburgh University.  Non-GFP 
expressing SCD/NOD mice exposed to a sub-lethal dose of irradiation to induce 
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bone marrow suppression will undergo haematopoietic reconstitution by intravenous 
transfusion of haematopoietic stem cells (2x106 cells) from the GFP expressing strain. 
Transfected mice will be maintained in sterile conditions until bone marrow full 
recovery has been achieved. Mice will then be anaesthetised and exposed to 
endovascular injury by angioplasty using a 2F fogarty catheter introduced into the 
femoral artery. The presence of GFP+CD34+CD45- cells circulating in the 
peripheral blood will be determined by flow cytometry in injured mice at baseline 
and at one, six and 24 hours hours following vascular injury. Animals will be 
humanely killed at 4 weeks post vascular injury and the presence of GFP expressing 
endothelial cells at the site of vascular injury will be determined by 
immunohistochemistry. The role of the CD34+CD45- cells on neo-intimal 
hyperplasia will be further assessed directly using an ex-vivo expanded 
GFP+CD34+CD45- late outgrowth population obtained using FACS of peripheral 
blood withdrawn from GFP expressing mice. Following vascular injury in non-GFP+ 
SCD/NOD mice as described, GFP+CD34+CD45- cells will be transfused via a tail 
vein. Mice will be killed humanely at 12 weeks and the degree of neo-intimal 
hyperplasia related to vascular injury will be compared with a control population 
subjected to vascular injury without treatment with cell infusion.  
 
Clinical study experimental design 
We will recruit 40 patients requiring elective PCI for flow limiting coronary 
stenoses. Patients with a recent acute coronary syndrome or coronary intervention 
(<3 months), renal or hepatic failure, or a systemic inflammatory disorder or 
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malignancy will be excluded. Standard baseline data will be collected including, 
cardiovascular risk factors, past medical history, medical therapy, clinical 
presentation and angiographic findings. Peripheral venous blood will be collected for 
enumeration of CD34+CD45- cells, in addition to routine clinical tests including lipid 
profile, HbA1c, fasting glucose, renal and liver function.  
Coronary angiography will be performed via the right radial artery with 6F 
arterial catheters. Prior to PCI a 6F sheath will be placed in the right femoral vein 
and the coronary sinus will be cannulated using a suitable guide catheter (Amplatz or 
SO2 sheath) a venous sampling run will be performed involving simultaneous blood 
sampling from the proximal coronary artery via a guide catheter and vein at t=0 and 
30s and at 1, 3, 5, 10 and 15 minutes. The operator will then proceed to perform 
PCI. At the onset of the first balloon inflation a further sampling run identical to the 
control run will be performed. Once a satisfactory result has been achieved from 
PCI, catheters and sheaths will then be removed and vasculotomies closed under 
manual pressure or the use of a compression device. The patient will then be 
returned to recovery, and at six hours following PCI a further peripheral venous 
sample will be taken to confirm a systemically detectable mobilisation of 
CD34+CD45- cells and an inflammatory response (IL-6, differential leukocyte count). 
 
Expected Outcomes 
Animal studies: We anticipate that if CD34+CD45- expressing cells are derived 
from the bone marrow we will observe an increase in GFP+CD34+CD45- cells 
following endovascular injury. If CD34+CD45- cells are derived from the vessel wall 
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CD34+CD45- cells will be GFP-. The regenerative capacity and of CD34+CD45- 
cells will be determined by the proportion of CD34+CD45-GFP+ that constitute neo-
endothelium following vascular injury and the impact on the development of neo-
intima. 
Clinical studies: We anticipate that vascular injury will cause an early increase 
in CD34+CD45- cells that will be sustained to six hours. If CD34+CD45- cells are 
liberated from the coronary artery they will necessarily pass through the coronary 
veins before entering the systemic circulation, and will therefore be detected at higher 
concentrations in the coronary sinus compared to the coronary artery proximal to 
the site of vascular injury. If CD34+CD45- cells are derived from the bone marrow 
we will not observe such a rise in the CD34+CD45-. Indeed if CD34+CD45- cells are 
BM derived and are specifically homing to sites of vascular injury, we expect that 
CD34+CD45- cells will be detected at lower concentrations in the venous blood due 
to engraftment of cells in the injured coronary artery.  
 
8.3.3. Can intracoronary stent design enhance EPC engraftment? 
The modern strategy adopted to avoid ISR is based on the use of drug-eluting 
stents designed to suppress cellular proliferation [Muldowney et al., 2007]. However, 
local anti-proliferative therapy may also interfere with stent re-endothelialisation and 
increase the risk of stent thrombosis. Therefore directly accelerating re-
endothelialisation may be a more favourable strategy. Efforts to attract ‘EPC’ using 
stents coated with monoclonal antibodies directed against CD34 have reported 
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acceptable safety data [Aoki et al., 2005; Co et al., 2008; Duckers et al., 2007; Lee et 
al.; Miglionico et al., 2008; Silber et al.], however CD34 capture stents may potentiate 
ISR [Cervinka, 2009] possibly through attracting non-endothelial vascular 
precursors. This difficulty in identifying the relevant cell type may be obviated by 
coating stents with pro-angiogenic biopolymers that specifically enhance re-
endothelialisation without accelerating smooth muscle hyperplasia [Chan et al., 2008; 
Mooney et al., 2008].  
 
Experimental design 
From a library of polyurethane and polyacrylate polymers [Anderson et al., 
2004; Tourniaire et al., 2006], we have generated a polymer microarray on 
aminoalkylsilane-treated, agarose coated glass slides. Putative late outgrowth cells 
sourced from umbilical cord blood [Tura et al., 2007], human umbilical vein cells and 
CD34+CD45- cells will be cultured to confluence and then seeded onto the 
microarray. Arrays are then stained for endothelial antigens following a period of 
incubation. Endothelial growth on each polymer member can then be determined by 
scanning of the polymer spots using automated software PathfinderTM (IMSTAR 
S.A., Paris, France) (Figure 8.5). 
 
Sponge experiments 
Using an established sponge model of in-vivo angiogenesis [Hague et al., 2002] 
we can assess the in-vivo effect of these polymers on angiogenesis. Polyurethane 
sponges can be dip-coated in growth factors or polymers of interest and cultured with 
various cell populations or implanted subcutaneously in severe combined 
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immunodeficient/non-obese diabetic (SCD/NOD) mice. Sponges are subsequently 
retrieved and examined for evidence of neoangiogenesis using, scanning electron 
microscopy and immunostaining. In preliminary experiments certain polymers have 
shown promise. For instance the polyacrylate, 8G7 was associated with a high density 
of endothelial coverage using late out-growth and HUVEC on the microarray, and 
sponges impregnated with 8G7 showed increased formation of vascular networks 
compared to growth factor reduced matrigel® (GFR-M) treated sponges (Figure 8.6a 
(1-6)). Furthermore, histological analysis using haematoxylin/eosin immunostaining 
of excised sponges has demonstrated significantly greater vascularisation in 8G7 
coated sponges compared with GRF-M treated control sponges (Figure 8.6 b). 
Figure 8.4 Polymer library: Molecular structure of selected polyurethane and polyacrylate 
polymers used to culture HUVEC and EOC. Chemical compositions of the best eighteen 
polymers. Abbreviations: St: Styrene; NIPAAm: N-isopropylacrylamide; MMA: methyl 
methacrylate; MA-H: methacrylic acid; EGMP-H: ethylene glycol methacrylate phosphate; 
MEMA: 2-methoxyethylmethacrylate; V-4: 4-vinylpyridine; V-2: 2-vinylpyridine; HEMA: 2-
hydroxyethylmethacrylat; A-H: acrylic acid; DEAEA: 2-(diethylamino)ethyl acrylat; GMA: 
glycidyl methacrylat; DnHA: di-n-hexylamine; EMA: ethyl methacrylate; BMA: butyl 
methacrylate; DMAEA: 2-(diethylamino)ethyl acrylate; BICH: 1,3-
bis(isocynanatomethyl)cyclohexane; PTMG: poly(butylene glycol); BD: 1,4-butanediol; HDI: 1,6-
diisocyanohexane; DEAPD: 3-(diethylamino)-1,2-propanediol; MDI: 4,4’-
methylenebis(phenylisocyanate); PPG: poly(propylene glycol); DMAPD: 3-dimethylamino-1,2-
propanediol; PHNGAD: poly[1,6-hexanediol/neopentylglycol/diethylene glycol-alt-(adipic 
acid)]diol; EG: ethylene glycol. See figure overleaf. See figure 8.5 
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Similarly, the concentration of haemoglobin within explanted sponges (a surrogate 
measure of perfused blood vessels) was ~3-fold higher in 8G7 coated sponges than in 
GRF-M treated sponges (Figure. 8.6c). Supplementary analysis using quantitative 
polymerase chain reaction (qPCR) also indicates that 8G7 coating promotes 
endogenous neovascularisation with increased relative expression of mouse vWF 
compared with sponges treated with GFR-M. Expression of human vWF was 
unchanged (Figure. 8.6d).  
 
Stent experiments 
Polymers with angiogenic potential will be applied to intracoronary stents to explore 
their potential clinical utility. Coated stents are co-incubated with late outgrowth 
endothelial cells or HUVEC for several days before being inspected using SEM for 
evidence of increased cell attachment and confluence. Platelet and monocyte 
adherence to intra-coronary stents are critical components in the development of 
both stent thrombosis and restenosis, therefore it will be important to determine the 
propensity for monocytes to bind to polymers identified as having angiogenic 
potential. We have performed preliminary studies examining the effects of 8G7 on in-
vitro re-endothelialisation and platelet-monocyte binding of inta-coronary stents by 
means of scanning electron microscopy. These have demonstrated improved 
endothelialisation associated with 8G7 coating with encouragingly low levels of 
platelet monocyte binding (Figure 8.7).
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Figure 8.5 Endothelial late outgrowth cells and HUVEC incubated on polymer 
microarrays for 3 days: Endothelial late outgrowth cells (endothelial colony forming cells) 
and human umbilical vein endothelial cells were grown on various polyurethane and 
polyacrylate polymers. The rhodamine channel (red) shows the endothelial phenotype (CD31). 






Figure 8.6. Subcutaneous sponge implant assay.  
Here sponges excised from male SCID/NOD mice after 20 days following implantation are 
analysed for evidence of neovascularisation. a) Electron microscopy analysis of sponges 
impregnated with the polyacrylate, 8G7 (1-3) and growth factor reduced matrigel (GFR-M) (4-6) 
loaded with endothelial outgrowth cells (EOC) (arrows show vascular networks). b) Blood vessel 
density in sponges, determination by Chalkley counts on two sections per sponge. The results 
presented are a mean of four animals ± SEM. *P<0.05. c) Haemoglobin assay: measure of the 
amount of haemoglobin (mg/ml) present in the samples (n=3) **P<0.01 d) Relative expression of 
both mouse and human von Willebrand factor measured by qPCR n=3. *P<0.05. Statistical 
analyses were performed using Mann-Whitney U test. 
Figure 8.7 In-vitro stent experiments: Late outgrowth EPC , platelets and monocytes were 
incubated with an uncoated or an 8G7-coated chromium-cobalt alloy coronary stents. After 96 h 
incubation, in endothelial basal medium, cells were fixed and examined by electron microscopy. 
Late outgrowth EPC binding is shown on a,b) an uncoated stent and c,d) an 8G7 coated stent. 
Platelet binding is shown on e,f) uncoated and 8G7 coated stents g,h). Monocyte binding on 
uncoated stents i,j) (arrows (j) show modest monocyte binding) and 8G7 coated stents k,l). Late 
outgrowth EPC cultured with the uncoated stent showed no cell attachment whereas late 
outgrowth EPC cultured with the 8G7-coated stent exhibited a consistent adhesion with around 
80% confluence. Platelet adhesion on the uncoated stent was relatively increased compared to the 





We anticipate that by using comprehensive assessment of a wide variety of polymers 
we will identify a platform that will encourage endothelial seeding and proliferation. 
Polymers such as 8G7 that show potential for improving re-endothelialisation may 
then be then employed in animal models of PCI to determine whether they affect re-
endothelialisation, thrombus formation and neo-intimal hyperplasia.
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8.4 CLINICAL PERSPECTIVE 
The technological advances in PCI over the last 30 years have been quite 
remarkable. At its inception, simple balloon angioplasty was considered most 
adventurous, the use of intra-coronary stents have now become routine practice, and 
stent design has become increasingly more refined, providing greater flexibility and 
deliverability of intra-coronary stents. Drug eluting stents are now well established as 
a means of reducing in-stent restenosis, and as the volume and complexity of 
percutaneous coronary interventions continues to increase, we move forward into the 
era of bio-absorbable stents. These developments combined with the development of 
a wide array of adjunctive equipment for accessing, imaging, and recannalising 
diseased coronary arteries, has allowed increasingly more complex lesions to be 
treated effectively with high degrees of safety and a commensurate improvement in 
patient outcomes. However, endothelial injury associated with PCI has remained a 
constant feature, with little technological advance specifically addressing this 
important obstacle.  A means of accelerating re-endothelialisation of implanted stents 
continues to be most attractive. So far attempts to achieve this therapeutic goal have 
been disappointing, be that through direct transfusion or pharmacological 
mobilisation of putative progenitor cells, or by the use of innovative EPC ‘capture’ 
stents. Perhaps these shortcomings have been largely due to an incomplete 
understanding of the cell populations involved in neo-endothelialisation and neo-
intimal formation.  
 
An improved understanding of endogenous vascular repair via circulating 
progenitors may allow us to move forward in developing novel treatments for 
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iatrogenic vascular injury incurred during PCI. The studies contained within this 
thesis provide some contribution to our understanding of the characteristics and 
clinical relevance of a variety of putative EPC populations that may be of use in 
subsequent pre-clinical and clinical studies of EPC. Identifying the optimal cell 
populations and means of regulating their behaviour remain important research 
goals in this field.  
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